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Abstract
Merkel cell carcinoma (MCC) is an aggressive skin cancer of neuroen-
docrine origin with a high likelihood of recurrence and metastasis.
In 2008, Merkel cell polyomavirus (MCPyV) was discovered mono-
clonally integrated within the host genome of at least 80% of MCC
tumours. MCPyV transforms and maintains MCC tumours via the
expression of the large and small tumour (LT and ST) antigens. Specif-
ically, ST is thought to be the major transforming factor in the tu-
mourigenesis of MCC. Since the discovery of MCPyV, a number of
mechanisms have been suggested to account for replication and tu-
mour formation, but to date, little is known about potential links be-
tween MCPyV T antigen expression and the highly metastatic nature
of MCC.
In this thesis, the link between MCPyV and MCC metastasis is ex-
plored by focusing on the role of MCPyV ST in promoting cell motil-
ity. Cell motility and migration is a complex, multi-step, and multi-
component process, intrinsic in cancer progression and metastasis.
Previous work in the Whitehouse laboratory has implicated the micro-
tubule network in MCPyV ST-induced cell motility. This thesis builds
upon those findings to show that MCPyV ST-induced cell motility is
dependent on multiple factors, including the activity of integrin re-
ceptors, Rho-family GTPases and the actin cytoskeleton, and intracel-
lular chloride channels. This thesis also further explores the MCPyV
ST-PP4C interaction in MCPyV ST-induced cell motility and proposes
a mechanism by which this interaction activates integrin receptors to
promote cell motility, thereby contributing to the metastatic nature of
MCC. Furthermore, the relocalisation of intracellular chloride chan-
nels CLIC1 and CLIC4 to the cell surface is shown to be important in
MCPyV ST-induced cell motility.
Overall, results presented herein describe a novel mechanism by which
iii
a tumour virus induces cell motility, ultimately leading to cancer metas-
tasis. Therefore, there may be implications for the potential future
therapeutic targets for disseminated MCC.
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Introduction
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1.1 Oncogenic viruses
1.1 Oncogenic viruses
Cancer is the cause of approximately 13% of deaths worldwide, more than AIDS,
tuberculosis, and malaria combined [1]. It remains a growing public health con-
cern, with prevention, management, and treatment costing individuals, charities,
and governments billions. In 2010 alone, the associated cost of cancer care in the
US was $124.57 billion, estimated to grow to $157.77 billion in 2020 [2]. In the UK,
2 million people live with cancer, a figure expected to rise by a million a decade.
It is projected that by 2040, almost a quarter of people aged 65 will be cancer
survivors [3].
There are many different causes of cancer, among them viruses and other in-
fectious agents. 12.7 million new cancer cases occurred in 2008, and 16.1% (i.e.
around 2 million new cancer cases) are attributed to infection. There is a clear
geographic and economic divide in the distribution of infection-related cancers:
22.9% of cases in underdeveloped countries (32.7% of that in sub-Saharan Africa)
vs 7.4% in developed countries (3.3% of that in Australia and New Zealand). The
vast majority of these new cases, 1.9 million, were due to either Hepatitis B and
C virus, human papillomavirus (HPV) or Helicobacter pylori infections, which re-
sulted in mainly liver, cervix/uteri or gastric cancers. Around half the infection-
related cancers in women were cervix/uteri, more than 80% in men were liver or
gastric. In addition, around 30% of infection-attributable cases occur in people
younger than 50 years [4].
Thus, there is a clear role for viruses in the global burden of cancer. The field
of tumour virology began in the early 20th century, with experiments performed
on chickens by Francis Rous in the USA and by Vilhelm Ellerman and Oluf Bang
in Denmark. In 1908, they showed that avian erythroblastosis can be transmitted
between chickens using a cell-free tumour extract. Three years later, in 1911, Rous
showed that a sarcomatous chest tumour can also be transmitted between chick-
ens using a cell-free tumour extract [5]. However, these findings were considered
mere curiosities by the wider scientific community, and tumour virology did not
garner much attention until the 1930s. In that decade, Rous returned to tumour
virology, and worked on the cottontail rabbit papilomavirus [6], including inves-
tigations of the co-carcinogenic effects of coal tars on virus-induced tumours [7].
In the 1950s, two transforming mouse viruses were discovered: murine leukaemia
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retrovirus (MLV) and murine polyomavirus (MPyV) [8]. This led to increased in-
terest in tumour viruses, accelerated by the discovery of simian virus 40 (SV40)
in the 1960s [9]. Research on SV40 has yielded many important discoveries in the
field of molecular cell biology, e.g. identification of the p53 tumour suppressor
[10], the first nuclear localisation signal [11], and tyrosine phosphorylation [12].
To date, 7 viruses have been conclusively linked to human cancers: Epstein-Barr
virus (EBV), Hepatitis B virus (HBV), human T-lymphotropic virus 1 (HTLV-
1), high risk human papillomaviruses (HPV16 and HPV18), Hepatitis C virus
(HCV), Kaposi’s sarcoma herpesvirus (KSHV) and Merkel cell polyomavirus
(MCPyV). Table 1.1 provides information on year of discovery, associated can-
cers and genome type.
Table 1.1: Human tumour viruses
Virus Discovery Major associated cancers Genome Refs
EBV 1964 Burkitt’s lymphoma
and nasopharyngeal
carcinoma
Large dsDNA [13]
HBV 1965 Hepatocellular carcinoma ss and dsDNA [14]
HTLV-
1
1980 Adult T cell lymphoma Retrovirus RNA [15]
HPV16,
HPV18
1983-1984 Cervical, penile, head and
neck cancers
Small dsDNA [16] [17]
HCV 1989 Hepatocellular carcinoma (+)RNA [18]
KSHV 1994 Kaposi’s sarcoma, pri-
mary effusion lymphoma
(PEL), multicentric
Castleman’s disease
Large dsDNA [19]
MCPyV 2008 Merkel cell carcinoma Small dsDNA [20]
ss: single-stranded, ds: double stranded, (+): positive strand
1.2 Polyomaviruses
The Polyomaviridae family of viruses is characterised by circular, double-stranded
DNA genomes capable of infecting a variety of mammals and birds. The first
polyomaviruses to be characterised, in the 1950s and 1960s respectively, were
MPyV and SV40. The former was discovered when it was observed that filter-
able extracts from murine leukaemia could induce tumours in the parotid gland
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of neonatal mice [8]. The latter was identified in African green monkey kidney
cells, which were used in the production of the polio vaccine [9]. Historically,
polyomaviruses were classified together with papillomaviruses into the papova
virus family, but since the 7th International Committee on Taxonomy of Viruses
(ICTV) report in 2001, it has been recognised that they are a distinct family of
small double-stranded DNA viruses. Currently, polyomaviruses are known to
infect birds, rodents, cattle, and primates, but an individual viral species has a
very narrow host range and cell specificity.
1.2.1 Classification of polyomaviruses
Historically, polyomaviruses were classified into one genus. However, in 2010,
the ICTV reclassified polyomaviruses into 3 separate genera: Orthopolyomavirus
and Wukipolyomavirus for mammalian virus species and Avipolyomavirus for bird
virus species. Figure 1.1 shows the phylogenetic relationship among polyomavi-
ruses based on whole genomic nucleotide sequences.
There are some startling differences between the genera. For example, while
mammalian polyomaviruses have a narrow host and cell specificity, avian poly-
omaviruses have a much broader host range [21]. Conversely, while a number of
mammalian polyomaviruses display tumourigenicity under certain conditions
(discussed in Section 1.2.6), avian polyomaviruses are agents of inflammation in
non-immunosuppressed hosts [22].
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Figure 1.1: A phylogenetic tree of polyomaviruses based on whole genome sequences.
Three large groups are distinguished: wukipolyomaviruses, avipolyomaviruses and or-
thopolyomaviruses.
1.2.2 Human polyomaviruses
Twelve human polyomaviruses have been discovered to date, ten of them since
2007. The first two human polyomaviruses were identified in 1971 from two
different patient samples, and named after the initials of the patients: JC poly-
omavirus (JCPyV) and BK polyomavirus (BKPyV).
JCPyV was isolated from the brain tissue of a patient suffering from progressive
multifocal leukoencephalopathy (PML), a disease characterised by the demyeli-
nation of the central nervous system [23]. It has since been conclusively deter-
mined that JCPyV is the causative agent of PML [24], and that the virus is a com-
mon childhood infection, with a seroprevalence of 70–90% of the adult popula-
tion [25]. In an immunocompetent host, JCPyV establishes a latent, asymptomatic
infection in the gastrointestinal tract and kidneys [26], but in an immunocompro-
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mised host, it can reactivate and establish a lytic infection in oligodendrocytes,
leading to PML [27].
BKPyV was identified from a urine sample of a kidney transplant recipient pre-
senting with chronic pyelonephritis and advanced renal failure [28]. Like JCPyV,
BKPyV is prevalent in approximately 80% of the adult population, with an asymp-
tomatic, latent presence [29]. Upon immunosuppression, BKPyV can reactivate
and enter a lytic replication cycle, and, in the context of kidney transplants, the
virus can cause polyomavirus-associated nephropathy (PVAN), which is associ-
ated with 50% allograft failure [30].
Currently, there is somewhat of a renaissance in human polyomavirus discov-
ery. Table 1.2 summarises all the human polyomaviruses known so far. Only
Merkel cell polyomavirus (discussed in detail in Section 1.4) and Trichodyspla-
sia Spinulosa-associated polyomavirus (TSPyV) have been implicated in disease.
TSPyV causes a rare skin disease, Trichodysplasia Spinulosa, but only in condi-
tions of immunosuppression [31]. The role of the remaining new human poly-
omaviruses in disease is under investigation, but so far it is unclear whether they
are involved in any pathologies.
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Table 1.2: Human polyomaviruses
Virus Discovery Origin Refs
JCPyV 1971 Brain tissue extract of PML patient [23]
BKPyV 1971 Urine of renal translpant patient [28]
KIPyV 2007 Respiratory tract (acute infection) [32]
WUPyV 2007 Respiratory tract (acute infection) [33]
MCPyV 2008 Merkel cell carcinoma (MCC) tumour [20]
HPyV6 2010 Healthy skin samples [34]
HPyV7 2010 Healthy skin samples [34]
TSPyV 2010 Skin samples from TS patient [31]
HPyV9 2011 Healthy skin and serum samples [35]
MWPyV
(HPyV10,
MXPyV)
2012 Healthy stool sample, WHIM patient
sample, acute diarrhoea sample
[36]
[37]
[38]
HPyV12 2013 Liver resection sample [39]
STLPyV 2013 Healthy stool sample [40]
NJPyV 2014 Muscle biopsy of pancreatic transplant
patient
[41]
J. C. and B. K.: patient initials, PML: progressive multifocal leukoencephalopathy,
KI: Karolinska Institute, WU: Washington University, St. Luis, TS: trichodysplasia
spinulosa, MW: Malawi, MX: Mexico, STL: St Louis, NJ: New Jersey
1.2.3 The polyomavirus genome
The polyomavirus genome is an approximately 5,000 base pair circle of double-
stranded DNA, with a non-coding control region (NCCR) flanked by an early
gene region on one side and a late gene region on the other. The NCCR con-
tains the early and late promoters, their transcription start sites and the origin of
replication.
The early and late gene regions are encoded on opposite strands of the template
DNA. The early gene region encodes the large T antigen (LT) and the small T
antigen (ST). In addition, alternatively spliced variants of LT (LT’ in Figure 1.2)
have been characterised for some polyomaviruses, such as MCPyV [42]. MCPyV
has also been found to encode an alternative large T open reading frame (ALTO)
transcript [43]. The newly-discovered STLPyV may express 229T, a third early
transcript that shares the first 190 residues of small T antigen with an additional
39 residues from an alternative reading frame of LT [40]. However, none of the
human polyomaviruses seem to encode a middle T antigen, which is present in
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other mammalian polyomaviruses, such as MPyV [44].
The late gene region encodes the viral coat proteins VP1, VP2, and VP3. SV40
encodes an additional viroporin, VP4 [45]. The reading frames for VP2, VP3 and
VP4 are identical, but translation starts at successive initiating AUG codons to
generate the different proteins. SV40, JCPyV, and BKPyV late transcripts also
encode the agnoprotein [46], a small protein of as-yet-unknown function. Figure
1.2 shows the generalised polyomavirus genome.
ST
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Agno
VP1
VP2
VP3
VP4
m
iR
NA
LT
LT
’
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Origin
Figure 1.2: A generalised polyomavirus genome, including the non-coding control re-
gion, the early gene region and the late gene region. The early gene region commonly
encodes LT, ST, and at least one alternative T antigen product (LT’). The late gene region
encodes the structural VP proteins, and, in some polyomaviruses, the agnoprotein. Some
polyomaviruses also express a microRNA. Agno: agnoprotein, LT: large T antigen, LT;:
alternatively-spliced T antigen product, miRNA: polyomavirus-expressed micro RNA,
NCCR: non-coding control region, ST: small T antigen, VP: viral protein/
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1.2.4 The polyomavirus life cycle
The polyomavirus life cycle reflects the nature of DNA viruses, with entry both
into the cell and into the nucleus. A generalised polyomavirus life cycle is sum-
marised in Figure 1.3, using the SV40 lytic life cycle as the model.
Virus entry
Early mRNA and 
protein synthesis
Late mRNA and 
protein synthesis
Virus production
Virus DNA 
Early 
proteins
Early 
mRNA
Late 
mRNA
Late 
proteins
Figure 1.3: The polyomavirus life cycle in a permissive cell line. SV40 is taken as a
model for the polyomavirus life cycle as its replication has been most widely studied.
In order to infect an animal cell, a virus first attaches to specific receptor molecules
on the cell surface. SV40 entry is mediated by attachment to sialic acid moieties.
The ganglioside GM1 is thought to be required in many cases for SV40 entry [47],
but attachment to the major histocompatibility complex (MHC) has also been
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observed [48]. MPyV and BKPyV bind to sialylated glycans, e.g. GT1B [49] [50],
while JCPyV is tropic for α-2-6-linked sialic acids [51].
Polyomaviruses enter the cell through endocytosis, but the mechanism of this
vary for different viruses. SV40, for example, depends on caveolin-mediated en-
docytosis [52], while JCPyV utilises a clathrin-dependent mechanism [53]. After
entry, the virus must be transported to the nucleus to continue its lifecycle. All
three SV40 VPs have nuclear localisation signals (NLS) [54]. In addition, JCPyV
VP1 also contains an NLS sequence, which allows binding to cellular importins
and entry into the nucleus via the nuclear pore complex (NPC) [55].
Polyomavirus DNA is transcribed and replicated in the host cell nucleus. After
entering the nucleus and uncoating, the early gene region is transcribed, with
SV40 LT being able to transactivate the early promoter region as well as binding
to the origin of replication to promote the replication of the viral genome [56].
Polyomavirus transcription, translation, and replication depend on host cell ma-
chinery, including proteins expressed only during S-phase, thus both LT and ST
promote entry of the host cell into S-phase.
Once a sufficient concentration of LT is reached, it acts to inhibit the activity of the
early promoter and instead activates the late promoter to drive the production of
the structural proteins [56]. Translated structural proteins are re-imported into
the nucleus, where virion assembly takes place. Virion assembly occurs by addi-
tion and organisation of the capsid proteins around the viral minichromosome,
rather than by incorporation of DNA into pre-formed capsids [57] Each VP1 pen-
tamer combines with a molecule of either VP2 [58] or VP3 [59] due to strong hy-
drophobic interactions. Interestingly, studies using capsid proteins with mutated
NLS indicated that VP1 and VP2/3 are transported to the nucleus as a single unit
[54]. This suggests that VP15VP2/3 is the building block for the SV40 capsid.
1.2.5 Polyomavirus early proteins
All polyomaviruses encode at least two proteins in the early region of their ge-
nome. LT and ST are ubiquitous among polyomaviruses, and are required for
viral replication. They are produced from one transcript via differential splic-
ing, and share a common amino-terminal region (first 80–82 residues) [60]. The
known products of the T antigen locus are discussed in the following sections.
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The functions of T antigens are commonly discussed in terms of SV40 and MPyV,
as their early gene products are the most widely characterised. LT and ST pro-
mote the switch to S phase in quiescent host cells, and thus are required for vi-
ral DNA replication [61]. The S phase switch ensures the presence of the nec-
essary host cell machinery to replicate viral DNA, since polyomaviruses do not
encode any proteins for DNA synthesis [60]. This process is considered to re-
sult in polyomavirus-induced cellular transformation, as early gene expression
in non-permissive cells results in aberrant cell cycle stimulation and interference
with host cell signalling pathways [62].
1.2.5.1 The large T antigen
LT is one of the products of the polyomavirus early transcript. It is a protein of
approximately 700 amino acids, with an amino-terminal DnaJ domain, common
to all T antigen transcripts, and a unique carboxy-terminal domain. The DnaJ
domain contains the Hsc70 binding domain and the highly conserved Cr1 do-
main. The unique region contains multiple different protein binding domains
(discussed below), a DNA-binding domain, a nuclear localisation signal (NLS), a
zinc (Zn) finger domain and an ATPase domain. Figure 1.4 shows the structure
of SV40 LT.
LT is involved in viral DNA replication, binding to the origin of replication within
the NCCR and promoting DNA unwinding and transcription/replication com-
plex formation via its DNA-binding and ATPase domains [63], [64]. In addition,
SV40 [65] and JCPyV [66] LTs can promote the transcription of late region genes.
In addition, LT promotes cell cycle dysregulation and host cell entry into S phase
[60].
These functions depend on the ability of LT to bind to a wide variety of host
cell proteins. SV40 LT can bind to a number of factors associated with DNA
replication. For instance, the J domain and the ATPase domain of SV40 LT are
necessary to directly bind to the catalytic subunit of DNA polymerase-α in vitro
[67]. SV40 LT can also bind to replication protein A (RPA), a factor involved in
replication assembly [68]. In addition, SV40 LT, like all polyomavirus LT studied,
forms a hexameric complex to initiate DNA replication via its helicase function.
Two of these LT complexes are required, binding in head-to-head configuration to
the viral origin of repliation. In addition to LT, this helicase complex also contains
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Figure 1.4: The structure of SV40 LT. SV40 LT contains an amino-terminal DnaJ domain
that binds Hsc70, and multiple domains with many different binding partners, including
a nuclear localisation signal, a DNA-binding domain, and an ATPase/helicase domain.
BUB1: budding uninhibited by benzimidazoles 1 protein, CREBBP: CREB-binding pro-
tein, CUL7: cullin 7 protein, DBD: DNA-binding domain, EP300: E1A-binding protein
300, FAM111A: family with sequence similarity 111 member A, FBXW7: F-box and WD
repeat domain containing 7, HSC70: heat shock chaperone 70, IRS1: insulin receptor
substrate 1, KPNA: karyopherin alpha, NLS: nuclear localisation signal, POLA: DNA
polymerase alpha, pRB: retinoblastoma protein, PRIM: DNA primase, RPA: replication
protein A, TOP1: topoisoerase 1.
the host factors nucleolin and topoisomerase [69].
In addition to its function in viral DNA replication, LT also promotes host cell
entry into S phase. A number of cellular proteins regulate the progression of the
cell from G1 to S-phase. One such protein is the retinoblastoma protein (pRb),
a tumour suppressor which binds to and sequesters the E2F transcription factor.
Phosphorylation of pRb releases the E2F transcription factor, allowing the switch
to S-phase [70] [71]. SV40 LT binds to and sequesters pRb [72] and pRb family
proteins (e.g. p107 and p130), allowing for the release of E2F [73]. BKPyV LT can
also reduce the levels of pRb family proteins by promoting the proteolysis of p130
and other pRb family members in mouse fibroblast cells [74]. In addition, the
Hsc70-binding domain of LT has cis-acting properties aiding in the dissociation
of E2F from pRb in an ATPase-dependent manner [75]. As such, there appears to
be ample redundancy in subverting the pRb signalling pathways by LT.
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Table 1.3: Polyomavirus large T antigen binding partners
Protein Function Effect of LT binding Refs
Cullin7
(CUL7)
Core part of Cullin-
RING E3 ubiquitin
ligase complex 7
(CLR7)
Suppresses activity of CLR7,
leading to impaired proteoly-
sis of insulin receptor substrate
1 (IRS1)
[76]
Insulin
receptor
substrate 1
(IRS1)
Part of the insulin re-
sponse pathway
Translocation of IRS1 into the
nucleus, leading to inhibition
of DDR
[77]
[78]
β-catenin Part of the Wnt sig-
nalling pathway
Increased stability of β-catenin
and enhancement of target
gene (e.g. c-myc) activation
[79]
[80]
Thyroid
embryonic
factor-1
(TEF-1)
Transcription factor Early-to-late switch in viral
gene expression
[81]
p300/CREB-
binding
protein
(CBP)*
Transcriptional
adapter proteins
LT acetylation [82]
Bub1 Mitotic spindle
checkpoint protein
Perturbation of the spindle
checkpoint leading to genomic
instability
[83]
Nbs1 Part of the MRN
complex in DDR
Disruption of DNA replication
control
[84]
* Indirect interaction through p53.
p53 is another significant tumour suppressor targeted by polyomavirus LT. It
is a crucial regulator of cell cycle, apoptosis, and DNA damage repair (DDR)
processes [85]. SV40, JCPyV and BKPyV LTs all bind p53 in an ATP-dependant
manner [86] [87] [74]. LT sequestration of pRb leads to the transcription of E2F-
responsive genes, which in turn lead to the activation of p53 and transcription
of p53-responsive genes [88]. Activation of p53 normally leads to the arrest of
cell growth and apoptosis. In order to prevent this cascade, LT binds p53, which
stops p53 from accessing gene promoter regions and renders it transcriptionally
inactive [89] [90]. SV40 LT expression is therefore sufficient to downregulate the
expression of p53-responsive genes [91]. In permissive cell lines, this facilitates
viral replication, but in non-permissive cell lines, it can lead to cellular transfor-
mation.
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LT binding to pRb and p53 has been widely studied. However, LT binds to a
number of other host cell factors. Table 1.3 lists a selection of other known LT
binding partners, their functions, and the effect LT binding achieves.
Polyomavirus LT binding to host cell proteins has the primary purpose of pro-
moting the switch to S-phase and facilitating viral replication. However, in non-
permissive cell lines, this can lead to cellular transformation and tumourigenesis.
The role of LT in cancer will be discussed in Sections 1.2.6.2 and 1.4.4.1
1.2.5.2 The small T antigen
ST is 17kDa protein comprising 170 amino acids. The amino-terminal portion
of ST contains the shared DnaJ domain, while the carboxy-terminal region is
unique to ST in most polyomaviruses, although the MPyV MT amino-terminal
region shares most of this sequence. This portion of ST contains the protein phos-
phatase 2A (PP2A) binding domain (CxxP/CxC). PP2A is the major cellular ser-
ine/threonine (Ser/Thr) phosphatase [92]. In many polyomaviruses, the inter-
action between ST and PP2A is considered to be the major function of the viral
protein. Figure 1.5 shows the structure of SV40 ST.
DnaJ Unique region
HSC70 PP2A
1 82 170
Figure 1.5: The structure of SV40 ST. SV40 ST shares the DnaJ domain with SV40 LT,
and contains a unique region that binds PP2A. HSC70: heat shock chaperone 70, PP2A:
protein phosphatase 2A.
PP2A is a heterotrimeric holoenzyme, made up of subunits A, B, and C. Subunit A
is 65 kDa in size and acts as the scaffold. The carboxy-terminus of subunit A binds
to subunit C (32 kDa), which functions as a catalytically-active phosphatase [93].
Subunit B binds to subunit A through its amino-terminal region [94], and the va-
riety of these subunits allows for the regulation of substrate specificity [92]. Due
to its ability to dephosphorylate a wide range of substrates, PP2A is an important
regulator of multiple downstream signalling pathways, involved in apoptosis,
cell cycle regulation, and proteolysis [95]. The ability of ST to bind PP2A gives
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polyomaviruses access to these signalling pathways, thus subverting them for vi-
ral replication. Crystallisation studies of SV40 ST have determined that both the
DnaJ and the unique domain are involved in binding with the PP2A A subunit,
particularly to the Aα isoform [96]. Furthermore, both SV40 and JCPyV ST bind
directly to the A subunit and thus come into contact with the C subunit [97] [98].
The SV40 ST PP2A A subunit binding site overlaps with the B subunit binding
site [99], indicating that ST competes with B subunits for A subunit binding.
These findings suggest that ST may function as a negative inhibitor or a pos-
itive activator of the PP2A holoenzyme, or potentially both, as some evidence
suggests. In other words, replacing the B subunit with ST may inhibit dephos-
phorylation of specific substrates, such as Raf, MEK and ERK in the MAP kinase
pathway [100], but it may also redirect PP2A to different cellular targets. For ex-
ample, SV40 ST increases the dephosphorylation of histone protein H1 by PP2A
[101]. In permissive cell lines, the interaction of ST with PP2A likely facilitates
viral replication, while in non-permissive cell lines it may contribute to cellular
transformation.
While polyomavirus LT is thought to be the main driver of viral replication, an
auxiliary role in enhancing the function of LT has also been uncovered for ST.
Supporting this, expression of SV40 ST mutants leads to reduced viral replica-
tion [102], while expression of ST increases early promoter and LT-mediated late
promoter activity [103] [56]. Thus although ST is not essential for polyomavirus
replication, it does have a role in increasing replication efficiency.
The interaction of ST with PP2A contributes to viral replication by helping dis-
rupt the cell cycle and drive cells into S-phase [104]. One example of this is MPyV
ST, which activates the MAP kinase cascade in a PP2A-dependent manner, result-
ing in increased binding by transcription factors such as AP-1 to stimulate the
transition from G1 to S-phase [100]. In addition, ST can decrease the levels of a
cyclin-dependent kinase (CDK) inhibitor, p27/kip1 [105]. p27/kip1 prevents ef-
ficient complex formation between CDK4 and pRb, which normally leads to cell
cycle arrest [106]. It is possible that ST binding to PP2A reduces the dephospho-
rylation of cyclin E/cdk2, which regulates p27/kip1, in turn leading to cell cycle
progression. Finally, ST expression stimulates other factors involved in cell cycle
progression, including cyclin D1, cyclin B, and thymidine kinase [107].
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1.2.5.3 The middle T antigen
Alternative splicing of rodent polyomavirus early transcript results in the pro-
duction of MT, a 55kDa protein. The amino-terminal region of MT is identical to
that of ST (apart from the last 4 carboxy-terminal amino acids), sharing the DnaJ
and PP2A binding domains. The carboxy-terminal part of MT is unique and con-
tains multiple phosphorylation sites. This part of MT is also hydrophobic, and
able to span the lipid bilayer [108]. Figure 1.6 shows the structure of MPyV MT.
MPyV MT can bind the origin of replication and affects the expression of a num-
ber of host cell transcription factors, e.g. AP-1 transcrption factors [109], includ-
ing c-Jun [110], and the Ets protein family of transcription factors such as PEA3
[111]), thus facilitating viral replication. MT is also important in virion assembly,
as absence of MT expression leads to inefficient virion assembly due to aberrant
phosphorylation of VP1 [112]. Despite this, transcripts of MT have not been iden-
tified in human polyomaviruses so far.
Common region (ST and 
MT) Unique region (MT only) TM
1 191 421HSC70 PP2A
Src 
TKs
Phosphorylation sites
250 257 315 322
Shc
14-3-3 PI-3K
PLCγ-1
Figure 1.6: The structure of MPyV MT. MPyV MT contains an amino-terminal com-
mon region with ST that binds Hsc70 and PP2A. The unique region of MPyV MT con-
tains multiple phosphorylation sites that lead to the activation of various cellular factors.
A carboxy-terminal transmembrane (TM) domain is also present. HSC70: heat shock
chaperone 70, PI-3K: phosphatidylinositol 3-kinase, PLCγ-1: phospholipase C gamma
1, PP2A: protein phosphatase 2A, Shc: Src, TKs: tyrosine kinases, TM: transmembrane
domain
Like ST, MT can bind both isoforms of PP2A (Aα and Aβ) [113], which activates
c-Jun via this interaction [114]. In addition, MT can associate and sequester Src
family tyrosine kinases (TKs) in a PP2A-dependent manner [115]. In addition, the
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amino-terminal domain of MT is involved in this function [115] [116]. Binding of
Src TKs to MT leads to the phosphorylation of MT at residues 250, 257, 315, and
322 [117]. Phosphorylation at any of the specific sites then leads to the activation
of a number of important pathway initiators. For instance, phosphorylation of
Tyr 315 leads to the activation of phosphatidylinositol 3’-Kinase (PI-3K), and is
associated with MT-facilitated tumourigenesis [118].
1.2.5.4 Other T antigen locus transcripts
LT, ST, and MT are the three most widely investigated of T antigen transcripts. In
addition to these, many polyomaviruses encode other proteins in the early gene
locus. For example, SV40 produces 17kT via alternative splicing from the amino-
terminus of LT [119]. The functions of 17kT are not clear, although there is some
evidence that it may contribute to promoting cell proliferation [120]. In addition,
17kT can rescue LT activity and immortalise human fibroblasts [121].
Another polyomavirus that encodes additional early proteins is JCPyV: T135,
T136 and T165. T135 and T136 are composed of the amino-terminus of LT, while
T165 comprises the amino-terminal LT region and the last 32 amino acids of LT
carboxy-terminus [122]. These proteins are expressed during JCPyV lytic infec-
tion, and play an important role in viral replication [123]. In addition, there is
evidence to suggest that these alternative T proteins may contribute to cellular
transformation [124].
MCPyV also encodes additional early proteins which will be discussed in Sec-
tions 1.4.2.2.3 and 1.4.2.2.4.
1.2.6 Polyomaviruses and cancer
A number of polyomaviruses have been shown to be directly oncogenic, includ-
ing the model viruses SV40 and MPyV. Both of these classic polyomaviruses can
transform rodent cells and have been demonstrated to cause tumours in mice
[125], [126]. Polyomaviruses tend to have a narrow host and cell specificity.
Therefore only one or a few cell types will permit productive replication of a
specific polyomavirus, and may contribute to the ability of several different poly-
omaviruses to transform non-permissive cells.
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1.2.6.1 Polyomavirus oncogenicity
Polyomaviruses have been observed integrated into host cell chromosomal DNA.
This occurs when the viruses infect non-permissive cell lines, and has previously
been demonstrated for SV40 [127], MPyV [128], JCPyV [129] and BKPyV [130],
alongside MCPyV, whose integration is discussed in detail in Section 1.4.4. How-
ever, the role of most human polyomaviruses in cancer remains controversial.
JCPyV and BKPyV were proposed to have oncogenic properties soon after their
initial isolation [131] [132]. However, their role in cancer remains controversial
due to high seroprevalence in healthy individuals. There have been single case
reports of BKPyV oncogenicity in urothelial and renal tubular malignancies [133]
[134] in kidney transplant patients. Conversely, in other reports, BKPyV is not
found convincingly in such tumors [135] [136]. However, there are also reports
on the detection of BKPyV DNA in colorectal, pancreatic, brain, prostate, and a
range of sarcoma tumours [137]. All in all, no causative link has been established.
At the moment, WHO classifies BKPyV and JCPyV as “possibly carcinogenic to
humans” (Group 2B) [138].
Currently there is no evidence to suggest that KIPyV and WUPyV are oncogenic,
although KIPyV VP1 DNA was found in 9/20 lung cancer cases of unknown
origin [139]. HPyV6, HPyV7, TSPyV, HPyV9, and HPyV10 have not been con-
clusively linked to any malignancies. In fact, the only human polyomavirus cur-
rently known to cause cancer is MCPyV.
A striking example of an oncogenic polyomavirus in a non-human mammalian
species is the racoon polyomavirus (RacPyV). It has been associated with 100% of
neuroglial tumours in wild-ranging racoons. Interestingly, it does not appear to
integrate into the host genome and persists in tumours in an episomal form [140].
1.2.6.2 The large T antigen in transformation
In oncogenic polyomaviruses, the T antigen transcripts play the major role in cel-
lular transformation. It appears that the DnaJ domain is of vital importance for
transformation as well as for viral replication, as SV40 LT and ST DnaJ deletions
inhibit transformation [141]. The DnaJ domain, through its functions in promot-
ing S-phase entry, likely promotes replication in permissive cells and transforma-
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tion in non-permissive cells. In addition, the DnaJ domain contains the conserved
Cr1 domain, which functions analogously to the adenovirus E1A protein. Both
LT and E1A bind p300, the cellular transcriptional co-factor, facilitating cellular
transformation [142].
SV40 LT alone can transform rat fibroblast cells [143], due to LT binding to the
tumour suppressor proteins, p53 and pRb [62]. The cell cycle checkpoint protein
p53 is activated by cell stress and blocks DNA replication under non-permissive
conditions. p53 promotes the expression of genes that induce DNA repair, cell cy-
cle arrest, and apoptosis [144]. Binding of SV40 LT to p53 inhibits its activity and
induces inappropriate cell proliferation [10]. pRb controls entry into S-phase, and
is bound to E2F outside of this part of the cell cycle. pRb phosphorylation dis-
rupts this complex and permits E2F to activate the transcription of genes needed
for cell cycle progression. LT binding to pRb inhibits its interaction with E2F
and, again, induces cell proliferation [72]. Figure 1.7 illustrates the effect of LT
on cell proliferation. However, mutations within LT that do not abrogate its abil-
ity to bind either pRb or p53 can inhibit transformation, thus other LT functions
must contribute to tumourigenesis [145]. For example, BKPyV and SV40 LT have
the ability to induce mutagenic effects in the host DNA by more than 100-fold,
through LT binding to Mre11, a double-stranded break response component [62]
[60].
As referred to in Table 1.3, LT can bind to a whole host of different cellular fac-
tors, and these interactions can also play a role in transformation. For example,
the interaction of SV40 LT with cullin7 is important in tumourigenesis, as LT mu-
tants that are defective in cullin7 binding are unable to transform primary mouse
embryo fibroblasts [146]. IRS1 is another important binding partner, and domi-
nant negative IRS1 expression inhibits anchorage-independent growth of JCPyV
LT-transformed cells [78]. This suggests the possibility that LT utilises more than
one mechanism for inducing anchorage-independent growth. Another contribut-
ing mechanism of LT-induced tumourigenesis is via the Wnt pathway, which
has been associated with tumour formation and progression [147]. JCPyV LT
can directly bind β-catenin, a component of this pathway, and this interaction
is thought to enhance the stability of β-catenin and enhancing activation of tar-
get genes, such as c-myc [79]. Furthermore, thyroid embryonic factor-1 (TEF-1),
a transcription factor, has been identified as a binding partner of SV40 LT. This
interaction allows LT to inhibit TEF-1-mediated repression of the late viral pro-
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Figure 1.7: Effect of LT on cell proliferation. Upon MCPyV infection and T antigen
expression, LT binds the regulatory protein pRb, thus inactivating it. This allows E2F to
activate the transcription of cell cycle progression-associated genes, which switches the
cell into S-phase and leads to cell proliferation. E2F: transcription factor E2F, LT: large T
antigen, pRB: retinoblastoma protein.
moter, thereby stimulating DNA replication [81]. It may also play a role in trans-
formation, as LT mutants unable to bind TEF-1 showed reduced numbers of foci
in transformation assays [148].
1.2.6.3 The small T antigen in transformation
In SV40 and other oncogenic polyomaviruses, ST plays an accessory role in trans-
formation. The interaction of ST with PP2A stimulates cell entry into S-phase,
which in non-permissive cells can contribute to cellular transformation. When
LT expression is low, ST is required in SV40-driven transformation of rodent cells
[149]. Interestingly, for SV40 to fully transform human cells, both LT and ST
expression is required, in combination with oncogenic H-ras and hTERT [150].
In this setting, ST is essential for cell cycle progression, anchorage independent
growth, and transformation [150].
The ST-PP2A interaction (Figure 1.8) inhibits the dephosphorylation, promoting
stabilisation of c-myc [151], an important transcription factor [152]. This effect
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alters cell proliferation, cell growth, and apoptosis signalling, all of which can
contribute to transformation [153]. In addition, ST activates a number of other
transcription factors, e.g. AP-1, CREB, and NF-κB, all of which have been impli-
cated in tumourigenesis [154] [155] [156]. ST can also induce the PI-3K pathway
activation, which has been implicated in tumourigenesis [157]. The result is the
phosphorylation of targets like Akt, a Ser/Thr kinase important in cell persis-
tence, metabolism, and angiogenesis [100].
ST
B 
subunit
A subunit
PP2A
C subunit
PP2A
ST
Transformation
A subunit
C subunit
Figure 1.8: Interaction of ST with PP2A. Polyomavirus ST competes with the B subunit
of PP2A for binding to the structural A subunit and the catalytic C subunit. In SV40, this
interaction between ST and PP2A Aα leads to cell transformation. Although the interac-
tion of MCPyV ST with PP2A Aα may not be necessary for transformation, interaction
with PP2A Aβ or the related PP4C may play a role. A subunit: scaffold, B subunit: regu-
latory, C subunit: catalytic, PP2A: protein phosphatase 2A, ST: small T antigen.
Another fascinating aspect of the role ST plays in transformation is the upregula-
tion of telomerase upon SV40 ST expression, which together with the ST-induced
inhibition of Akt dephosphorylation [158] promotes an increase in telomerase
phosphorylation and activity, leading to cell immortalisation. In addition, the
ST-PP2A interaction may have an effect in the hyperphosphorylation of Bub1, a
mitotic spindle checkpoint protein [159], which can induce tumourigenesis and
aneuploidy [160].
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1.2.6.4 The middle T antigen in transformation
Unlike SV40 and many other polyomaviruses, MT is thought to be the major
transforming factor in rodent polyomaviruses. MPyV MT expression alone has
been shown to induce transformation in rat cells [161]. Structurally, the carboxy-
terminal hydrophobic region is required for transformation, as deletion of the last
six amino acids of this region fully ablates the ability of MT to induce transforma-
tion [162]. Furthermore, both the amino-terminal and carboxy-terminal regions
are required for MT binding to various cellular protein kinases [116] [162], and
through these interactions, as well as with PP2A, MT-induced transformation is
enhanced.
1.3 Merkel cell carcinoma
Merkel cell carcinoma (MCC) was first described in 1972 by Cyril Toker [163], as
a flesh-coloured or bluish-red glassy painless nodule with solid trabeculae in five
different areas (forearm, lip, face, leg and buttock) of two older men and three
older women. Toker named the cancer trabecular carcinoma of the skin to de-
scribe these tumours, due to the assumption that they represented an endocrine,
sweat gland-derived carcinoma.
MCC is now described as a rare and highly malignant primary neuroendocrine
carcinoma of the skin. Over 90% of cases arise in sun-exposed areas of the body,
particularly around the head and neck. This suggests that sunlight, primar-
ily as ultraviolet radiation, plays a role in the development of MCC. MCC can
also develop on the trunk and genitals but at a frequency of under 10% [164].
MCC metastasises to other parts of the body by transiting through the lymphatic
drainage [165], and metastases have been reported at distant sites including the
pancreas and breast [166], the heart [167], and the palatine tonsil [168].
1.3.1 Merkel cells
Merkel cells are mechanoreceptors, first described by the German histopatholo-
gist Friedrich Sigmund Merkel at the end of the 19th century [169]. The Merkel
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cell-neurite complex is one of the four main classes of mammalian sensory re-
ceptors, for sensing light touch, shape, texture, and curvature [170]. Figure 1.9
shows that this receptor complex is made up of Merkel cells situated at the epi-
dermal/dermal border and the afferent somatosensory fibres that stimulate them
[169]. These complexes are located in touch sensitive regions of the skin, e.g. sur-
faces of the hands and feet, whisker follicles, and touch domes, i.e. specialised
epithelial structures in hairy skin [171].
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Figure 1.9: Skin layers in the context of Merkel cells. All skin layers are shown, as well
as the Merkel cell-neurite complex at the epidermal/dermal border.
Merkel cells are oval and approximately 10–15 µm in diameter with spinous pro-
jections on the surface [171]. The exact mechanism of action of Merkel cells is as
yet unclear, although there is evidence that neuropeptides accumulate near the
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nerve fibre junctions and are required for synaptic transmission via voltage gated
ion channels [172]. In addition, histochemical markers indicate that Merkel cells
may also act in a paracrine manner [172].
The origin of Merkel cells was disputed for a long time. Conflicted evidence
suggested descent from skin or from the neural crest. Atoh1 is a transcription
factor expressed by and necessary for the production of Merkel cells [173] [174].
Selective deletion of Atoh1 from the neural crest in mice had no effect on the
Merkel cell population, while deleting the gene from the skin lineage resulted in
the loss of Merkel cells in all areas of the skin. This study provided conclusive
evidence that mammalian Merkel cells are of epidermal origin [170].
1.3.2 Merkel cell carcinoma presentation
MCC primary tumours present as pink or purple nodules, less than 2mm in di-
ameter, or as a mass more than 2mm in diameter (Figure 1.10A) [175]. These
tumours are visibly similar to small-cell lung carcinoma and Ewings sarcoma tu-
mours [176], and have historically been difficult to identify.
A B
Figure 1.10: Merkel cell carcinoma presentation. (A) A primary MCC tumour nodule
present on the leg of a patient (provided by Howard Peach, Leeds Teaching Hospital
NHS Trust, UK). (B) MCC tumour cells characterised by dispersed granular chromatin,
scanty cytoplasm and large nuclei [177].
Under the microscope, an MCC tumour appears as a lesion of nested or stranded
small round cells, with an oval or round nucleus, dispersed granular chromatin
and scanty cytoplasm, in a bed of vascular and infiltrating cells (Figure 1.10B)
[178]. Recently, an effective detection system has been established, based on the
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findings that MCC cells display a specific arrangement of cytokeratin 20 (CK20)
filaments [179]. CK20 is now used as a specific and highly sensitive MCC biomarker
which can clearly distinguish MCC from other tumours.
On the other hand, while most MCC tumours are CK20-positive and CK7-negative,
a few CK20-negative and CK7-positive tumours have been characterised [180].
Therefore, several other biomarkers are used, such as chromatogranin, somato-
statin, and neuron-specific enolase [179] [181]. Overall, clinical MCC diagnosis
normally includes reactivity to CK20, a thyroid transcription factor, leukocyte
common antigen, and one of the above neuro-endocrine markers [176].
1.3.3 Merkel cell carcinoma epidemiology
MCC is considered to be a rare cancer. The annual incidence of MCC is 0.6 per
100,000, but is increasing, with around 1,600 new cases per year in the US [182].
Overall, there has been a tripling of cases in the last 20 years [183], and this rise
in MCC is a worldwide trend. In Australia, between 1986–2001, the age-adjusted
incidence rose at an annual increase of 8% [184]. In the Netherlands, the inci-
dence increased from 0.17 per 100,000 in 1993–1997 to 0.35 per 100,000 in 2003–
2007 [185]. The median age at diagnosis is 76.2 years for women and 73.6 years
for men. Only 4% of patients are diagnosed at 49 years or younger, and it is ex-
tremely rare in children [186]. MCC cases are 11-fold to 13-fold greater in patients
with AIDS and 5-fold to 10-fold greater for people with a solid organ transplant
[187]. 66% of MCCs present with local disease, 27% with nodal disease and 7%
metastatic disease. Patients with local disease had a 64% relative survival at five
years, as compared to 39% in regional nodal disease and 18% in metastatic dis-
ease [188]. The increase in MCC incidence is partially due to recent advances in
diagnostic techniques, especially CK20 staining.
UV light appears to be an important factor in MCC. For example, there is a
positive correlation between geographic UVB radiation indices and age-adjusted
MCC incidence among Caucasians [184]. In general, pale skin is a risk factor
for MCC, with 94.9% of patients being of European origin with tumours in the
head and neck region, and patients of African origin making up only 1% of MCC
cases [186]. Immunosuppression is another known risk factor for the develop-
ment of MCC, specifically in immunosuppressed patients with T-cell dysfunc-
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tion, i.e., solid organ transplant recipients, AIDS patients and chronic lympho-
cytic leukemia patients. Interestingly, there have been cases of MCC regressing
following improvement in immune [189] function and sudden clearance of MCC
after recognition by the immune system [190].
1.3.4 Merkel cell carcinoma prognosis and treatment
The clinical staging system for MCC is a four-tier arrangement. Stage I disease is
classified as a localised tumour with a nodule of less than 2 mm, stage II disease
as a localised tumour with a mass of more than 2 mm, stage III disease as a re-
gional metastasis, and Stage IV disease as a distant metastasis [191]. This is the
general system, and it can be modified to reflect individual differences in regional
metastases and other factors [192].
MCC is highly aggressive, with 28% of patients dying within the first 2 years of
diagnosis and over 55% of patients dying within 5 years due to the high rate of
metastasis [193]. 45% of MCCs recur locally, 70% present with early involvement
of local lymph nodes, and half of MCCs result in distant metastases. The mortal-
ity rate for patients with distant metastases is 80% [194]. This high mortality rate
of MCC is due to the metastatic nature of the tumour [182]. Despite this, there are
currently no specific therapeutic treatments available for MCC.
Currently MCC is treated with a wide surgical excision of the primary tumour, in-
cluding a pathological verification of complete tumour removal, followed by ion-
ising radiation therapy to decrease the incidence of local recurrence [195] [176]. If
the tumour has metastasised to local lymph nodes, the treatment involves surgi-
cal removal of tumours, lymphadenectomy, and radiation therapy at the excision
sites and lymph nodes [191]. Distant metastasis is treated with broad-spectrum
chemotherapy, including cyclophosphamide, anthracyclines, and etoposide. The
prognosis upon diagnosis of distant metastases has a median survival of 21.5
months [196].
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1.4 Merkel cell polyomavirus
MCPyV is a double-stranded DNA virus of the Polyomaviridae family. It was dis-
covered in 2008 by Patrick S. Moore and Yuan Chang at the University of Penn-
sylvania, who utilised digital transcriptome subtraction (DTS), a novel method
of detecting viruses in cancerous tissue. DTS involves extracting mRNA from
tumour cells, converting it to cDNA to prepare a library, and then pyrosequenc-
ing. The cDNA obtained is then compared to known human sequences, and
matching stretches of DNA are subtracted, leaving the remainder as likely non-
human. The remaining sequences are then compared against the pathogen se-
quence database. The analysis highlighted a sequence related to polyomaviruses,
but distinct enough to be considered a novel virus [20].
3’ rapid amplification of cDNA ends (3’-RACE) followed by viral genome walk-
ing were used to generate a complete circularised MCPyV genome. Generation
of identical RACE products from both primary and metastatic tumours found in
lymph nodes indicated clonal viral integration prior to tumour formation and
metastasis [20]. This suggests that MCPyV is not a passenger virus, but a con-
tributing factor to MCC development and progression.
Overall, MCPyV is thought to be clonally integrated into and thus to be the
causative agent of MCC in 80–97% of cases, depending on the technique utilised
[20] [197].
Although MCC is a rare disease, MCPyV is prevalent in the general popula-
tion. Enzyme-linked immunosorbent assays (ELISA) that detect MCPyV struc-
tural proteins VP1 and VP2 highlight the fact that 50% of children under 15 and
80% of healthy adults are infected with MCPyV. Therefore, it is now thought that
MCPyV is a common skin commensal [198].
1.4.1 Merkel cell polyomavirus phylogeny
A number of phylogenetic studies of human polyomaviruses have been con-
ducted, using VP1, VP2 and LT sequences (Figure 1.11) [36]. Initially, it was
thought that MCPyV is most closely related to the African Green Monkey Lym-
photrophic polyomavirus [199], but more recent analysis suggest that it is more
closely related to MPyV and Chimpanzee polyomavirus (ChPyV), as these viruses
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share high sequence homology of their VP2 and LT genes [36]. In addition, the
MCPyV VP1 gene is closely related to that of ChPyV and HPyV9 [36].
MCPyV is currently classified as belonging to the Orthopolyomavirus genus of
the Polyomaviridae family [200]. Interestingly, MCPyV LT, VP1, and VP2 all share
a high degree of sequence homology with TSPyV [36]. This may be reflected in
the fact that both MCPyV and TSPyV are common skin commensals.
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Figure 1.11: Merkel cell polyomavirus phylogeny. Whole genome nucleotide sequence
analysis was performed using a maximum likelihood phylogenetic analysis. Phyloge-
netic analysis suggests that among human polyomaviruses MCPyV is most closely re-
lated to TSPyV, HPyV9, HPyV10 [201].
There also seems to be variability within the MCPyV genome. For example,
Japanese and Asian strains of the virus form a distinct dominant clade, as do
Caucasian strains [202]. It is yet unclear whether differences between clades af-
fect MCPyV pathogenesis, but this is a novel and important field of research.
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1.4.2 Merkel cell polyomavirus genome organisation
The MCPyV genome structure is closely related to that of other polyomaviruses.
It comprises 5387 base pairs, with a non-coding control region (NCCR), that con-
tains the bipartite origin of replication separating the early and late gene coding
regions. This separation allows for temporal control of viral gene expression [20].
Figure 1.12 illustrates the MCPyV genome.
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Figure 1.12: The Merkel cell polyomavirus genome. NCCR contains the bipartite ori-
gin of replication. The early gene region encodes LT, ST, 57kT, ALTO, and the miRNA.
The late gene region encodes the capsid proteins (VP1-3). 57kT: 57 kiloDalton T antigen,
ALTO: alternative large T open reading frame, LT: large T antigen, miRNA: microRNA,
NCCR: non-coding control region, ST: small T antigen, VP: viral protein.
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1.4.2.1 Merkel cell polyomavirus NCCR
The MCPyV NCCR contains a 71 base pair long origin of replication (ori). Similar
to other polyomaviruses, ori has an AT-rich region, an early enhancer domain and
a binding site for LT to initiate viral replication. The LT binding site is made up of
ten guanine-rich pentanucleotide sequences: eight corresponding to the general
polyomavirus consensus of 5’-GAGGG-3’, one with a 5’-GGGGC-3’ sequence and
one with a 5’-GAGCC-3’ sequence. The proximity and number of sequences are
distinct from other polyomaviruses [203].
1.4.2.2 Merkel cell polyomavirus T antigen locus
The MCPyV T antigen locus comprises approximately 3,000 base pairs in length,
and is transcribed as a single transcript. Post-transcriptional splicing produces
LT, ST, and the 57 kiloDalton (57kT) T antigens [20]. MCPyV LT, ST and 57kT
all share the same amino-terminal region including the DnaJ domain. However,
alternative splicing produces a distinct carboxy-terminus, which determines the
variability in the functions of the spliced products. Figure 1.13 illustrates the
different T antigen locus-encoded proteins.
1.4.2.2.1 Merkel cell polyomavirus LT
MCPyV LT consists of 816 amino acids and is spliced together from two exons.
It has numerous functions in MCPyV infection, including the initiation of viral
replication and manipulation of the host cell cycle, which will be discussed in
more depth below. MCPyV LT contains several conserved domains found across
polyomaviruses: the pRb binding domain, a NLS, and the OBD region. The
carboxy-terminal half of LT has viral DNA binding and helicase features [204].
The presence of a NLS allows MCPyV LT to localise to the nucleus when ex-
pressed in mammalian cells [205]. In general, MCPyV LT binds to similar cellular
factors elaborated on in Section 1.2.5.1 and Table 1.3. It has equivalent DNA-
binding and helicase functionality as SV40 LT [206]. However, despite the simi-
larities in binding partners, MCPyV LT shares only 34% sequence identity with
SV40 LT [204]. It also contains the MCPyV unique region (MUR), a 200 amino
acid sequence found between the first exon and the OBD [207]. This unique re-
gion binds the host factor Vam6p and causes it to relocalise to the nucleus [207].
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Figure 1.13: The Merkel cell polyomavirus T antigen locus and its gene products. The
schematic shows the relative locations of each gene that encode specific protein binding
domains and splicing patterns associated with differential splicing of the primary early
transcript. The three T antigens are LT, ST and 57kT. All three encode CR1 (LXXLL) and
DnaJ (HPDKGG) domains. ST also contains two PP2A Aα binding sites (R7 and L142),
a PP2A Aβ/PP4C binding site (amino acids 97–111) and an large T antigen-stabilisation
domain (LSD, amino acids 91–95). LT shares the pRb binding domain with 57kT and has
unique origin binding (OBD), zinc finger, leucine zipper, ATPase and helicase domains.
The MCPyV-unique region (MUR) of LT contains the hVam6p binding site.
In addition, the MUR encodes a miRNA [208].
1.4.2.2.2 Merkel cell polyomavirus ST
MCPyV ST consists of 186 amino acids, with a unique carboxy-terminal region
produced by transcriptional read-through of the exon splice site used by LT and
57kT. ST localises to the nucleus and the cytoplasm [60]. It contains the common
polyomavirus PP2A binding site [20]. However, recently, an alternative PP2A
and/or protein phosphatase 4C (PP4C) binding site near the carboxy-terminus
has also been discovered, which may have a role in protecting MCPyV from
the cellular immune response [209] and in cell motility [210]. MCPyV ST also
contains a LT-binding domain (LBD), which stabilises LT and aids in the repli-
cation of the MCPyV genome [211]. In addition, recent evidence suggests that
MCPyV ST may also be an iron-sulphur cluster protein, which may also enhance
LT-mediated viral replication [212].
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1.4.2.2.3 Merkel cell polyomavirus 57kT
MCPyV 57kT is 432 amino acids in length. It is the product of alternative splicing
linking three exons, and shares the DnaJ domain and CR1 epitope with LT and
ST, as well as the MUR region and the pRb-binding domain. 57kT is homologous
with SV40 17kT [44], which is known to promote cell proliferation [120].
1.4.2.2.4 Merkel cell polyomavirus ALTO
As well as the three T antigen products, the MCPyV early gene locus also encodes
a fourth protein, the alternative T antigen open reading frame (ALTO). ALTO is
encoded by overprinting within the T antigen locus, and is transcribed from the
MUR region of LT. Phylogenetic analysis shows that ALTO may be evolutionarily
related to MPyV MT. It has a hydrophobic carboxy-terminus, analogous to MT,
and this region is required for its subcellular localisation [43]. No known function
of ALTO has been described to date.
1.4.2.3 Merkel cell polyomavirus late proteins
The MCPyV late gene region contains three open reading frames which encode
the capsid/structural proteins, VP1, VP2, and VP3. Three structural proteins are
typical for all polyomaviruses. VP1 is the major capsid protein, VP2 is the minor
capsid protein, and they have been shown to self-assemble into virus like parti-
cles (VLPs) in vitro [213] [214]. It is unclear whether VP3 is expressed at all, as its
sequence is not conserved and it does not form part of the capsid [215].
The MCPyV capsid is non-enveloped and icosahedral, made up of 72 pentamers
of VP1. The overall capsid size is around 40–55 nm, similar to other polyomaviruses,
with a VP1 to VP2 ratio of 5:2 [215]. The structure of VP1 monomers has been
crystallographically shown to be two antiparallelβ sheets that form aβ-sandwich
structure with a jelly-roll topology. The overall shape of VP1 is a symmetrical,
ring-shaped homopentamer arranged around a central axis with variable loops
that create unique interaction surfaces on the outside of the pentamer. It also has
a NLS at its amino-terminus, showing a diffuse nuclear staining pattern [216].
MCPyV VP2 appears to be superfluous to entry in most cell lines studied, and
it does not affect viral DNA packaging, viral protein trafficking, or cell receptor
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binding. It is possible that myristoylation of VP2 may help disrupt cellular mem-
branes [216]. VP2 lacks a NLS, but co-expression with VP1 redistributes VP2 into
the nucleus [215].
1.4.2.4 Merkel cell polyomavirus miRNA
SV40, BKPyV and JCPyV all encode microRNAs (miRNAs) which regulate early
gene transcription [217] [218]. In SV40, these miRNAs are complementary to
and target early gene transcripts for degradation at late stages of infection [217].
MCPyV encodes a 22-nucleotide-long miRNA, MCPyV-miR-M1-5p, antisense to
the LT gene sequence [208]. It regulates the expression of the early genes and re-
duces levels of early gene transcripts in a negative feedback loop to facilitate the
switch from early to late gene expression [208]. It may also have a role in trans-
formation, as its expression is preserved in at least half of MCPyV-positive MCC
tumours [219].
1.4.3 Merkel cell polyomavirus life cycle
The cellular tropism for MCPyV infection has not yet been firmly established,
as MCPyV was discovered within a tumour rather than within the milieu of
its natural host. The origin of MCC as well as the fact that MCPyV virions
are shed from the skin of healthy adults indicate an epidermal source of host
cells [34]. However, recent data suggests human dermal fibroblasts as natural
host cells for MCPyV, which can also support productive MCPyV infection [220].
In addition, MCPyV pseudovirions can infect human skin-derived primary ker-
atinocytes (HEKa) and transformed melanocytes, but not primary transformed
keratinocytes (HeCat) or primary melanocytes, or, indeed, sixty human tumour
cell lines investigated [221]. Regardless, a MCPyV genome capable of produc-
tive viral infection has been established [215] [222]. In one instance, a full-length
wild-type MCPyV genome was isolated from surface skin swabs of healthy adult
volunteers, and the DNA was amplified using random hexamer-primed rolling
circle amplification (RCA) [215]. In the other case, a synthetic MCPyV genomic
clone was generated from sequence data of MCPyV genomes [222]. Both of these
approaches have produced plasmids, such as pR17b, containing the full recircu-
larised MCPyV genome.
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Currently, efficient replication of the MCPyV viral genome, both early and late
gene expression and viral particle formation, can be achieved by transfection of
the pR17b plasmid in HEK-293 cells that overexpress the MCPyV LT and ST in
trans, known as HEK-293-4T cells [223]. This viral replication system is key to
understanding the MCPyV life cycle and viral-host interactions that contribute
to MCC pathology. As mentioned above, human dermal fibroblasts have been
suggested as the natural host for MCPyV, allowing a new cell culture model to be
developed. MCPyV infection of dermal fibroblasts is facilitated by epithelial and
fibroblast growth factors as well as the β-catenin signalling pathway [220]. This
cell culture model will most likely be invaluable in future studies of the viral life
cycle and MCC tumourigenesis.
1.4.3.1 Merkel cell polyomavirus attachment and entry
Most polyomaviruses, such as MPyV, SV40, and BKPyV use sialic acid-containing
glycolipids, or gangliosides, for initial attachment to host cells [224] [225]. How-
ever, MCPyV appears to involve glycosaminoglycans, in particular heparan sul-
phate and chondroitin sulphate, for initial attachment [223]. In addition to this
initial binding, binding to gangliosides, specifically Gt1b, which carries three dif-
ferent sialic acids, is required for post-attachment entry [223]. MCPyV can still
attach to cells deficient in gangliosides, although this leads to impaired MCPyV
gene transduction [223]. X-ray crystallography has determined that the MCPyV
VP1 has a shallow binding site for cellular glycans containing sialic acid with a
Neu5Ac moiety, specifically a linear Neu5Ac-α2,3-Gal motif. Interestingly, mu-
tating these binding sites has no effect on initial virus attachment [216]. The cur-
rent MCPyV entry model is a two-step attachment-and-entry process involving
two separate types of host cell plasma membrane molecules, as shown in Figure
1.14.
The fact that MCPyV uses glycosaminoglycans for cellular attachment is similar
to papillomavirus entry [226]. Papillomaviruses are exclusively tropic for ker-
atinocytes, a type of epithelial cell. This similarity may be a possible example of
convergent evolution, and further suggests the skin as host to MCPyV.
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Figure 1.14: MCPyV attachment and entry. MCPyV entry is a two-step attachment-and-
entry process. MCPyV binds GAG, specifically heparan sulphate as the initial mode of
attachment. MCPyV then binds a ganglioside with a Neu5Ac motif to facilitate viral
entry. GAG: glycosaminoglycan, Neu5Ac: N-acetylneuraminic acid-α2,3-galactose.
1.4.3.2 Merkel cell polyomavirus replication
MCPyV is able to complete its replication cycle and form virions without induc-
ing tumourigenesis in permissive cells. As other small DNA viruses, MCPyV
relies upon many different host cell factors to replicate its genome. The expres-
sion of viral T antigens is essential for this function, and they are transcribed
immediately upon virus entry into the nucleus of the host cell. LT and 57kT are
transcribed first, with ST shortly afterwards [227]. The T antigens force the host
cell to enter S-phase. This alters the cellular environment, making it more hos-
pitable to viral replication.
In later stages of viral replication, it is suggested that further early gene tran-
scription is inhibited by the MCPyV miRNA, likely by causing the degradation
of early gene transcripts [208]. This then shifts the focus to the transcription of
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the late region and also to the replication of the viral genome itself.
1.4.3.2.1 The role of LT in Merkel cell polyomavirus replication
Polyomaviruses require expression of the LT antigen to initiate genome replica-
tion. LT oligomerises to form hexameric molecules, two of which bind to the ori
in a head to head orientation [228]. The LT helicase domain then unwinds DNA
and replication proceeds in a bidirectional manner, with the two hexamers mov-
ing in opposite directions. The LT OBD interacts with the ori by recognising the
GAGGC-like motifs. A crystal structure of the ori shows that to initiate replica-
tion, three of these pentanucleotide sequences are required [229]. The number
and proximity of LT binding sites on the origin likely allows for intermolecular
OBD-OBD interactions between molecules of LT [203].
MCPyV LT is thought to function in a similar fashion to other polyomavirus LTs.
However, there are several unique MCPyV LT-host interactions that affect viral
replication. For example, MCPyV LT binds to the cytoplasmic vacuolar sorting
protein, hVam6p, via its MUR domain [207]. hVam6p is a member of the ho-
motrophic fusion and protein sorting (HOPS) complex, and it is redistributed
from the cytoplasm to the nucleus upon MCPyV LT expression, resulting in a dis-
ruption of lysosome clustering. Overexpression of hVam6p leads to a reduction
in MCPyV virus formation by more than 90%, suggesting an inhibitory role [227].
Furthermore, abrogating the hVam6p binding domain increases infectious virion
production by 4-fold to 6-fold [207] [227]. The inhibitory role of hVam6p may
function to diminish viral replication and establishing a persistent infection. An-
other factor important for MCPyV LT-mediated viral replication is the chromatin-
associated bromodomain containing protein 4 (Brd4). Brd4 is a member of the
BET protein family and plays a role in recruitment of cellular replication factors
required for viral replication. The interaction of MCPyV LT with Brd4 helps re-
cruit replication factor C (RFC) to MCPyV replication complexes [230]. RFC fa-
cilitates loading of the PCNA clamp and tethering of the processive DNA poly-
merase δ, and this action allows for the elongation of MCPyV DNA [227]. The
importance of the MCPyV LT-Brd4 interaction is highlighted by findings that the
expression of dominant negative Brd4 inhibits MCPyV replication [230]. In addi-
tion, DNA damage response (DDR) factors are also involved in MCPyV replica-
tion [231], with both DDR pathways, ATM and ATR, being involved. MCPyV LT
expression relocalises DDR factors to the nucleus, into the replication foci where
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they co-localise with LT [231]. Interestingly, both DDR [232] and Brd4 [233] acti-
vation and recruitment have been observed in HPV replication. These findings
stress the importance of the DDR pathways in viral replication across multiple
viral families.
1.4.3.2.2 The role of ST in Merkel cell polyomavirus replication
While MCPyV LT is the primary factor in the replication of MCPyV DNA, it does
not facilitate replication efficiently on its own. MCPyV ST is required to enhance
replication, and its depletion leads to inhibition of replication [203]. This is in
contrast to SV40 ST, as its co-expression has little effect on SV40 LT-mediated vi-
ral replication [234]. Interestingly, the mechanism by which MCPyV ST enhances
viral replication does not depend on its ability to bind PP2A or Hsc70, and the
equivalent SV40 ST domains cannot enhance MCPyV LT-mediated viral replica-
tion [234]. This suggests an alternative mechanism for MCPyV ST enhancement
of viral replication.
One possible mechanism by which MCPyV ST could function in replication en-
hancement is by promoting the hyperphosphorylation of the translation regula-
tor eIF4E binding protein (4E-BP1) [234]. This leads to increased production of
cellular proteins, including host factors necessary for viral replication. In addi-
tion, MCPyV ST targets the cellular SCF ubiquitin E3 ligase complex, of which
Fbw7 is the recognition component [235]. This complex targets MCPyV LT for
proteasomal degradation, but binding of MCPyV ST to SCFFbw7 via its LSD re-
gion inhibits MCPyV LT degradation [211]. This prevents the turnover of MCPyV
LT, whose half-life without MCPyV ST expression is 3-4 h, going up to 24 h when
the two proteins are co-expressed [211].
Overall however, neither MCPyV ST nor MCPyV 57kT are sufficient for replica-
tion in the absence of MCPyV LT. Co-expressing MCPyV 57kT with MCPyV LT
shows no increase in replication efficiency [203].
1.4.3.3 Merkel cell polyomavirus and the immune response
In order to establish an infection, viruses need to evade the cellular immune
response. Host cells use innate immunity as a barrier against invaders, and
pathogens of all types have evolved mechanism to evade or subvert it. MCPyV
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T antigens appear to play an intriguing role in overcoming the innate immune
response to allow the establishment of viral infection.
MCPyV ST downregulates the innate immune response by interfering with the
NF-κB family of transcription factors [209]. NF-κB is an important regulator of
a number genes involved in both the inflammatory and antiviral response. It
is activated in response to various innate immunity signalling, for instance from
pattern recognition receptors (PRRs). PRRs detect pathogen associated molecular
patterns (PAMPs), e.g. proteins or nucleic acids. PAMP recognition results in
the production of antimicrobial peptides, cytokines, and chemokines capable of
fighting against and clearing microbial infections [236].
This recognition also activates a coordinated signalling cascade, leading to the ac-
tivation of the IKK complex [236] [237]. The IKK complex consists of two catalytic
components, IKKα and IKKβ, and a regulator subunit, NF-κB essential modula-
tor (NEMO). NEMO is a molecular scaffold which can recruit upstream signalling
complexes [237]. IKK activation causes the phosphorylation and degradation of
IκB, which in turn induces the release of NF-κB from the complex. Free NF-κB
translocates to the nucleus, where it stimulates the transcription of proinflamma-
tory cytokine and type 1 interferon genes [236]. Figure 1.15 depicts the NF-κB
signalling pathway.
Many viruses produce proteins that can interfere with NF-κB signalling [238],
such as HCV core protein [239] and HPV E7 [240], both of which prevent IκB
degradation. Furthermore, murine cytomegalovirus (mCMV) [241] and mollus-
cum contagiosum poxvirus [242] directly target NEMO, disrupting IKK activa-
tion. Conversely, SV40 ST upregulates NF-κB activation in a PP2A-dependent
manner, while some inflammatory targets like interleukin-8 (IL-8) are downreg-
ulated upon SV40 ST expression [107]. MCPyV ST is able to inhibit IKKα/IKKβ
phosphorylation via an interaction with NEMO, thus preventing NF-κB release
and translocation into the nucleus. This interaction appears to be dependent on
protein phosphatases PP2A Aβ and/or PP4C [209]. Moreover, a number of NF-
κB target genes are downregulated upon MCPyV ST expression, e.g. CCL20, IL-8,
TANK, and CXCL-9 [209].
Viruses also act upstream of NF-κB to inhibit receptors involved in innate im-
munity, such as Toll-like receptors (TLRs), a subset of PRRs. EBV [243], HPV
[244], and HBV [245] all downregulate TLR9 expression. TLR9 detects viral or
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bacterial double-stranded DNA containing multiple non-methylated CpG mo-
tifs [236]. Upon recognition of pathogen DNA, TLR9 activates NF-κB in im-
mune cells, which upregulates the production of inflammatory molecules [246].
MCPyV LT also inhibits TLR9 expression [247] by reducing the mRNA levels of
the C/EBPβ transactivator, a positive regulator of the TLR9 promoter. This leads
to greatly reduced binding of C/EBPβ to its response element on the TLR9 pro-
moter, therefore MCPyV LT targeting of C/EBPβ may be important in establish-
ing viral persistence [247].
It appears that MCPyV has a complex and multifaceted defence against innate
immunity, targeting different parts of the various pathways and utilising both
major T antigen products. This allows the virus to persist, and may even con-
tribute to tumourigenesis.
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Figure 1.15: NF-κB signalling in the cellular immune response. PAMP recognition by
PRRs or cytokine or TNFα stimulation of other receptors leads to the activation of the
IKK complex. Activation leads to the proteasomal degradation of IκB and the release of
NF-κB, which can then translocate into the nucleus and activate the transcription of genes
that have functions in the innate immunity. IKK: IκB kinase complex, IκB: inhibitor of κB,
NEMO: NF-κB essential modulator, NF-κB: nuclear factor κB, TNFα: tumour necrosis
factor α.
1.4.3.4 Merkel cell polyomavirus assembly and egress
Little is known about MCPyV virion assembly and egress, although more re-
search may be forthcoming with the discovery of a potentially permissive cell
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line [220]. MCPyV virions tend to cluster in the nucleus and its periphery before
egress [222]. Unlike other polyomaviruses, including SV40, JCPyV, and BKPyV,
MCPyV does not encode an agnoprotein, which is known to be important in virus
particle assembly and maturation [248]. Nor does MCPyV encode an equivalent
of the SV40 VP4, which triggers lytic virion release [249]. Therefore, an alterna-
tive mechanism must be utilised by MCPyV. It is possible that redistribution of
the lysosomal factor, hVam6p, to the nucleus by MCPyV LT contributes to egress
via lysosomal processing during virus replication [207].
Polyomavirus virion release is thought to occur primarily through cell lysis, al-
though shedding of accumulated viral particles in SV40-infected cells has also
been observed [250]. It is possible that if the natural host of MCPyV is a type
of skin cell, lysis might not be required for release, as the natural process of ker-
atinocyte desquamation may serve this purpose. The newly-developed dermal
fibroblast cell culture model may help to fully address these specific questions
about the MCPyV life cycle.
1.4.4 Merkel cell polyomavirus-induced tumourigenesis
MCPyV is a common skin commensal, usually acquired at some point during
childhood. In contrast, MCC is rare, thus the development of the cancer following
viral infection must require multiple contributing factors, such as age, immune
suppression, and UV light. MCPyV is a direct carcinogen, since it expresses onco-
proteins (the T antigens) that directly contribute to the transformation of the host
cell. Supporting evidence for this comes from MCPyV-positive MCC cell lines
which demonstrate growth arrest and cell death when both MCPyV LT and ST
protein expression is depleted [251].
The major feature of MCPyV-positive MCC tumours is the presence of mutations
in MCPyV LT that truncate it at the carboxy-terminus [42] [252]. These mutations
lead to the loss of functional domains associated with viral replication, and are
randomly distributed in different tumours, although with the consistent preser-
vation of the pRb binding site. Therefore MCPyV LT proteins in different tumours
vary in size, depending on where their specific truncating mutations lie [253].
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Figure 1.16: Merkel cell polyomavirus-induced tumourigenesis. MCPyV infection oc-
curs in childhood in most cases. Loss of immunosurveillance leads to proliferation of
the virus prior to tumourigenesis. At least two mutations are needed before MCPyV can
transform cells. In model A, the first mutation is the integration of the full-length viral
genome into host DNA, while the second mutation is the truncation of LT. In model B,
truncation of LT occurs prior to integration. These changes in the virus lead to cellular
transformation and tumour proliferation.
MCPyV-induced tumourigenesis has several key stages illustrated in Figure 1.16.
Initially, the MCPyV genome integrates into the host chromosome in a mon-
oclonal pattern [20] [254]. Upon integration, the viral genome retains the full
length MCPyV LT, which can initiate host DNA replication, and this unlicensed
replication results in fork collision and DNA breakage, thus leading to cell death
[42]. Therefore, once MCPyV integrates, there is a strong selective pressure to
eliminate MCPyV LT-mediated DNA replication and this is achieved via the trun-
cation of MCPyV LT and the resulting loss of replication capabilities [253]. This
requirement for two separate events may at least in part explain why MCPyV is
so rare. Alternatively, it may be that MCPyV LT is truncated prior to integration
[255]. To support this possibility, it has been shown that expression of truncated
MCPyV LT upon exposure of UV radiation leads to defective DNA repair, leading
to increased genomic instability which may promote MCPyV integration [256].
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1.4.4.1 The role of LT in Merkel cell polyomavirus-induced tumourigenesis
As mentioned in Section 1.4.4, MCPyV LT truncation is a defining feature of MCC
tumours. However, current evidence suggests that neither full-length nor trun-
cated MCPyV LT can initiate transformation [234]. Despite this, MCPyV LT is
expressed in 75% of MCPyV-positive MCC tumours samples, and its DNA is
present at around 5.2 copies per tumour cell [257]. This likely means that there is
a role for MCPyV LT in MCPyV-induced tumourigenesis.
One reason why MCPyV LT cannot transform cells, unlike its SV40 counterpart,
may be because all truncated MCPyV LT forms lose the p53 binding site [258].
However, truncated MCPyV LT is more effective at inducing cellular prolifera-
tion than full-length MCPyV LT, as the carboxy-terminal region, lost during trun-
cation, exhibits growth inhibitory effects [258]. It is also possible that loss of the
carboxy-terminal region prevents activation of host DDR and thus apoptosis, as
p53 is not activated. This possibility is highlighted by the findings MCPyV in-
fection results in the activation of the DDR pathway in a MCPyV LT-dependent
manner [206]. In addition, MCPyV LT maintains its pRb binding domain after
truncation, and this interaction is known to interfere with pRb binding to E2F
and thus promotes cell proliferation [259].
MCPyV LT also increases the levels of the cellular oncoprotein, survivin [259].
Survivin is a member of the inhibitor-of-apoptosis family of proteins, and it is
elevated in a number of cancers [260]. Survivin mRNA is increased 7-fold in
MCPyV-positive MCC tumours, and MCPyV LT expression alone can upregulate
survivin, whereas knocking down the T antigens decreases both the mRNA and
protein levels of survivin, leading to cell death [259]. Survivin may be a viable
drug target for MCPyV-positive MCC treatment, and a small molecule inhibitor,
YM155 is able to initiate selective MCC cell death [259].
1.4.4.2 The role of ST in Merkel cell polyomavirus-induced tumourigenesis
Unlike other oncogenic polyomaviruses, MCPyV ST seems to be the primary tu-
mourigenic factor in MCC development. 92% of MCPyV-positive MCC tumours
are positive for MCPyV ST, while only 75% are positive for MCPyV LT. Moreover,
knock down of MCPyV ST induces cell growth arrest, and expression of MCPyV
ST but not LT is sufficient to induce rodent fibroblast transformation, loss of con-
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tact inhibition, and anchorage- and serum-independent growth [234]. All these
features are typical of a viral oncogene, although it is uncharacteristic for a poly-
omavirus ST to be the main factor in tumourigenesis.
SV40 ST is an accessory to SV40-induced transformation, and primary contributes
by targeting PP2A, specifically the Aα subunit, to alter the substrate specificity
of the holoenzyme (as discussed in Section 1.2.5.2). This interaction is critical
for SV40 ST-facilitated transformation and cell proliferation. However, disrupt-
ing the equivalent MCPyV ST-PP2A Aα interaction does not reduce the ability
of MCPyV ST to induce rodent cell transformation and anchorage-independent
colony formation [234]. Thus an alternative mechanism is utilised by MCPyV ST.
One possibility is that SV40 and MCPyV ST proteins affect the PI-3K-Akt-mTOR
signalling pathway at different stages. This signalling pathway is an important
regulator of translation in tumourigenesis [261] [262] [263]. SV40 ST activates
the pathway by preventing the PP2A Aα-mediated dephosphorylation of Akt
[100], however MCPyV ST has little effect at that stage of the Akt-mTOR pathway,
instead acting downstream [234], at the level of the translation factor 4E-binding
protein 1 (4E-BP1).
Cap-dependent translation depends on the binding of the eukaryotic translation
initiation factor 4E (eIF4E) to mRNA molecules. eIF4E is part of the eIF4F com-
plex that initiates ribosome recruitment [264]. This pathway is regulated by 4E-
BP1, by binding eIF4E to prevent eIF4F complex formation [265]. 4E-BP1 is reg-
ulated by phosphorylation, whereupon it releases eIF4E, allowing assembly of
eIF4F and cap-dependent translation [266]. 4E-BP1 is phosphorylated by mTOR,
and MCPyV ST reduces the turnover of hyperphosphorylated 4E-BP1, which in-
creases eIF4F activity and thus encourages cap-dependent translation. This effect
of MCPyV ST on 4E-BP1 is independent of PP2A Aα and Hsc70 binding [234].
Figure 1.17 illustrates the different stages of the PI-3K-Akt-mTOR pathway where
SV40 and MCPyV ST proteins function.
Furthermore, the MCPyV ST LSD domain may be required for transformation,
since a mutation within this region abrogates MCPyV ST ability to transform ro-
dent cells, but does not affect the ability of MCPyV ST to bind PP2A Aα [211].
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Figure 1.17: MCPyV ST promotes cell proliferation downstream of the Akt pathway.
MCPyV ST targets the translational regulator 4E-BP1, and reduces hyperphosphorylated
4E-BP1 turnover, promoting eIF4E activity and cap-dependent translation. On the other
hand, SV40 ST promotes Akt activity by preventing PP2A-mediated Akt dephosphory-
lation. 4E-BP1: 4E binding protein 1, eIF4E: eukaryotic translation initiation factor 4E,
MCPyV: Merkel cell polyomavirus, mTOR: mammalian target of rapamycin, mTORC:
mammalian target of rapamycin complex, PI-3K: phosphatidylinositol 3-kinase, ST: small
T antigen, SV40: simian virus 40.
There is still some controversy as to the tumourigenic nature of MCPyV ST, be-
cause its levels in MCC cell lines and tissues appears to be low [267]. Regardless,
it is more commonly detected in MCC tissues than MCPyV LT, and MCPyV ST
depletion inhibits MCPyV-positive MCC cell growth [234]. It may also be the
case that MCPyV ST is essential for initial transformation while MCPyV LT is
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more important in subsequent persistence and proliferation of tumour cells.
1.5 Merkel cell carcinoma treatment
Conventional MCC treatment depends on the stage of cancer progression. If the
tumour is localised, the standard therapy is surgical excision with 2-3 cm mar-
gins. If the cancer has metastasised into the regional lymph nodes, these are
excised together with the primary tumour, and adjuvant radiotherapy to the tu-
mour and regional lymph node sites is given. This mode of treatment has been
associated with reduced risk of regional relapse [268]. MCC is a radiosensi-
tive tumour, thus if surgery cannot be performed, radiation on its own can also
be effective [269] For metastasised MCC, various regimens of broad-spectrum
chemotherapy are used, such as anthracyclines, cyclophosphamide, etoposide,
and platinum derivatives, alone or in combination, with a notoriously poor prog-
nosis [196]. Therapies available for MCC at the moment are generic, but this is
likely to change as the causative agent for the majority of cases has been discov-
ered, and thus new drug targets are being researched. As MCPyV T antigen ex-
pression is necessary for the survival of MCPyV-positive MCC cells, both MCPyV
LT and ST could be potential therapeutic targets.
Preliminary inhibitors of MCPyV-positive MCC have been identified in vitro. For
instance, IFN reduces MCPyV LT expression and causes cell death in MPyV-
positive MCCs [270], although IFN treatment did not induce a clinical response
in two patients with late-stage MCPyV-positive MCC [271]. A more promis-
ing target is YM155, an inhibitor of surivin expression, which is cytotoxic in
nanomolar quantities and shows a cytostatic, though not cytotoxic, effect in MCC
mouse xenograft tumours in mice [259] [272]. At the moment, pazopanib, a small-
molecule TK inhibitor, is undergoing a phase II clinical trial [273]. In addition,
controlling MCPyV infection in immunosuppressed and elderly patients might
be a preventative measure for MCC, and the FDA-approved drug trametinib has
been suggested as a therapy [220]. Novel drugs, particularly those targeting the
various interactions of MCPyV T antigens with host cellular proteins, will likely
remain a focus of intense research.
MCC is an immunologically responsive cancer, as it contains viral antigens within
the tumour cells. Improved immunosurveillance has been behind occasional
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spontaneous regression of disseminated MCC tumours [274]. Thus in parallel to
small molecule inhibitors, immuno-based treatments for MCPyV-positive MCC
are also being researched. Specific T lymphocytes recognising various MCPyV
epitopes have been identified, both within tumour cells and in the blood of both
MCC patients and healthy test subjects [275]. 58 CD8+ T lymphocytes against 35
MCPyV T antigen epitopes have been identified, present only in MCC patients.
Despite this response, MCC tumours persist and grown, thus it appears MCCs
can inhibit T lymphocyte cytotoxicity or otherwise evade the immune response
[276].
Alternatively, a DNA vaccine could be a viable therapy for MCC. Murine tu-
mour models have demonstrated that it is possible to target both MCPyV LT
and ST to induce CD4+ and CD8+ T lymphocyte responses [277] [278]. Fur-
thermore, MCPyV-specific CD8+ T lymphocytes produce targetable exhaustion
markers PD-1 and Tim-3 that are associated with reversible T-lymphocyte dys-
function [279]. Therefore, the investigation of potential antagonists of PD-1 and
Tim-3 pathways may yield additional MCC treatment measures.
Due to the highly metastatic nature of Merkel cell carcinoma, designing drugs to
inhibit this property would limit the mortality rate of late-stage disease. Uncov-
ering the mechanism of what drives MCC metastasis is therefore of paramount
importance, particularly determining the role of the T antigens. Interactions of,
for example, ST with cellular factors at one or more stages of the motility path-
ways employed by cells are highly targetable, and inhibitors of such interactions
would be of great interest in further research.
1.6 Cell motility
Cell motility is a vital part of the proper functioning of a number of different cell
types. For example, movement of cells from one location to another is vital for
embryonic development, migration of cells into a wound is important for healing,
while cells of the immune system “patrol” tissues searching for pathogens and
can migrate quickly under the influence of chemoattractants. On the other hand,
cell motility in cancer is part of the metastatic cascade (discussed in Section 1.7),
and is a sign of disease progression.
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Prokaryotic cells and sperm cells use appendages such as cilia and flagella to
propel themselves, while eukaryotic cell motility is much more complex, and of-
ten involves several different mechanisms. These mechanisms mainly involve
changes in cell shape driven by rearrangements of the cytoskeleton. The eukary-
otic cytoskeleton consists of three different types of filament: actin filaments, mi-
crotubules, and intermediate filaments.
1.6.1 The actin cytoskeleton
Actin is ubiquitous and universally conserved in eukaryotic cells, and is involved
in muscle contraction, cell motility, cell division, cell signalling, cellular junctions,
vesicle and organelle movement, and cell shape maintenance. Monomeric actin
(G-actin) is globular and around 42 kDa. G-actin subunits polymerise into fila-
ments (F-actin). Filament formation requires a sufficient concentration of G-actin
for nucleation sites to form. Actin filaments are polar, with the plus end growing
faster than the minus end. G-actin binds adenosine triphosphate (ATP), which
is hydrolysed after the formation of filaments, and this may prime filaments for
disassembly.
Actin, together with myosin, was first discovered in muscle in the 1940s, and
in other cells in the 1960s. Currently, there are over 100 known accessory pro-
teins and actin regulators [280]. A number of regulators are important in actin
nucleation, contributing to the growth of actin filaments. The largest such regu-
lator group are the formins, Rho-family GTPase-regulated proteins with a highly
conserved FH2 domain [281]. Rho-family GTPases release formins from their
autoinhibitory state, which allows them to promote the incorporation of G-actin
monomers at the plus end of growing filaments [282]. Formins produce straight
actin filaments.
However, the best-studied of the major actin regulators is the seven subunit actin-
related protein complex (Arp2/3). Arp2/3 binds to the minus end of an actin
filament and caps it, all the while initiating the assembly of a new filament at a Y
angle. Thus Arp2/3 promotes actin branching, which is very important for cell
motility. Arp2/3 relies on the co-operative functions of an array of nucleation-
promoting factors (NPFs), as it has little nucleation capability on its own [283].
Class I NPFs have a WCA domain, composed of the WH2 region that binds actin
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monomers, an ampiphatic linker, and an acidic peptide that binds Arp2/3. Class
I NPFs include the Wiskott-Aldrich syndrome protein (WASP), neural WASP (N-
WASP), and the WASP family verprolin homology proteins (WAVE1-3). N-WASP
is the best-studied NPF, and it requires activation by a number of different pro-
teins, including cortactin, in order to interact with Arp2/3 [284]. NPFs have roles
in diverse aspects of cytoskeletal change. For example, N-WASP has roles in the
formation of filopodia, membrane ruffles, and phagocytic structures, as well as in
endocytosis [285]. The WAVE proteins function mainly in cell motility, although,
for example, WAVE2 has also been implicated in forming cell-cell contacts [285].
F-actin
G-actin
Arp2/3
Class I NPF
Cla
ss 
II N
PF
F-actin
F-actin
Figure 1.18: The action of Arp2/3 and NPFs in the formation of actin fibres. The Arp2/3
complex is recruited by Class I NPFs close to cellular membranes. The NPFs serve the
purpose of bringing the Arp2/3 complex together with the first G-actin subunit in the
new filament and generate a branch. Arp2/3 branch-points can be stabilised by F-actin-
binding Class II NPFs, e.g. cortactin. Arp2/3: actin-related protein complex 2/3, F-actin:
filamentous actin, G-actin: globular actin, NPF: nucleation-promoting factor.
Class II NPFs do not contain a WCA domain, and the best-studied of these is
cortactin. It is important in a variety of actin-driven cellular processes, includ-
ing cell migration and invasion, axon guidance and neuron morphogenesis, as
well as tumour metastasis [286]. Cortactin binds and stabilises active Arp2/3 us-
ing an acidic amino-terminal peptide, while binding F-actin with its specific cor-
tactin repeats domain. Cortactin stabilises actin filament Y-branches by prevent-
ing Arp2/3 from spontaneously dissociating [287]. Alone, cortactin is a weak
NPF, but it interacts with N-WASP by releasing it from its autoinhibited state
to help enhance Arp2/3 activation [287]. Figure 1.18 illustrates the function of
Arp2/3 and its NPFs.
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Actin turnover involves treadmilling, i.e. loss of G-actin monomers from the plus
end of the filament, severing, i.e. cutting a filament into two without loss of
polymer mass, and catastrophic disassembly. The latter two are facilitated by
cofilin and a number of accessory factors, such as coronin [288]. In any case, actin
turnover involves ATP hydrolysis, and returns G-actin monomers to the cytosolic
pool, where they can be used to make new filaments.
1.6.1.1 Actin structures in cell motility
The actin cytoskeleton is key in the formation of cellular protrusions: lamellipo-
dia, filopodia, invadopodia, and non-apoptotic blebs, as illustrated in Figure 1.19
[285]. Filopodia are the simplest protrusive actin-based structures, thin cylinders
that can extend tens of µms from out of the cortex of the cytoskeleton. They
contain a tight bundle of actin filaments bundled together by accessory proteins
such as fimbrin [289] and fascin [290]. Filopodia are considered to be early mark-
ers of cell motility, as they are utilised by cells to explore the surrounding area
[291]. Lamellipodia are thin sheet-like projections dominating the leading edge
of motile cells They are shaped by branched webs of actin filaments, with Arp2/3
complexes at the intersections between branches, with WAVE the primary NPF
[292]. Lamellipodia are thought to be the major motile structures, actually re-
sponsible for moving cells forward. Invadopodia are specialised actin-rich pro-
trusions able to break down the extracellular matrix (ECM). Arp2/3 and N-WASP
are the main factors in invadopodia formation [293]. All these structures are also
important in the mesenchymal form of migration (discussed in Section 1.6.5).
Actin is also involved in amoeboid migration, playing a role in the formation of
membrane blebs. Blebbing occurs when the cortical actin meshwork becomes dis-
rupted, leading to a large protrusion lacking F-actin. As the bleb grows, an actin
cross-linker, ezrin, is recruited to its cortex, leading the the re-polymerisation of
actin and the retraction of the bleb [294].
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Figure 1.19: Cellular protrusions in cell motility. Lamellipodia and filopodia are actin-
rich protrusions at the leading edge of mesenchymally-migrating cells. Non-apoptotic
blebs are actin-poor protrusions involved in amoeboid migration. Arp2/3: actin-related
protein complex 2/3, IRSp53: insulin receptor substrate protein 53, mDia2: mammalian
diaphanous 2, N-WASP: neural Wiskott-Aldrich syndrome protein, WAVE: WASP family
verprolin homology protein.
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1.6.1.2 Signalling cascades in actin regulation
Actin reorganisation, including the formation of motile structures and cell polar-
isation, depends on signalling cascades. Actin filament formation is directly de-
pendent on the activity of Rho-family GTPases. These signal mediators activate
NPFs such as N-WASP and WAVE1-3, recruiting the Arp2/3 complex. There are
22 known Rho-family GTPases in mammals, and three have been studied exten-
sively: Rac, RhoA and Cdc42. Rac can induce the formation of lamellipodia, and
is thought to be the main Rho-family GTPase involved in their extension, as it
activates the major actin nucleator involved in lamellipodia, WAVE2 [295]. RhoA
has been found to be active at the tailing edge of the motile cell, and is involved
in the retraction of membrane protrusions [296] and formation of stress fibres
[297]. Finally, Cdc42 is the major Rho-family GTPase involved in filopodia and
invadopodia formation, activating N-WASP and the formin mDia2 [298].
Receptors that are ultimately responsible for changes in the actin cytoskeleton
include G-protein coupled receptors (GPCRs), receptor tyrosine kinases (RTKs),
and integrins [299]. Integrins, for instance, are involved in the formation of fo-
cal adhesions, which connect the actin cytoskeleton to the ECM. Integrin activa-
tion in turn leads to the activation of focal adhesion kinase (FAK) and Src kinase,
which then affects factors that activate the Rho-family GTPases [299]. A simpli-
fied version of this pathway is illustrated in Figure 4.18.
1.6.2 The microtubule network and intermediate filaments
The microtubule network is important for cell maintenance and also functions in
intracellular vesicle transport [300], organelle positioning [301], and mitotic spin-
dle formation for segregation of chromosomes during mitosis [302]. In addition,
the microtubule network facilitates the control of cell shape and polarised cell
motility [303].
Microtubule growth is coordinated at the microtubule organising centre (MTOC),
a structure that also plays a major role in cell division [304]. Microtubules are hol-
low tubes composed of αβ-tubulin heterodimers that form a dense cytoplasmic
network. Their structure, just like F-actin, is polarised, with β-tubulin exposed
at the plus and α-tubulin exposed at the minus end. They can be formed either
by de novo nucleation or by disruption of pre-existing structures [305]. There are
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many accessory proteins that maintain the balance between microtubule growth
and shrinkage, and are grouped into microtubule-stabilising and microtubule-
destabilising proteins [306].
Intermediate filaments are a diverse group of structures that contribute to the
overall cell shape, anchor organelles, and are structural components of the nu-
clear lamina, as well as being part of the cell-cell and cell-ECM junctions [307].
They are tissue-specific, and composed of different building blocks, e.g. vimentins
(mesenchymal cells), keratin (epithelial cells), neurofilaments (neural cells), lamin
(nuclear envelope), or desmin (muscle cells) [307]. Unlike the actin cytoskeleton
or the microtubule network, intermediate filaments do not generally participate
in cell motility.
1.6.3 Ion channels in cell motility
In addition to the cytoskeleton and all associated proteins, ion channels are also
involved in cell motility. The role of ion channels in motility is related to their
housekeeping functions, i.e. maintaining the cell membrane potential, and regu-
lating cell volume, calcium concentration, and pH. Ion channels is a broad term
covering channels that are permeable to potassium, sodium, chloride, calcium,
and other ions.
Broadly speaking, regulating cell membrane potential and cell volume are the
major contributions that ion channels make to cell motility, although some indi-
vidual transporters have been found to be involved in cell motility in a manner
that is not dependent on their conductive properties, e.g. as adhesion receptors
[308].
1.6.3.1 Cell membrane potential
Cell membrane potential plays a role in maintaining the cell volume and pH. In
addition, it sets the electrical driving force for calcium influx and controls the gat-
ing of voltage-dependent calcium channels. The importance of this function for
cell migration is illustrated in neutrophils, where proton channels (VSOP/Hv1)
prevent the depolarisation of the cell membrane potential during respiratory burst
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and thereby sustain calcium influx required for cell migration, while depletion or
inhibition of these channels leads to defects in cell motility [309].
In addition, depolarisation of the cell membrane potential modulates the cy-
toskeleton [310] [311]. For instance, the actin network can sense cell membrane
potential and this determines the actin polymerisation/depolymerisation ratio,
affecting cell stiffness [312]. Changes in membrane potential strongly influence
the electrical field of the cell, and changes in the electrical field can control the
conformation and thus the activity of voltage-gated ion channels. Another ex-
ample of the importance of the electric field is that it promotes the interaction of
potassium Kv11.1 channels with β1 integrins. Kv11.1 activation causes the hy-
perpolarisation of the cell membrane, which in turn leads to the recruitment of
downstream signalling molecules, like the focal adhesion kinase (FAK) and Rac1
[313]. Furthermore, recent research has shown that electric fields extend beyond
the cell membrane into the cytosol [314], thus potential effects of changes to cell
membrane potential brought on by ion channels towards cell motility could be
much more extensive.
1.6.3.2 Cell volume changes
The migratory cycle of a cell can be depicted as the gain of volume at the front of
the cell and the loss of volume at the rear of the cell, as shown in Figure 1.20
Cell volume rises during the protrusion of lamellipodia and decreases during the
retraction of the rear end. Local changes of up to 35% have been observed in
cells [315] [316]. Studies on neutrophil migration have shown that their volume
increases on chemotactic stimulation [317]. Volume changes remain restricted
to one cell pole due to the elastic structure of the actin network and cytoplasm
within lamellipodia, which prevents equalisation of local volume changes [318]
[319] [320]. The cell body is softer and more deformable than lamellipodia [321],
and lamellipodia are attached more firmly to the substratum as the cell moves
[315]. Thus lamellipodia retain more fluid compared to the cell body when ion
channels are activated, so local volume changes mechanically support protrusion
and retraction of front and rear ends of the cell [322] [323] [316].
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Figure 1.20: Volume changes in cell migration. Cell motility can be modelled as a cycle
of isosmotic volume increase at the cell front and isosmotic volume decrease at the rear
end. This process is facilitated by ion channels.
Amoeboid blebbing is another example of volume change in migrating cells.
While blebs form mainly due to changes in intracellular volume distribution,
there seems to be role for channels, as aquaporins have been found in the plasma
membrane of blebs [324]. Furthermore, increasing the extracellular osmolarity
inhibits bleb formation [325].
Cell volume regulation depends on ion channel activity. Cells return to their
stable volume by either activating potassium or chloride channels and releasing
potassium chloride and water (volume decrease) or by activating sodium, potas-
sium, and chloride co-transport, sodium/hydrogen exchange, and non-selective
cation channels to uptake potassium chloride and water (volume increase) [326].
Thus many ion channels are involved in cell volume regulation, and as such can
be thought of as participating in cell motility, including KCa3.1 [327], Kv1.3 [328],
to name but a few.
The actin cytoskeleton undergoes rapid polymerisation and depolymerisation
following osmotic shrinkage or swelling, respectively [329] [330] [331]. Actin-
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associated protein localisation is affected by volume changes as well, as in the
case for cortactin [332] and ezrin [333]. The Rho-family GTPases are highly sensi-
tive to cell volume changes [332] [334] [335]. These findings support the hypoth-
esis that there is interdependence between ion channel activity, cell volume, and
the cytoskeleton during cell motility.
1.6.4 Tumour viruses and cell motility
The actin cytoskeleton is co-opted by a number of different viruses for entry, repli-
cation, assembly, and egress. Thus, viruses need to interact with multiple factors
involved in actin dynamics. Furthermore, some tumour viruses use their own
oncoproteins to interfere with pathways that regulate cell motility. Figure 1.21
illustrates some of the viral proteins (oncogenic and not) that interfere with these
signalling cascades.
Cellular morphology changes were observed early on in tumour virus research.
The first oncoprotein to be associated with cytoskeletal changes was the RSV-
encoded viral Src protein (v-Src). v-Src induces morphological changes in cells by
reorganising actin stress fibres [336], and it also co-localises with actin-associated
proteins in motile structures [337]. Furthermore, v-Src phosphorylates the actin-
associated proteins vinculin [338] and cofilin [339], suggesting it is involved in
invadopodia formation [340].
Another viral protein that affects the actin cytoskeleton is SV40 ST, which has
been implicated in the loss of actin filaments [341]. The well-described SV40
ST-PP2A interaction leads to the rearrangement of filamentous actin network,
causing Rac-induced lamellipodia formation, Cdc42-induced filopodia forma-
tion, and the loss of RhoA-dependent stress fibres [342]. This occurs due to SV40
ST expression increasing the levels of Rac1 and Cdc42, while reducing RhoA lev-
els [342].
These actin cytoskeleton changes have also been seen in other tumour viruses.
For example, EBV-transformed B cells show a 200-fold increase in fascin, a type
of actin bundling protein [343], while EBV nuclear antigen 2 (EBNA2) interferes
with Rho-family GTPase signalling by inducing PI-3K [344]. HBV protein X inter-
acts with Rac1 to redistribute it to the tips of membrane protrusions [345], while
HPV E7 enhances the accumulation of p27, a positive regulator of motility and
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invasiveness, in the cytoplasm, leading to cell migration [346]. Finally, KSHV
vFLIP protein promotes remodelling of the actin cytoskeleton via activation of
the NF-κB pathway [347].
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Figure 1.21: Tumour viruses in the cell motility pathway. SV40 ST upregulates Rac1 and
Cdc42 while downregulating RhoA activity. HPV E7 upregulates Rac1 while downreg-
ulated RhoA activity. HBV HBx upregulates Rac1. EBV EBNA2 induces PI-3K and RSV
v-Src induces Src activity. Direct phosphorylation/stimulation: black arrows. Inhibi-
tion: black lines, indirect interaction: dotted lines. Arp2/3: actin-related protein complex
2/3, Cdc42: cell division cycle protein 42, EBNA: EBV nuclear antigen, EBV: Epstein-
Barr virus, FAK: focal adhesion kinase, HBV: hepatitis B virus, HBx: hepatitis B virus x
protein, HPV: human papillomavirus, LIMK1/2: LIM domain kinase 1/2, mDia: mam-
malian diaphanous, N-WASP: neural Wiskott-Aldrich syndrome protein, PI-3K: phos-
phatidylinositol 3 kinase, Rac1: ras-related C3 botulinum toxin substrate 1, RhoA: ras
homolog gene family, member A, ROCK1/2: rho-associated protein kinase 1/2, RhoA:
RSV: Rous sarcoma virus, ST: small T antigen, SV40: simian virus 40, v-Src: viral Src,
WAVE: WASP family verprolin homology protein [348].
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Therefore, tumour viruses subvert the actin cytoskeleton both to affect cell motil-
ity, but also in other contexts. The major focus of this thesis is the effect of MCPyV
ST on cell motility, thus the role of this oncoprotein in actin dynamics is important
to consider, and it will be explored in the results sections.
1.6.5 Cell migration
Cell motility in eukaryotes can take several different forms. which are classified
into three types: amoeboid, mesenchymal, and collective migration. Amoeboid
migration is usually defined by the presence of plasma membrane blebs, weak
or absent adhesion to the substratum and little or no ECM proteolysis [349]. On
the other extreme, mesenchymal cell migration is a multi-step cycling type of
cell motility mode characterised by cell polarisation to form a leading edge that
extends actin-rich protrusions, e.g. lamellipodia and filopodia (Section 1.6.1.1).
Such migration involves adhesive interactions with the substratum and prote-
olytic ECM remodelling. The final stage in mesenchymal migration is the re-
traction of the contractile cell rear to achieve cellular movement [350]. There is
substantial interchangeability between these forms of cell migration, and it is not
always clear cut which mode of migration a cell is undertaking [349]. Amoeboid
and mesenchymal cell migration characterise single cell motility. Collective cell
migration occurs when cells move as a sheet without breaking the cell-cell junc-
tions between them [351]. Here, cells at the leading edge of movement generate
proteases to degrade the ECM, creating a path [352]. Unlike mesenchymal mi-
gration, collective migration requires active adhesion complexes [350]. Less is
known about this mode of cell migration, due to difficulties of in vitro modelling.
The different types of motility are illustrated in Figure 1.22.
Cell migration can be separated into discrete components, including cell polar-
isation, protrusion formation, adhesion to the substratum, and retraction of the
rear. Cell polarisation is defined as the presence of a stable front and rear, and of-
ten arises from the presence of directional cues, e.g. chemoattractants, substrate
concentration differences, electric fields, or others, as well as combinations of dif-
ferent cues. In mesenchymal cell migration, the leading edge is characterised by
actin-rich protrusions and adhesion to the substrate, while the rear edge is char-
acterised by stable bundle and disassembly of adhesion [353]. The main Rho-
family GTPase contributing to cell polarity is Cdc42 [354]. Protrusion formation,
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discussed in Section 1.6.1.1, occurs at the leading edge, and is also regulated by
Rho-family GTPases.
integrin receptor
adherens junction
amoeboid migration
mesenchymal migration
collective migration
ECM
ECM
ECM
ECM
ECM
ECM
Figure 1.22: Modes of cell migration. Amoeboid motility is characterised by amorphous
cell shape, random integrin distribution, and rapid changes in direction. Cells are able to
squeeze through the ECM without degrading it. Mesenchymal motility is characterised
by elongated morphology, and localised integrin contacts with the ECM. Cells need to
degrade the ECM via the action of MMPs to migrate. Collective motility is characterised
by groups or sheets of migratory cells, with many still retaining cell-cell contacts. Cells
use MMPs to degrade the ECM. ECM: extracellular matrix.
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Adhesion to the substratum is another important aspect of cell migration, and
occurs mainly via the activity of integrin receptors. Ligand binding to integrins
triggers signalling pathways regulating the formation of protrusions. This links
the substratum to the actin cytoskeleton, which provides traction for migration
[355]. Adhesion sites can be small, i.e. focal complexes, or large, i.e. focal ad-
hesions. Adhesion sites close to the leading edge actively promote actin poly-
merisation and are quick to assemble/disassemble, while those further away
from the leading edge are more stable, larger, and anchor bundles of actin fila-
ments [356]. Adhesion sites are composed of many different proteins, including
signalling complexes. Paxilin and FAK are two important kinases in adhesions
[357], involved in regulating Rho-family GTPases. Other adhesion components,
like talin, vinculin, and α-actinin link the actin cytoskeleton to the substratum
through integrins [358] [359] [360].
Finally, retraction of the rear requires the coordinated contraction of the actin cy-
toskeleton and the disassembly of adhesions at the trailing edge. This occurs
in several different ways: contraction of actin to rip the adhesions, microtubule-
induced disassembly, integrin endocytosis, and the proteolytic cleavage of pro-
teins that link integrins to the actin cytoskeleton [361].
1.7 Cancer metastasis
Cancer metastasis is the primary cause of the vast majority of cancer-related
deaths [362]. Metastasis is a complex process, with several discrete steps required
for the formation of secondary tumour sites: loss of cell adhesion, gain of cell
motility, dissemination via the vasculature, and colonisation of distant sites. Cell
motility is thus a key stage of cancer metastasis, and the metastatic nature of MCC
can be potentially linked to the effects of MCPyV ST on enhancing cell motility,
first presented in the literature [210], and further explored in this thesis.
1.7.1 Loss of cell adhesion
Epithelial tissue is the primary origin of solid tumours, as it is composed of cell
sheets separated from the basement membrane by stroma. These cell sheets are
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organised into highly complex structures that require cell-cell and cell-ECM ad-
hesion. During the early stages of metastasis, cells from the solid tumour needs to
detach, thus cell adhesion complexes have to be deconstructed. Unsurprisingly,
carcinoma cells lose adhesive properties [363]. Invasive tumours of epithelial
origin show the loss of E-cadherin [364]. E-cadherin is a member of the tissue-
specific cadherin family of transmembrane glycoproteins required to maintain
tissue integrity [365]. Cadherins localise to cell junctions called zonula adherens
and are responsible for calcium-dependent cell adhesion and signalling [366].
Carcinoma in situ
Invasive carcinoma
basement membrane
vasculature
EMT
Loss of cell-cell junctions
Cadherin switching
Mesenchymal marker expression
MMP expression
Motility/invasiveness
Figure 1.23: Tumour spread from the primary site. The process of a primary tumour
spreading into the vasculature involves EMT, as cells gain motility and express specific
markers, integrins, and MMPs. These factors are required for invasion of local tissue
and passage through the basement membrane into the vasculature. EMT: epithelial-
mesenchymal transition, MMP: matrix metalloproteinase.
A characteristic of many cancers, correlating with increased invasiveness, is a
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process known as “cadherin switching”, i.e. loss of E-cadherin and increased
expression of N-cadherin [364]. This process is part of a wider process, epithelial-
to-mesenchymal transition (EMT). EMT is characterised by a loss of cell polarity
and epithelial proteins such as E-cadherin, occludins, claudins, catenins, and cy-
tokeratin, all of which are responsible for maintaining cell-cell junctions, and a
gain of a mesenchymal, migratory and invasive phenotype [367], as illustrated in
Figure 1.23.
Multiple signalling pathways control EMT [367], and many of these are deregu-
lated in metastatic tumours, through transcriptional repression, proteolytic degra-
dation, or receptor domain cleavage [364]. In addition, increasing N-cadherin ex-
pression promotes tumour invasion via the activation of fibroblast growth factor
receptor (FGFR), which stimulates cell survival, migration, and invasion [368].
Tumour viruses express a number of oncoproteins, which promote the loss of cell
adhesions. For instance, HPV E6 expression promotes degradation of epithelial
cell tight junctions through an interaction with E6AP, an ubiquitin ligase, which
allows for proteosomal degradation of cell adhesion molecules, in an EMT-like
manner [369] [370]. Furthermore, HBV HBx downregulates E-cadherin expres-
sion resulting in the loss of intracellular adhesion molecules [371]. In addition,
SV40 ST promotes, in a PP2A-dependent manner, the redistribution and down-
regulation of E-cadherin, ZO-1, claudin-1, and occludin, all proteins involved in
cell junctions [342]. MCC tumours also show a pronounced redistribution of E-
cadherin from the cell membrane to the nucleus [372], suggesting mesenchymal
qualities that promote the deadly invasive phenotype of the cancer.
1.7.2 Gain of cell motility
In order for tumour dissemination to be possible, cells must become motile. Cell
motility and different types of migration have been extensively discussed in Sec-
tion 1.6. Up to 40% of cancers undergo EMT and migrate in a mesenchymal man-
ner [373], while cancers that do not undergo EMT tend to migrate in an amoeboid
manner [374]. Collective motility has been demonstrated in breast, colon, and
ovarian cancers [374].
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1.7.3 Dissemination via the vasculature
The basement membrane is a barrier for invasive tumours of epithelial origin,
which must be passed through to access the vasculature. It is important for ep-
ithelial structure and integrity, and consists of a dense network of proteoglycans
and glycoproteins, including laminin and collagen. The basement membrane
can be broken down by extracellular matrix proteases, which are normally un-
der strict regulatory control by their localisation, inhibitors, and autoinhibition
[375]. Therefore, malignant cells that use the mesenchymal mode of migration
need to activate these proteases to degrade the ECM, which can further lead to
the production of bioactive peptides able to mediate migration, angiogenesis, and
tumour survival [374]. One subset of matrix proteases are are calcium-activated,
zinc-containing matrix metalloproteinases (MMPs) [376].
DNA tumour viruses can promote matrix degradation and tumour invasion. For
instance, HPV E7 and HBV HBx induce the expression of matrix transmembrane
metalloproteinase 1 (MT1-MMP), which is crucial for the degradation of the ECM
and activation of matrix metalloproteinase 2 and 9 (MMP2 and MMP9) [377],
[345]. MT1-MMP expression promotes tumour growth and angiogenesis by up-
regulating expression of the vascular endothelial growth factor (VEGF), and this
correlates with invasiveness [378]. Interestingly, induction of MMP gene expres-
sion by the WNT/β-catenin signalling pathway and other growth factors stim-
ulates MCPyV infection. These findings could further the hypothesis that MCC
risk factors such as UV radiation and ageing, known to stimulate WNT signalling
and MMP expression, may promote viral infection, thus driving MCC [220].
1.7.4 Colonisation and secondary tumour growth
In order for tumour cells to access remote tissues and organs, they must access
the vasculature. Angiogenesis is the process of growing new blood vessels, and
is an important step in cancer malignancy. Angiogenesis prevents hypoxia and
necrosis of the growing tumour, as well as providing nutrients and removing
waste products [374]. VEGF is a key factor in angiogenesis, and some virus onco-
proteins, e.g. EBV LMP1, can induce hypoxia-inducible factor 1 alpha (HIF-1α)
expression, which in turn promotes the expression of VEGF [379].
Entry into the vasculature is known as intravasation, and is initiated by tumour
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cells orienting towards the vasculature and migrating towards it [374]. The vast
majority of tumour cells are either trapped in the capillary bed or rapidly die in
the circulatory system. Only a minority of tumour cells that enter the circulation
can exit the vasculature and establish metastases [374]. Exit from the vasculature
is extravasation and is largely dependent on the principles involved in intrava-
sation. Establishment of tumour cells in new sites and eventual secondary tu-
mour growth is not necessarily a random process. For example, breast, lung, and
prostate cancers preferentially metastasise to bone tissue [380]. This suggests that
the organ must be compatible with the metastasising cells, known as the seed and
soil hypothesis.
1.8 Thesis Aims
The major aim of this thesis was to build upon earlier work in the Whitehouse
laboratory investigating the role that MCPyV ST plays in cell motility and cancer
metastasis.
MCPyV ST has been previously reported to affect the microtubule network, thereby
promoting cell motility [210]. Chapter 3 describes the effect of MCPyV ST on the
actin cytoskeleton, including morphological changes in several cell lines and the
upregulation of a number of actin-associated proteins in cell culture and MCPyV-
positive MCC tumour samples. The morphological changes upon MCPyV ST
expression were shown to be filopodia formation, a marker for cell motility. In
order to further explore MCPyV ST-induced cell motility, i293-GFP and i293-GFP-
ST cell lines were developed, and increased motility upon MCPyV ST expression
was confirmed. The Rho-family GTPases, particularly Cdc42 and RhoA, were
implicated in MCPyV ST-induced cell motility and filopodia formation, using in-
hibitors and transdominant mutants.
Chapter 4 expands on the results of Chapter 3, as well as building on previous
work implicating protein phosphatases in MCPyV ST-induced cell motility. Poly-
omavirus ST antigens contain binding sites required for interactions with cellular
phosphatases, such as PP2A Aα and PP2A Aβ [234], and recent findings also
show that MCPyV ST can bind to PP4C [209]. MCPyV ST PP4C non-binding mu-
tants showed reduced cell motility and filopodia formation compared to wild-
type MCPyV ST. The effect of phosphorylation on Rho-family GTPases was in-
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vestigated, although results showed that MCPyV ST expression does not directly
affect the phosphorylation status of Cdc42 or Rac1. Furthermore, the role of inte-
grins was shown to be important in MCPyV ST-induced cell motility and filopo-
dia formation, using inhibitory peptides. Finally, it was shown that integrin β1
shows reduced phosphorylation at the Thr788/789 upon MCPyV ST expression,
but not upon the expression of MCPyV ST PP4C non-binding mutants. This led
to a model by which the MCPyV ST-PP4C interaction leads to the dephosphory-
lation of integrin β1, which activates the downstream cell motility pathway.
Chapter 5 implicates chloride channels in MCPyV ST-induced cell motility. Patch
clamping showed an increase in ion channel activity upon MCPyV ST expression,
and inhibitor studies showed that chloride channels are involved in MCPyV ST-
induced cell motility and filopodia formation. In addition, MCPyV ST expression
upregulated the protein levels of two intracellular chloride channels, CLIC1 and
CLIC4, both in cell culture and MCPyV-positive MCC tumour samples. Knock-
down of CLIC1 and CLIC4 reduced MCPyV ST-induced cell motility. Further-
more, both were found to have increased redistribution to the cell surface upon
MCPyV ST expression.
These findings stress the importance of the MCPyV ST-PP4C interaction as a po-
tential therapeutic target to treat metastasised MCC. Results also show the first
detailed molecular mechanism of MCPyV ST-induced cell motility and filopodia
formation, incorporating the activity of integrin receptors and Rho-family GT-
Pases. Furthermore, a novel avenue of chloride channel research in the context of
MCC is presented, providing additional potential drug targets for disseminated
MCC.
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2.1 Materials
2.1.1 Chemicals
All analytical grade chemicals and solvents were provided by Sigma-Aldrich R©,
Melford Laboratories Ltd., and Life TechnologiesTM, unless stated otherwise. So-
lutions were sterilised using 0.22 µm filters (Millex), or by autoclaving (121◦C,
30 min, 15 psi). All water used throughout, unless mentioned otherwise, was
deionised water sterilised through an ELGA PURELAB ultra machine (ELGA).
2.1.2 Enzymes
All restriction enzymes and supporting reagents were supplied by New England
Biolabs R© Inc, as well as Alkaline Phosphatase, Calf Intestinal (CIP) and the T4
DNA ligase. Other enzymes and their suppliers are listed in Table 2.1.
Table 2.1: Enzymes and their suppliers
Enzyme Supplier
Platinum R© Pfx DNA polymerase Life TechnologiesTM
Superscript R© II reverse transcriptase Life TechnologiesTM
Proteinase K Life TechnologiesTM
RNase Out Life TechnologiesTM
DNA-freeTM DNase I treatment kit AmbionTM
2x SensiMixTM SYBR No-ROX Kit Bioline Reagents Ltd
2.1.3 Antibodies and beads
Primary antibodies were purchased from a number of suppliers and used at a
variety of concentrations, details of which are listed in Table 2.2.
Horseradish peroxidase (HRP) conjugated anti-mouse and anti-rabbit secondary
antibodies (DakoTM) were used for immunoblotting at concentration of 1:5,000.
Alexa-fluor conjugated anti-mouse and anti-rabbit Immunoglobulin G (IgG) anti-
bodies (Life TechnologiesTM) were used at a concentration of 1:500 for immunoflu-
orescence microscopy and at a concentration of 1:200 for flow cytometry. To vi-
sualise actin, Alexa-fluor-tagged phalloidin (Life TechnologiesTM), an actin inter-
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calating agent, was used at a concentration of 1:10,000. The 2T2 antibody (kindly
provided by Dr Christopher Buck, National Cancer Institute, Bethesda, MD),
which recognises the DnaJ-domain leader peptides present in both MCPyV ST
and MCPyV LT was used at a dilution of 1:5 for immunoblot analysis. Anti-Flag
beads in agarose were purchased from AbcamTM and GFP-trap R© beads were
purchased from ClontechTM.
2.1.4 Mammalian cell culture reagents
All mammalian tissue culture media and culture supplements were supplied
by either Life TechnologiesTM, LonzaTM or Sigma-AldrichTM. Selection antibi-
otics were provided by either InVivoGenTM or Life TechnologiesTM. Transfection
reagents used were LipofectamineTM 2000 (Life TechnologiesTM) for HEK-293-
derived cell lines and TransIT-X2 R© Dynamic Delivery System (Mirus LLC) for
MCC13 cells and siRNA transfections.
2.1.5 Cell lines
The HEK 293 Flp-InTM cell line (HEK-239) was purchased from Life TechnologiesTM.
The i293-ST-flag (by Laura Knight), i293-GFP and i293-GFP-ST cell lines were de-
rived from the HEK-293 cell line (see Chapter 3). The MCC13 cell line was pur-
chased from Health Protection Agency Culture Collection.
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Table 2.2: Primary antibodies, their origins, their working dilutions, and their suppli-
ers
Antibody (catalogue
number)
Origin Working dilution Supplier
Anti-Flag (F7425) Rabbit 1:1,000 (WB), 1:250
(IF)
Sigma-
Aldrich R©
Anti-HA (H9658) Mouse 1:1,000 (WB), 1:250
(IF)
Sigma-
Aldrich R©
Anti-Myc (M4439) Mouse 1:1,000 (WB), 1:250
(IF)
Sigma-
Aldrich R©
Anti-EE (ab24627) Mouse 1:1,000 (WB), 1:250
(IF)
Abcam
Anti-GAPDH (ab8245) Mouse 1:5,000 (WB) Abcam
Anti-GFP (632569) Mouse 1:5,000 (WB) Living Colours
Anti-Arp3
(GTX115345S)
Rabbit 1:1,000 (WB) GeneTex
Anti-Cortactin
(GTX11065)
Rabbit 1:1,000 (WB) GeneTex
Anti-Cofilin-1
(GTX11062)
Rabbit 1:1,000 (WB) GeneTex
Anti-GM130 (ab52649) Rabbit 1:200 (IF) Abcam
Anti-Rac1/Cdc42
(phospho Ser71) (2461S)
Rabbit 1:1,000 (WB) CST
Anti-Integrin beta 1
(phospho T788 + T789)
(ab5189)
Rabbit 1:1,000 (WB) Abcam
Anti-CLIC1 (sc-
374202)/(ab77214)
Mouse 1:1,000 (WB), 1:50
(FC)
Santa Cruz
Biotech/Abcam
Anti-CLIC4 (sc-
130723)/(ab183043)
Rabbit 1:1,000 (WB), 1:50
(FC)
Santa Cruz
Biotech/Abcam
Rabbit IgG1 isotype
(abab172730)
Rabbit 1:50 (FC) Abcam
Mouse IgG1 isotype
(ab91353)
Mouse 1:50 (FC) Abcam
2.1.6 Oligonucleotides
Oligonucleotide primers for polymerase chain reaction (PCR) and real-time quan-
titative PCR (RT-qPCR) were supplied by Sigma-Aldrich R©. The list of primers is
shown in Table 2.3. Oligo(dT)12–8 was supplied by Promega.
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Table 2.3: Oligonucleotides used in cloning or RT-qPCR, including sequences for both
forward and reverse oligo pairs
Oligonucleotide Technique Sequence
GFP Forward Cloning GGG (EcoRV)GAT ATC ATG GTG
AGC AAG GGC GAG GAG
GFP Reverse Cloning CCC (ApaI)GGG CCC CTA GAA
AAG GTG CAG ATG CAG
GFP-ST Forward Cloning GGG (KpnI)GGT ACC ATG GTG
AGC AAG GGC GAG GAG
GFP-ST Reverse Cloning CCC (NotI)GCG GCC GCT TAT CTA
GAT CCG GTG GAT CC
Arp3 Forward RT-qPCR TTC ATC ACC CTC CTT TGA GC
Arp3 Reverse RT-qPCR GTG TGG TGG ACT GTG GCA
Cortactin Forward RT-qPCR TAA TCC AAT GAG GAA TTT CCA
Cortactin Reverse RT-qPCR TAG AGC CTG GTG CCT GGG
Cofilin-1 Forward RT-qPCR TGA CAC CAT CAG AGA CAG CC
Cofilin-1 Reverse RT-qPCR TCC TAC TAA ACG GAA GGG GC
CLIC1 Forward RT-qPCR GAC ACC TTC CAT CTT CAG CAC
T
CLIC1 Reverse RT-qPCR CAA GAA TTC AAA CCC AGC ACT
C
CLIC4 Forward RT-qPCR CAT CCG TTT TGA CTT CAC TGT
TG
CLIC4 Reverse RT-qPCR AGG AGT TGT ATT TAG TGT GAC
GA
GAPDH Forward RT-qPCR TGT CAG TGG TGG ACC TGA C
GAPDH Reverse RT-qPCR GTG GTC GTT GAG GGC AAT G
2.1.7 Plasmid constructs
Table 2.4 lists plasmid constructs, either purchased or supplied by other labora-
tories.
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Table 2.4: Plasmid constructs and their sources
Construct Source
pcDNA5-FRT-TO Life TechnologiesTM
pEGFP-C1 Clontech
pEGFP-ST David Griffiths, University of Leeds, UK
pcDNA5-ST-Flag David Griffiths, University of Leeds, UK
pEGFP-ST:R7A Hussein Abdul-Sada, University of Leeds, UK
pEGFP-ST:∆95–111 Hussein Abdul-Sada, University of Leeds, UK
pEGFP-ST102A Hussein Abdul-Sada, University of Leeds, UK
pEGFP-ST103A Hussein Abdul-Sada, University of Leeds, UK
RL-PP4C-HA Tse-Hua Tan, National Health Research Insti-
tute, Taiwan
pcDNA3.1-HA-PP2A Cα Peter Cron, University of Basel, Switzerland
pEGFP-mDia2 Shuh Narumiya, University of Kyoto, Japan
pRK5myc-IRSp53 Laura Machesky, Beatson Institute for Cancer
Research, UK
pcDNA3-EGFP-Cdc42-
T17N
Gary Bokoch (Addgene plasmid 12976)
pcDNA3-EGFP-Rac1-
T17N
Klaus Hahn (Addgene plasmid 13721)
pcDNA3-EGFP-RhoA-
T19N
Gary Bokoch (Addgene plasmid 12967)
pcDNA3.1-Cdc42-HA Ralf Gerhard, MH-Hannover, Germany
pcDNA3.1-Rac1-HA Ralf Gerhard, MH-Hannover, Germany
pcDNA3.1-Cdc42S71E-HA Ralf Gerhard, MH-Hannover, Germany
pcDNA3.1-Rac1S71E-HA Ralf Gerhard, MH-Hannover, Germany
2.1.8 siRNA constructs
siRNA constructs to knock down CLIC1 and CLIC4, as well as the negative con-
trol scramble siRNA were purchased from Life TechnologiesTM.
2.1.9 Inhibitors
Table 2.5 lists small-molecule and peptide inhibitors from a number of different
suppliers.
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Table 2.5: Small molecule inhibitors, their working concentrations and suppliers. i293
cells include HEK-293 and derived cell lines
Inhibitor (CAS
number)
Working concentration Supplier
ML-141 (CAS
71203-35-5)
15 µM (i293), 30 µM (MCC13) Tocris Bioscience
NSC23766 (CAS
733767-34-5)
50 µM (i293), 100 µM (MCC13) Santa Cruz Biotechnol-
ogy
ZCL278 (CAS
587841-73-4)
50 µM (i293), 100 µM (MCC13) Tocris Bioscience
Rhosin (CAS
1173671-63-0)
30 µM (i293), 60 µM (MCC13) Merk Millipore
R(+)-IAA-94
(RIAA) (CAS
54197-31-8)
50 µM (i293), 100 µM (MCC13) Sigma-Aldrich R©
NPPB (CAS
107254-86-4)
25 µM (i293), 50 µM (MCC13) Tocris Bioscience
DIDS (CAS
207233-90-7)
50 µM (i293), 100 µM (MCC13) Sigma-Aldrich R©
RGDS (CAS 91037-
65-9)
Various non-toxic Sigma-Aldrich R©
RGES (CAS 93674-
97-6)
Various non-toxic AnaSpec
2.2 Methods
2.2.1 Molecular cloning
DNA was amplified using PCR and separated by agarose gel electrophoresis,
then gel purified and ligated into a linearised double stranded DNA vector. This
was done via the Zero Blunt R© (Life TechnologiesTM) cloning vector kit. Table
2.4 and Table 2.5 list recombinant vectors and the corresponding primers used
for PCR amplification of the inserted fragments. After amplification in chemi-
cally competent bacteria and purification of plasmid DNA, presence of inserts
was verified by restriction digest analysis. All constructs were sequenced to
validate the identity of the inserted fragments. All cloning was carried out us-
ing Escherichia coli (E.coli) strain DH5α (Genotype: F-, Ψ80dlacZ∆M15, ∆(lacZYA-
argF)U169, deoR, recA1, endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA19,
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relA1).
2.2.1.1 PCR amplification
All PCRs were prepared in 0.2 ml GreinerTM PCR tubes in a total volume of 50
µl. PCR mixes were made up according to the manufacturer’s protocol (Life
TechnologiesTM). For cloning protocols, Platinum R© Pfx DNA polyomerase was
used. Each 50 µl reaction volume contained 0.2mM each of forward and reverse
primer, 1× polymerase amplification buffer, 1.5 mM MgSO4, 1–10 ng templated
DNA and 1 µl DNA polymerase, with miliQ water making up the full volume.
The PCR machine used was the TI-312 model from ThermeTM. The PCR cycle
involved initial denaturation (94◦C, 3 min), 35 cycles of denaturation (95◦C, 30
s), annealing (55–62◦C, 30 s) and extension (68◦C, 1 min), followed by a final ex-
tension stage (68◦C, 10 min). Reactions were done with the heated lid setting
on to prevent sample evaporation. PCR products were analysed by agarose gel
electrophoresis.
2.2.1.2 DNA gel electrophoresis
Double stranded DNA fragments were separated by agarose gel electrophoresis,
using 0.8–1.2% agarose gels. Agarose was dissolved in 1× TBE buffer [90 mM
Tris-base, 2 mM EDTA, 80 mM boric acid] with 0.5 µg/ml ethidium bromide. A
6× solution of gel loading buffer [0.25% (w/v) Orange G dye, 30% (v/v) glyc-
erol] was added to DNA samples at 1× final concentration. 1 kb DNA ladder
(Life TechnologiesTM) was loaded alongside samples. Electrophoresis was per-
formed at 120 V in 1× TBE buffer using a Sub-Cell R© or mini-Sub R© Cell hori-
zontal electrophoresis tanks (Bio-Rad Laboratories, Inc.). DNA bands were visu-
alised under ultra-violet light using a transilluminator and images taken using
the GeneGenius bio-imaging system (SyngeneTM).
2.2.1.3 DNA gel purification
Following agarose gel electrophoresis, DNA fragments were excised using a ster-
ile scalpel and purified using the QIAquick gel extraction kit (Qiagen), according
to the manufacturer’s instructions. The mass of the DNA gel slice was recorded
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and then incubated for 10 min at 50◦C with 3× gel volumes of buffer QG to melt
the agarose, after which 1 gel volume of isopropanol was added to the sample.
This solution was then applied to a QIAquick column and centrifuged for 1 min
at 13,000 × g at room temperature. DNA bound to the membrane was washed
using 750 µl PE buffer and centrifuged at 13,000 × g for 1 min at room tempera-
ture. DNA was eluted into a sterile microcentrifuge tube using 30 µl miliQ water,
incubated for 1 min and centrifuged at 13,000 × g for 1 min at room temperature.
Pure DNA was stored at -20◦C.
2.2.1.4 DNA ligation
A typical ligation reaction was set up in a total volume of 10 µl, using 5× T4 DNA
ligase buffer, 1 U of T4 DNA ligase (both Life TechnologiesTM), 10–100 ng lin-
earised vector and varied molecular proportions of insert DNA. Reactions were
performed at room temperature for 1 h. Ligation efficiency was determined via
control reactions lacking either DNA insert or DNA ligase.
2.2.1.5 DNA restriction digestion
DNA restriction digestions were carried out according to the manufacturer’s pro-
tocol (New England Biolabs, Inc). All reactions were prepared in a volume of 20
µl in 10× CutSmart R© buffer, with 1 U of restriction digest enzyme used per 1 µg
of DNA. Double digests, using two restriction digest enzymes to minimise DNA
loss as a result of purification of DNA, were done when possible. All digestion re-
actions were performed at 37◦C for 2 h. If the DNA was to be subsequently used
for ligation, CIP alkaline phosphatase (New England Biolabs, Inc) was added for
1 h at 37◦C (1 U per 1 pmol of DNA). Resulting digests were terminated by heat
inactivation at 65◦C for 20 min. Resulting fragments were analysed by agarose
gel electrophoresis (Section 2.2.1.2) and gel purified (Section 2.2.1.3).
2.2.1.6 Preparation of E. coli DH5α chemically competent cells
Chemically competent E. coli were prepared using a rubidium chloride-based
method and liquid cultures were grown in autoclaved Luria broth (LB) [1% (w/v)
tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract, pH 7.5] and incubated at
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37◦C with shaking (200 rpm). DH5α cells were streak plated on LB agar plates
[1% NaCl, 1% Tryptone, 0.5% Yeast Extract and 1.5% Agar] followed by overnight
incubation at 37◦C. One colony was used to inoculate 2 ml of LB media and incu-
bated for 5–7 h at 37◦C with shaking. 0.5ml of the culture was used to inoculate
50 ml of LB media and the cells were grown at 37◦C with shaking until an OD600
of 0.3–0.6 was reached. The cells were subsequently pelleted by centrifugation
at 5,000 × g for 5 min at 4◦C. The pellet was resuspended in 40 ml ice-cold filter-
sterilised TFB1 buffer [30 mM KOAc, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl,
15% (v/v) glycerol, adjusted to pH 5.8 with acetic acid] and incubated for 5 min
at 4◦C. The cells were centrifuged at 5,000× g for 5 min at 4◦C, followed by gentle
resuspension of cells in 2 ml ice-cold filter-sterilised TFB2 buffer [10 mM MOPS,
75 mM CaCl2, 10 mM RbCl, 15% (v/v) glycerol, adjusted to pH 6.4 with KOH].
This was followed by incubation at 4◦C for 15–60 min and subsequently cells
were aliquoted and flash-frozen on dry ice. Competent cells were stored at -80◦C.
2.2.1.7 Transformation of chemically competent cells
100 ng of a pre-chilled DNA expression construct was mixed with a 50 µl aliquot
of DH5α chemically competent cells, and incubated for 5–30 min at 4◦C. Mix-
tures were then heat shocked for precisely 1 min at 42◦C then placed for 2 min
at 4◦C. 250 µl of LB media were added to the samples and they were incubated
with shaking at 37◦C for 1 h. Samples were then spread plated onto LB agar con-
taining the appropriate selective antibiotic (either ampicillin or kanamycin) at a
concentration of 50 µg/ml. These plates were then incubated overnight at 37◦C.
2.2.1.8 Small scale (mini prep) DNA purification
QIAprep Spin miniprep kits (QIAGEN) were used for small scale DNA purifica-
tion according the the manufacturer’s protocol. Single transformed E. coli colonies
were used to inoculate 5 ml of LB media each with appropriate antibiotic (50
µg/ml), followed by overnight incubation at 37◦C with shaking. Cultures was
pelleted by centrifugation at 5,000 × g for 5 min at room temperature, then re-
suspended in 250µl of Buffer P1[50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100
µg/ml RNaseA] in microcentrifuge tubes. 250 µl of Buffer P2 [200 mM NaOH,
1% (w/v) SDS] were added for cell lysis and the tubes was inverted 4–6 times.
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350 µl of Buffer N3 [4.2 M Gu-HCl, 0.9 M KOAc (pH 4.8)] were added to neu-
tralise the samples and the tubes were inverted again 4–6 times. The samples
were centrifuged for 10 min at top speed in a table-top microcentrifuge. Super-
natants were then transferred to QIAprep spin columns and centrifuged for 1
min at top speed to bind DNA. The columns were washed with 0.75 ml buffer
PE [10 mM Tris-HCl (pH 7.5), 80% ethanol], centrifuged for 1 min at top speed,
then the supernatants were emptied and the columns were re-centrifuged for 1
min to collect residual buffer. DNA was eluted into clean 1.5 ml microcentrifuge
tubes with miliQ water (30 µl), incubated at room temperature for 1 min, then
centrifuged for 1 min. Purity and concentration of DNA was measured using a
NanoDrop-1000 spectrophotometer (NanoDrop Technologies) at 260/280 nm.
2.2.1.9 Large scale (maxi prep) DNA purification
QIAGEN plasmid maxi kits were used for large scale DNA purification according
to the manufacturer’s protocol. Single transformed E. coli colonies were used to
inoculate 5 ml of LB media each with appropriate antibiotic (50 µg/ml), followed
by incubation at 37◦C for 8 h with shaking. Day cultures were added to 200 ml
LB media and incubated at 37◦C overnight with shaking. The culture was then
centrifuged at 5,000× g for 20 min at 4◦C. The cell pellet was then resuspended in
10 ml Buffer P1 [10 mM EDTA, 50 mM Tris-HCl (pH 8.0), 100 µg/ml RNaseA] and
10 ml Buffer P2 [1% SDS, 200 mM NaOH], then inverted 10 times and incubated
at room temperature for 5 min. 10 ml of pre-chilled Buffer P3 [3 M KOAc, pH 5.5]
was added, the mixture was inverted 10 times, and incubated at 4◦C. Mixtures
were centrifuged at 5,000 × g for 30 min at 4◦C. The solution was added to a pre-
equilibrated QIAGEN-tip 500 column and allowed to drain by gravity to bind
DNA. The column was equilibrated with Buffer QBT [50 mM MOPS (pH 7.0),
750 mM NaCl, 0.15% (v/v) Triton X-100]. The column resin was subsequently
washed twice with 30 ml Buffer QC [50 mM MOPS (pH 7.0), 1 M NaCl, 15%
(v/v) isopropanol], followed by DNA elution by addition of 15 ml Buffer QF
[15% (v/v) isopropanol, 1.25 M NaCl, 50 mM Tris-HCl]. To precipitate DNA, 10.5
ml isopropanol was added to the eluted solution and pelleted by centrifugation at
5,000× g for 30 min at 4◦C. The pellet was washed with 5 ml 75% ethanol and re-
centrifuged for at 5,000 × g for 10 min at 4◦C. The DNA pellet was subsequently
air-dried and resuspended in 100–200 µl miliQ water. Purity and concentration
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of DNA was measured using a NanoDrop-1000 spectrophotometer (NanoDrop
Technologies) at 260/280 nm.
2.2.1.10 DNA sequencing
DNA sequencing was done by GATC, London. Plasmid DNA was sent at a con-
centration of 30 ng/µl in a total volume of 50 µl. Sequencing data was analysed
using BioEdit sequence alignment editor and ClustalW (EBI, UK) against corre-
sponding reference sequences obtained from the NCBI database.
2.2.2 Mammalian cell culture experiments
HEK-293 Flp-InTM, i293-ST-Flag, i293-GFP, i293-GFP-ST, and Cos7 cell lines were
maintained in Dulbecco modified eagle medium (DMEM) (Life TechnologiesTM),
supplemented with 5 U/ml penicillin and streptomycin and 10% (v/v) foetal calf
serum (FCS), (referred to as 10% DMEM). HEK-293 Flp-InTM cells were main-
tained in 10% DMEM supplemented with 100 µg/ml zeocin (Life TechnologiesTM).
i293-ST-Flag, i293-GFP and i293-GFP-ST cells lines were maintained in 10% DMEM
supplemented with 100 µg/ml Hygromycin B (Life TechnologiesTM). All above-
mentioned cell lines were passaged every 3-4 days, removing the confluent cells
layer using kinetic force from the surface of a 75 cm3 tissue culture vessel (Sigma-
Aldrich R©) and split in a 1:10 to 1:20 ratio into new flasks made up to a total
volume of 20 ml using 10% DMEM and supplemented with the corresponding
selective antibiotic.
MCC13 cells were maintained in Roswell Park Memorial Institute (RPMI) media,
supplemented with 5 U/ml penicillin and streptomycin and either 15% FCS or
10% FCS, respectively (15% RPMI or 10% RPMI). Cells were passaged every 3-
4 days, removing the confluent cell layer by trypsinisation or using non-trypsin
EDTA cell resuspension buffer (Life TechnologiesTM), and the cells were subse-
quently split 1:20 into new flask containing 15% RPMI.
All cell lines were incubated in an InCu saFe Copper-Enriched Stainless Steel CO2
incubator (Panasonic), with 5% CO2 concentration, unless otherwise stated.
For long term storage, cells were aliquoted into 1.8 ml CryotubesTM (NUNCTM)
at 1 × 106 cells/ml. Cells were resuspended in freezing media [90% (v/v) FCS,
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10% (v/v) DMSO]. Cryotubes were then stored at -80◦C for 24 h in an isopropanol
containing freeze flask and transferred to liquid nitrogen for long term storage.
2.2.2.1 Generating inducible cell lines
In order to generate cell lines capable of inducible expression of EGFP or GFP-
tagged MCPyV ST (EGFP-ST), HEK-293 Flp-InTM cells were co-transfected with
EGFP-C1 or EGFP-ST-C1 respectively and pPGK/Flip/ObpA (kindly supplied
by M.Walsh, University of Sheffield, UK) at a 1:3 ratio, using 0.5 µg of EGFP
or EGFP-ST and 1.5 µg pPGK/Flip/ObpA. The cell line was selected and main-
tained using Hygromycin B resistance at concentration of 100 µg/ml. Cells were
monoclonally selected to ensure the resulting cell line was derived from a single
cell colony.
2.2.2.2 Induction of inducible cell lines
3 x 105 cells (i293-ST-flag, i293-GFP or i293-GFP-ST) were seeded per 6-well plate
in 2 ml 10% DMEM. 24 h later, 4 µl doxyclycline hyclate (Life TechnologiesTM)
was added to 2ml 10% DMEM and mixed, resulting in a final concentration of 2
µg/ml per well. Cells were grown under induction for 24, 48, or 72 h.
2.2.2.3 Plasmid DNA transfection
A standard transfection protocol was followed for all assays unless stated other-
wise. Approximately 5 x 105 cells were seeded into a 6-well (35 mM diameter)
plate 24 hours before transfection, to allow cells to grow to 70–80% confluence at
transfection. All plasmid DNA transfections of HEK-293 and derived cell lines
used LipofectamineTM 2000, according to the manufacturer’s protocol. For each
reaction (1 well of a 6-well plate), 3 µl LipofectamineTM 2000 was diluted in 100
µl Opti-MEM R© (Life TechnologiesTM) and mixed with 1 µg total plasmid DNA
diluted in 100 µl Opti-MEM R©. This mixture was incubated for 20 min at room
temperature. Cell media was replaced with 1 ml of Opti-MEM R©. After incuba-
tion, the transfection mixture was added to cells drop-wise. Cells were incubated
at 37◦C overnight. Subsequently Opti-MEM R© was replaced with 10% DMEM
and transfected DNA was allowed to express for 24, 48, or 72 h. All plasmid
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DNA transfections of MCC13 cells used TransIT-X2 R© Dynamic Delivery System
(Mirus LLC), according to the manufacturer’s protocol. For each reaction (1 well
of a 6-well plate), 7.5 µl of the transfection reagent was mixed with 2.5 µg of plas-
mid DNA in 250 µl Opti-MEM R©, incubated for 30 min and added drop-wise to
cells in 1 ml/well Opti-MEM R©. Cells were incubated at 37◦C overnight. Sub-
sequently Opti-MEM R© was replaced with 15% RPMI and transfected DNA was
allowed to express for 24, 48, or 72 h.
2.2.2.4 siRNA transfection
A standard siRNA transfection protocol was followed for all assays unless stated
otherwise. Approximately 3 × 105 cells were seeded into a 6-well plate 24 h be-
fore transfection. For each reaction, 10 nM of siRNA and 7.5 µl of TransIT-X2 R©
Dynamic Delivery System (Mirus LLC) were mixed in 250 µl of Opti-MEM R©, in-
cubated for 30 min and added drop-wise to cells in 1 ml/well Opti-MEM R©. Cells
were incubated at 37◦C overnight. Subsequently Opti-MEM R©was replaced with
appropriate media and RNAi was allowed to proceed for at least 72 h.
2.2.2.5 Addition of inhibitors
Approximately 5× 105 cells were seeded into 6-well plates, and transfected and/or
induced if appropriate. 24 h before harvesting, appropriate concentrations of in-
hibitors dissolved in DMSO were added (up to a final concentration of 1 µl/ml
DMSO). 1 µl/ml of DMSO was also added to control cells. Otherwise, when cells
were seeded into 96-well plates or otherwise, the number of cells and the amounts
of inhibitors were adjusted accordingly.
2.2.3 Cell viability (MTS) assay
Approximately 5,000 cells per well were seeded into 96-well plates in quintu-
plicate for each treatment condition. Negative controls of cell-free medium, un-
treated cells and 1 µl/ml DMSO-treated cells were included. Cells were grown
overnight and appropriately treated the following day. 24 h later, 20µl of CellTitre
96 R©AQueous One Solution Cell Proliferation Assay reagent (Promega) was added
to each well. Cells were then incubated for approximately 1 h at 37◦C, and
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absorbance was read at 490 nm using the Infinite R© F50 absorbance microplate
reader (Tecan).
2.2.4 Immunofluorescence
Glass coverslips were sterilised in 100% ethanol and, placed in individual wells
of a 6-well plate, and air-dried before were treatment with 0.01% poly-L-lysine
solution (Life TechnologiesTM) for 5 min at room temperature. Coverslips were
washed 3× with 1 ml PBS and 3× with the appropriate culture medium. Ap-
proximately 2–3× 105 cells were seeded onto coverslips in their respective media
and incubated for overnight at 37◦C. Cells were either transfected, induced or
both. Following the appropriate incubation time and manipulation, media was
removed and the cell monolayer washed 3× in 2 ml PBS, followed by fixation in 2
ml PBS containing 4% (v/v) paraformaldehyde for 15 min at room temperature.
The cell monolayer was washed 3× with 2 ml PBS and permeabilised (if appro-
priate) with 2 ml PBS containing 1% (v/v) Triton X-100 for 15 min. Cells were
washed a further 3× in 2 ml PBS and blocked for 1 h at 37◦C in 2 ml blocking
solution [PBS, 1% (w/v) bovine serum albumin (BSA)]. After blocking, cover-
slips were transferred to a humidity chamber and incubated for 1 h at 37◦C or
overnight at 4◦C with an appropriate primary antibody (see Table 2.2) diluted
in blocking solution. Following incubation, cells were washed gently 5× with
PBS and incubated with the appropriate AlexaFluor conjugated secondary anti-
body for 1 h at 37◦C. Subsequently, cells were washed gently 5× with PBS and
mounted on microscope slides using VECTORSHIELD R© with DAPI mounting
media (Vector Laboratories) to stain the nucleus. Cells were then visualised us-
ing the LSM700 META laser scanning inverted confocal microscope and ZEN
2011 image analysis software (Zeiss).
2.2.4.1 Staining the actin cytoskeleton
The immunofluorescence microscopy protocol was followed. An actin stain, rho-
damine phalloidin (Life TechnologiesTM) was used at a 1:10,000 dilution in 1%
BSA at room temperature for 20 min. This stain was either used after washing
cells following permeabilisation with 1% (v/v) Triton X-100, if antibody stain-
ing was not required or following secondary antibody exposure. Cells were then
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gently washed 5× with PBS and mounted using VECTORSHIELD R© with DAPI.
2.2.5 Protein expression and immunoblotting
2.2.5.1 Preparation of mammalian cell lysates
Cells were removed from the tissue culture plates by pipetting with 1 ml PBS.
MCC13 cells were removed from the surface of the culture plate by scraping in 1
ml PBS. The cells suspension was then centrifuged at 3,500 × g at room tempera-
ture, washed 3× in 1 ml PBS, and re-centrifuged. The cell pellet was then resus-
pended and lysed in 100 µl pre-chilled RIPA lysis buffer [150 nM Tris-HCl, 50 mM
Tris base ultrapure, 1% NP40, pH 7.6, supplemented with 1× protease inhibitor
EDTA (Roche)]. Fresh 1× Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich R©)
was added if cells were to be probed for phosphorylated proteins. The samples
were immediately mixed and incubated on ice for 30 min, with mixing every 5
min. The lysates were then centrifuged in a centrifuge at 13,200 × g for 10 min at
4◦C. The supernatant was transferred to a clean microcentrifuge tube and stored
at -20◦C until further use.
2.2.5.2 Determination of protein concentration
All protein concentrations were determined using the DC Protein Assay Kit (Bio-
Rad Laboratories, Inc.), according to the manufacturer’s protocol. 5 dilutions of
a protein standard (BSA) were prepared in a 96-well plate, with concentrations
ranging from 0.2 mg/ml to 1.5 mg/ml. This was used to prepare a standard
curve for each plate measurement. The standard was prepared in the same buffer
as the test protein samples to ensure accuracy of the standard curve. 5 µl of each
standard and test sample were pipetted into the 96-well plate in triplicate. 20 µl
of Reagent S was mixed thoroughly with 1 ml Reagent A, and 25 µl of the mixed
solution were then added to each individual well, followed by 200 µl Solution B.
The plate was then agitated for 20 min and the absorbance read at 620 nm using
the Infinite R© F50 absorbance microplate reader (Tecan). Protein concentrations of
the test samples were determined by plotting a standard curve using the standard
dilution series.
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2.2.5.3 Preparation of tumour and cell samples
Frozen MCC tumour samples (originally obtained from Professor Julia Newton-
Bishop at St James University Hospital, Leeds) were physically homogenised us-
ing a mortar and pestle, then lysed for 1 hr using 10 ml pre-chilled RIPA lysis
buffer, sonicated twice for 5 min (20 s on/10 s off), then lysed for further 30 min
with mixing every 5 mins. The lysates were then centrifuged in a centrifuge at
13,200 × g for 10 min at 4◦C. The supernatant was transferred to a clean micro-
centrifuge tube and stored at -20◦C until further use. A fresh skin sample from a
consenting healthy donor (obtained by Professor Eric Blair at University of Leeds)
was treated identically to the frozen tumour samples and used as the control in
further experiments.
2.2.5.4 Tris-glycine SDS-polyacrylamide gel electrophoresis (PAGE)
Tris-glycine polyacrylamide running gels (Table 2.6) were overlaid with stacking
gels [per 1 ml: 170 µl acrylamide/bis acrylamide solution 37.5:1 (Severn Biotech
Ltd), 130 µl 0.25M Tris-HCL (pH 6.8), 10 µl 10% (w/v) SDS, 670 µl miliQ water,
10 µl 10% ammonium persulfate, 2 µl TEMED].
Table 2.6: Reagents and their volumes to prepare a range of tris-glycine polyacry-
lamide running gels
Reagent 6% 8% 10% 12%
milliQ water 2.6 ml 2.3 ml 1.9 ml 1.6 ml
Acrylamide/bisacrylamide
(37.5:1)
1 ml 1.3 ml 1.7 ml 2.0 ml
1 M Tris-HCl (pH 8.8) 1.3 ml 1.3ml 1.3 ml 1.3 ml
10% (w/v) SDS 50 µl 50 µl 50 µl 50 µl
10% (w/v) ammonium persu-
flate
50 µl 50 µl 50 µl 50 µl
TEMED 4 µl 3 µl 2 µl 2 µl
2× protein solubilising buffer [50 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 20%
(v/v) glycerol, 50 µg/ml Bromophenol Blue and 10 mM DTT] was added to pro-
tein lysates and the samples were denatured by heating at 95◦C for 3–5 min.
Heated samples were loaded onto appropriate polyacrylamide gels. Samples
were loaded next to pre-stained protein ladder (Bio-Rad Laboratories, Inc.), as
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an indicator of molecular weight (kDa). Prior to sample loading, gels were im-
mersed in Tris-glycine running buffer [0.25 M Tris-base, 192 mM glycine, 0.1%
(w/v) SDS]. Gels were run at 180 V for 4˜5 min or until the solubilising buffer
reached the bottom to the gel. All SDS-PAGE was carried out using a Bio-RadTM
Mini-PROTEAN 3 cell (Bio-Rad Laboratories, Inc.), set up according to the man-
ufacturer’s instructions. Proteins were then analysed by western blot.
2.2.5.5 Western (immuno-) blotting
Proteins from SDS-PAGE gels were transferred onto Thermo ScientificTM PierceTM
Nitrocellulose membranes (Thermo Fisher Scientific Inc.), using the Bio-Rad Mini
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories, Inc.), according to
the manufacturer’s protocol. 4 pieces of Whatman 3 mm filter paper, 1 SDS-PAGE
gels and one nitrocellulose membrane were soaked in transfer buffer [25 mM Tris-
base, 190 mM glycine, 20% (v/v) methanol] and placed in a cassette in sequential
order. Proteins were transferred from the gel to the membrane at 100 V for 1–2
h, depending upon protein size, followed by incubation of the membrane in 5%
TBS-Tween blocking buffer [500 mM NaCl, 20 mM Tris, 0.1% (v/v) Tween-20,
5% non-fat dried milk (Marvel)] at room temperature for 1 h. Subsequently, the
membrane was incubated in the corresponding primary antibody (See Table 2.3
for concentrations) diluted in 1% TBS-Tween blocking buffer [500 mM NaCl, 20
mM Tris, 0.1% (v/v) Tween-20, 1% non-fat dried milk (Marvel)] overnight at 4◦C.
The membranes were then washed 3× for 5 min in 1× TBS-tween buffer [20 mM
Tris, 0.1% Tween-20, 500 mM NaCl], and incubated for 1 h at room temperature
in the appropriate secondary antibody. The membranes were then washed 3× for
5 min in 1× TBS-tween solution. Protein bands were then visualised by enhanced
chemiluminescence using EZ-ECL enhancer solutions A and B kit (GeneflowTM)
(1:1 ratio) and exposed to ECLTM hyperfilm (AmershamTM). Films were devel-
oped using a Konica SRX-101A developer. All incubations and washes were done
with agitation.
2.2.6 Co-immunoprecipitation
MCC13 cells were seeded at 5 × 105 and transfected for 12 h. 24 h later cells were
harvested and lysed in 1 ml lysis buffer supplemented with protease inhibitor
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cocktail. Cell lysates were then incubated with GFP-TRAP A beads (Chromotek)
for 2 h at room temperature. Beads were then washed 3× in ice-cold PBS, resus-
pended in 2× protein solubilising buffer and analysed by immunoblotting with
appropriate antibodies.
2.2.7 Cell motility experiments
2.2.7.1 Life cell imaging
i293-GFP, i293-GFP-ST or MCC13 cells were seed at a density of 1 × 105 cells
per well in 6-well plates, grown overnight, and either induced with doxycycline
hyclate at 2 µg/ml or transfected with 1 or 2.5 µg of plasmid DNA per well using
the appropriate transfection reagent. Cells were incubated for 24 h at 37◦C, and, if
applicable, inhibitors were added at appropriate concentrations for another 24 h.
Cells were then imaged using the IncuCyteTM Live-Cell Imaging System (Essen
BioScience), as per the manufacturer’s protocol. Imaging was performed every
30 min over the course of 24 or 48 h and cell motility was then analysed using
Image J software.
2.2.7.2 Filopodia analysis
Cells were prepared as described for immunofluorescence, and, if appropriate,
induced, transfected and/or treated with inhibitors. Cells were visualised visu-
alised using the LSM700 META laser scanning inverted confocal microscope (n
= 75 for each condition), and filopodia were counted and their length measured
using ImageJ software.
2.2.7.3 Polarity assay
i293-GFP and i293-GFP-ST were seeded at a density of 5 × 105 on coverslips.
After 24 hours cells were either induced with 2 µg/ml doxycycline hyclate or
transfected. 6 h pre-fixation, cells were scratched using a p200 tip across the cov-
erslip, washed 3× with media and left to move back into the wound gap. Cells
were then fixed and stained for Golgi structures. Cells were visualised visualised
using the LSM700 META laser scanning inverted confocal microscope (n = 75 for
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each condition) and scored for polarity if the Golgi apparatus was seen in front
of the nucleus towards the wound gap, using ZEN 2011 image analysis software
(Zeiss).
2.2.7.4 Haptotaxis migration assay
HEK-293 Flp-In R©, i293-GFP and i293-GFP-ST cells were seeded at 3 × 105 per
6-well plate, and induced with doxycycline hyclate if appropriate for 24 h. Cells
were then treated with 1 µl/ml DMSO or appropriate concentrations of chloride-
channel inhibitors (Table 2.5) for 24 h. 1 × 106 cell suspensions in triplicate were
prepared in serum-free DMEM containing the appropriate inhibitors. CytoSelectTM
24-well Haptotaxis Assay, Collagen I plates (Cell Biolabs, Inc) were prepared ac-
cording to the manufacturer’s instructions. 500 µl 10% DMEM was added to the
bottom of the wells and 300 µl of cell suspension was added to the insert. Cells
were allowed to migrate towards the FCS chemoattractant for 24 h. Then media
was aspirated, inserts washed, transferred to clean wells and stained for 10 min
at room temperature in 400 µl of the Cell Stain Solution provided. Inserts were
then transferred to clean wells with 200 µl Cell Extraction Solution and agitated
for 10 min. 100 µl of each sample was transferred to a 96-well plate and read at
560 nm using the Infinite R© F50 absorbance microplate reader (Tecan).
2.2.8 Cell surface protein analysis
2.2.8.1 Flow cytometry
HEK-293 Flp-In R© cells were seeded at 3× 105 density in 6-well plates, then mock
transfected or transfected with 1 µg EGFP or EGFP-ST per well using the stan-
dard Lipofectamine R©2000 protocol for 6 h. 24 h post-transfection cells were har-
vested, washed with ice-cold PBS and resuspended at 1–2× 106 cells/ml in stain-
ing buffer [PBS, 10% FCS, 1% (w/v) sodium azide]. Cells were then fixed with
2% paraformaldehyde for 10 min at 37◦C, centrifuged at 1,000 × g and washed
3× with staining buffer. Cells were then incubated with appropriate dilutions
of primary antibody or staining buffer only for 1 h at room temperature in the
dark, washed 3× with staining buffer and incubated with Alexa-Fluor-tagged
secondary antibody or staining buffer only for 1 h at room temperature in the
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dark. Cells were then washed 3×with staining buffer and finally resuspended in
500 µl of staining buffer. Flow cytometry was performed immediately after stain-
ing. Flow cytometry experiments were performed in triplicate, and each exper-
iment included unstained and secondary-only stained controls. Isotype controls
were also performed for all antibodies used and the gates were set according to
Figure 2.1.
Figure 2.1: Isotype controls (rabbit and mouse) for flow cytometry experiments. HEK-
293 cells were grown in 6-well plates for 24 h. Cells were fixed with 2% paraformalde-
hyde, then stained with rabbit and mouse isotype control antibodies before performing
flow cytometry. FITC-A corresponds to EGFP fluorescence and APC-A corresponds to
secondary antibody staining.
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2.2.9 Patch-clamping assay
HEK-293 cells were seeded at 3 × 105 in 6-well plates, then transfected with 1
µg EGFP or EGFP-ST using Trans-IT-LT1 reagent (Mirus) and studied by elec-
trophysiology 2–5 days later. Patch pipettes were pulled from thin-walled fil-
amented borosilicate glass capillaries (Harvard Apparatus) and had resistances
between 2–4 MΩ in the experimental solutions. The intracellular pipette solution
contained 135 mM KCl, 20 mM NaCl, 1 mM CaCI2, 1 mM MgCI2, 11 mM EGTA,
10mM HEPES, pH 7.3, the extracellular bath solution contained 140 mM NaCI,
5 mM KOH, 2 mM CaCI2, 1 mM MgCI2, 10 mM HEPES, 30 mM D-mannitol,
pH 7.4. Membrane currents were recorded from single fluorescing cells using the
whole-cell configuration of the patch clamp technique using a HEKA EPC-10 am-
plifier under the control of PatchMaster software (HEKA Electronik), filtered at 3
kHz and digitised at 10 kHz. Cells were held at -80 mV and pulses were applied
to potentials between -100 and +100 mV. Current-voltage relationships were con-
structed for each cell by plotting the steady-state current at the end of the pulse
against the pipette potential.
2.2.10 Gene expression analysis
2.2.10.1 RNA extraction
i293-ST-Flag cells were seeded at a density of 4 × 105 in triplicate per condi-
tion (uninduced and induced) and induced for 48 h with 2 µg/ml doxycycline
hyclate. Cells were then directly lysed by addition of 1ml TRIzol reagent (Life
TechnologiesTM) per well, mixed by pipetting in an RNase-free microcentrifuge
tube, and incubated at room temperature for 5 min. Subsequently, 200 µl chloro-
form was added per sample, and samples were vortexed for 15 s and incubated
at room temperature for 3 min. Samples were then centrifuged at 12,000 × g
for 15 min at 4◦C. The top aqueous/colourless phase (5˜00 µl) was transferred to
a fresh RNase-free microcentrifuge tube. RNA was then precipitated by adding
500 µl isopropanol and incubating samples at room temperature for 10 min before
centrifugation at 12,000 × g for 10 min at 4◦C. The supernatants were carefully
aspirated and the pellets washed in 1 ml 75% ethanol and briefly vortexed, fol-
lowed by centrifugation at 7,500× g for 5 min at 4◦C. The supernatants were once
again aspirated and the pellets air-dried for 5 min. The pellets were resuspended
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in 49 µl DEPC-treated water and 1µl RNaseOUTTM (Life TechnologiesTM) and in-
cubated at 57◦C for 10 min. The RNA was stored at -80◦C or treated immediately
with DNase I treated and reverse transcribed.
2.2.10.2 DNase I treatment
A DNase I kit (AmbionTM) was used to remove contaminating DNA from ex-
tracted RNA samples as per the manufacturer’s protocol. 0.1 volume of DNase
reaction buffer and 0.5 µl Amplification Grade DNase I were added to each sam-
ple, gently mixed and incubated for 30 min. After incubation, 0.1 volume of Stop
solution was added, samples were mixed thoroughly and heated at 70◦C for 10
min. Samples were then briefly chilled on ice. The RNA concentration was mea-
sured using a NanoDrop-1000 spectrophotometer (NanoDrop Technologies) at
280 nm wavelength. Samples diluted in RNase-free water to a final concentration
of 50 ng/µl.
2.2.10.3 Reverse transcription
SuperscriptTM II Reverse Transcriptase (Life TechnologiesTM) was used to synthe-
sise cDNA from the total extracted cellular RNA, according to the manufacturer’s
protocol. The initial sample mixture contained 1 µg DNase I treated RNA , 1 µl
10 mM dNTP mix, 1 µl Oligo(dT)12-18 primer and made up to a total volume of
12 µl. Samples were then mixed and incubated at 65◦C for 5 minutes and then
quick-chilled on ice. Following this, 4 µl 5X First-Strand buffer, 2 µl 0.1 M DTT, 1
µl RNaseOUTTM and 1 µl SuperscriptTM II Reverse Transcriptase were added per
sample. Samples were mixed and incubated at 42◦C for 50 minutes, followed by
enzyme inactivation at 70◦C for 15 minutes. This was then followed by ethanol
precipitation to remove dNTPs.
2.2.10.4 Ethanol precipitation
2 µl 3 M sodium acetate (pH 5.6) and 60 µl ice cold 100% ethanol were added
to each cDNA sample (Section 2.2.10.3) and mixed, followed by incubation at
4◦C for 10 minutes. Samples were then centrifuged at 12,000 × g for 10 minutes
at 4◦C. The pellets were washed in 1 ml ice cold 100% ethanol and centrifuged
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again at 12,000× g for 10 minutes at 4◦C. The supernatants were removed and the
pellets briefly air-dried. The cDNA pellets were resuspened in 20 µl nuclease-free
water (SigmaTM). The cDNA concentration was measured using a NanoDrop-
1000 spectrophotometer (NanoDrop Technologies) at 260 mM and diluted to 2
ng/µl in nuclease-free water.
2.2.10.5 RT-qPCR
RT-qPCR samples were set up in Corbett tubes and a pre-chilled Corbett tube
rack (Corbett Life Sciences). Each primer pair were added in duplicate to RNA
samples extracted at different times (biological replicates). The PCR master mix
contained the following for each reaction: 10 µl SensiMixPlus SYBRTM No-ROX
(QuantaceTM), 1 µl primer mix (10 µM of both forward and reverse primers),
5 µl nuclease-free water and 4 µl cDNA (10 ng final amount). The PCRs were
performed using a Rotor-GeneTM Q 5plex MRM Platform (QiagenTM) using a 3
Step with Melt program. A typical PCR cycle parameter consisted of 95◦C for
10 min and then 35 cycles of: 95◦C for 15 s, 60◦C for 30 s, and 72◦C for 20 s.
Quantitative analysis was then performed using the comparative CT method as
previously described [381].
2.2.11 Statistical analysis
All experiments where statistical significance is given have biological replicates of
n = 3 or more. Between-condition significance was measured using the Student’s
two-tailed t-test for independent samples. Data is presented as bar charts with
standard deviation error bars.
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Merkel cell polyomavirus small T
antigen enhances cell motility via
Rho-GTPase-induced filopodia
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3.1 Introduction
3.1 Introduction
MCPyV has been established as the causative agent of the vast majority of MCCs.
It is clonally integrated in genomes of both primary and secondary MCC tumours
[20], and MCPyV LT derived from MCC tumours carries a tumour-specific mu-
tation which renders the virus replication-incompetent [42]. MCC is a highly
aggressive neuroendocrine cancer, with a propensity to spread via the lymphatic
system [382]. It has a poor 5 year prognosis [193], likely due to its metastatic
character.
The spread of cancer cells from the primary solid tumour to remote sites, leading
to the growth of secondary tumours, is a key problem facing cancer treatment.
This process, known as metastasis, results in more than 90% of cancer associated-
deaths [383]. The clinical importance of cancer metastasis cannot be overstated,
and while many aspects have yet to be elucidated, cell motility is considered one
of the major underlying processes.
Cell motility is complex, involving multiple signalling cascades and a large va-
riety of cellular factors. An important component of cell motility is the actin
cytoskeleton, with a number of actin-associated proteins implicated in tumour
progression in a variety of different cancers [384] [385] [386]. In addition, the
actin cytoskeleton provides the backbone of motile cellular structures, such as
lamellipodia, filopodia, or invadopodia. Filopodia, for instance, are structures
used to explore the immediate surroundings of a cell. They are considered to be
early markers of cell motility [387]. Therefore appearance of filopodia around the
cellular periphery can indicate a motile phenotype.
Cell motility requires the remodelling of the actin cytoskeleton. This function is
controlled by the Rho-family GTPases, a large group of signal mediators that are
vitally important in the motility pathway. The Rho-family GTPases affect both
the microtubule network and the actin cytoskeleton [388]. The three most widely
studied Rho-family GTPases are Cdc42, Rac1 and RhoA. Simply put, Cdc42 is
involved in filopodia formation [389], Rac1 in lamellipodia formation [390], and
RhoA in stress fibre formation [297]. While this classification is broadly valid,
recent research has shown that the functions of Rho-family GTPases are more
complex, involving cross-talk in the cell motility cascade. For instance, filopodia
formation is not exclusively due to Cdc42 signalling [391]. Importantly, Rho-
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family GTPases are not only vital for the normal functioning of many different
cell types, but also play a role in cancer [392] [393] [394]. For example, overex-
pression of RhoA has been observed in a number malignancies, including breast,
colon, lung, and gastric cancers [395] [396] [397].
This chapter begins with the initial observation of changes to the actin cytoskele-
ton, actin-associated protein expression and cell motility upon MCPyV ST expres-
sion. It then focuses on the involvement of the Rho-family GTPases in MCPyV
ST-induced cell motility and filopodia formation.
3.2 Quantitative proteomic analysis shows MCPyV ST
expression affects actin-associated proteins
Regulation of the actin cytoskeleton and associated proteins is an integral part of
cell motility. A SILAC-based quantitative proteomic approach was undertaken to
determine potential alterations in the host cell proteome upon inducible MCPyV
ST expression in a HEK-293-derived i293-ST cell line (previously described in
[210]). The microtubule network and the actin cytoskeleton were both observed
to be upregulated upon MCPyV ST expression. For example MCPyV ST expres-
sion results in the upregulation of the microtubule-associated protein, stathmin,
which affects microtubule dissociation [398] [210]. Moreover, the same approach
highlighted that a number of proteins associated with the regulation of the actin
cytoskeleton were also upregulated upon MCPyV ST expression. These proteins
are shown in Table 3.1.
In order to confirm increased levels in actin-associated proteins, i293-ST cells re-
mained uninduced or were induced with doxycycline hyclate for 48 h. In addi-
tion, MCC13 and Cos7 cells were transfected with EGFP or EGFP-ST. Cell lysates
were analysed by immunoblotting, and upregulation of actin-associated proteins
Arp3, cortactin, and cofilin-1 was confirmed upon expression of MCPyV ST, both
in 293 and in MCC13 cells, while cortactin and cofilin-1 upregulation was further
confirmed in the non-human Cos7 cell line (Figure 3.1A). Arp3 increased 4-fold
in i293-ST and MCC13 cells, cortactin increased 4-fold in i293-ST cells, 3-fold in
MCC13 cells, and 5-fold in Cos7 cells, while cofilin-1 increased 2-fold in i293-ST
and Cos7 cells, and 4-fold in MCC13 cells (Figure 3.1B).
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Table 3.1: Quantitative proteomic analysis shows an increase in actin-associated pro-
tein levels upon MCPyV ST expression
Protein Fold change over
uninduced
Peptide
hits
Function
Cofilin-1 5.1 16 Promotes rapid actin filament
turnover [399]
Cortactin 3.7 17 Contributes to the organisa-
tion of the actin cytoskeleton
and cell structure [287]
Actin-
related
protein
2/3 com-
plex
subunits
3.9 13 Regulates actin polymerisa-
tion and mediates the forma-
tion of branched actin net-
works [400]
This increase in protein levels appears to be at the translation stage, as transcrip-
tion levels, measured by RT-qPCR, are unchanged in i293-ST cells upon MCPyV
ST expression (Figure 3.1C). This could be due to previous findings that MCPyV
ST deregulates translation rather than transcription [234]. These results indicate
that the actin cytoskeleton is also altered upon MCPyV ST expression, which may
have implications in MCPyV ST-induced cell motility.
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Figure 3.1: Actin-associated proteins are upregulated upon MCPyV ST expression. (A)
i293-ST cells remained uninduced or were incubated for 48 h in the presence of doxycy-
cline hyclate. After induction, cell lysates were probed for Arp3, cortactin and cofilin-1
using specific antibodies. MCC13 and Cos7 cells were transfected with 1 µg EGFP or
EGFP-ST for 12 h. Lysates were probed for Arp3, cortactin, and cofilin-1. GAPDH was
used as a measure of equal loading, the 2T2 hybridoma was used to probe for MCPyV ST
expression. (B) Exposed film with immunoblotting results was scanned and uploaded
onto ImageJ software, which was used to compare band density (n = 3). (C) i293-ST
cells remained uninduced or were incubated for 48 h in the presence of doxycycline hy-
clate. After induction, cellular RNA was extracted using phenol/chloroform, reverse
transcribed and RT-qPCR was performed. Transcript levels were analysed using the com-
parative CT method (n = 3).
95
3.3 MCPyV T antigen-positive MCC tumours express actin-associated proteins
3.3 MCPyV T antigen-positive MCC tumours express
actin-associated proteins
MCPyV ST has been implicated in tumourigenesis [234], and MCPyV is found
clonally integrated in MCPyV-positive MCC tumours [20]. In order to investigate
whether actin-associated proteins are expressed and/or upregulated in MCPyV-
positive MCC tumours, two unrelated MCC tumour samples were used (MCC1
and MCC2). Healthy skin was used as a negative control. All samples were ho-
mogenised, lysed, and sonicated, and then probed for Arp3, cortactin and cofilin-
1. Arp3 and cortactin appear to be expressed to detectable levels in MCC1 and,
to a lesser extent, MCC2, but not in the healthy skin sample, while cofilin-1 is
upregulated in MCC1 compared to healthy skin, but not in MCC2 (Figure 3.2).
This may be due to varying expression of MCPyV tumour antigens in samples or
due to other unique tumour features. Overall, these results confirm the cell line
results and further indicate that the actin cytoskeleton is affected upon MCPyV
ST expression and may play a role in MCC tumourigenesis.
- + +MCPyV ST
Arp3
Cortactin
Cofilin
2T2
GAPDH
skin MCC1 MCC2
37 kDa
21 kDa
21 kDa
62 kDa
47 kDa
Figure 3.2: Actin-associated proteins are expressed in MCPyV-positive MCC tumours.
Healthy skin, MCC1, and MCC2 were crushed using a mortar and pestle on dry ice,
lysed with RIPA buffer for 30 min on ice and then further homogenised by sonication (5
min, 10 s on/10 s off). Tissue lysates were then probed for Arp3, cortactin and cofilin-1.
GAPDH was used as a measure of equal loading, the 2T2 hybridoma was used to probe
for MCPyV ST expression.
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3.4 MCPyV ST expression induces the formation of
actin-based protrusions
Altered actin-associated protein levels upon MCPyV ST expression indicated the
possibility of actin cytoskeleton-related phenotypic changes. To examine any
changes in MCPyV ST-expressing cells, HEK-293 cells were transfected with EGFP
or EGFP-ST. Cells were then fixed and stained with rhodamine phalloidin, an
actin-binding compound, to investigate any possible changes in the actin cy-
toskeleton. MCPyV ST-expressing HEK-293 cells showed a clear abundance of
actin-based protrusions, compared to the much smoother cell periphery of EGFP-
expressing HEK-293 cells (Figure 3.3A and Figure 3.4A). Similar results were also
observed in MCPyV ST-expressing MCC13 and Cos7 cells, showing an increased
number of longer protrusions, although the difference was less pronounced in
MCC13 cells (Figure 3.3B and Figure 3.4B). In Cos7 cells, expression of MCPyV ST
induced filopodia to a level comparable with HEK-293s (Figure 3.3C and Figure
3.4C). This different in results between cell lines may be due to the transformed
nature of MCC13 cells.
To further quantify the increase in actin-based protrusions upon MCPyV ST ex-
pression, the protrusions were counted and their lengths measured using Im-
ageJ software. Analysis showed a large increase in both the numbers and length
of these actin-based protrusions in MCPyV ST-expressing HEK-293 and Cos7
cells, and an increase in longer actin-based protrusions in MCPyV ST-expressing
MCC13 cells (Figure 3.4).
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Figure 3.3: Cell imaging shows an increase in actin-based protrusions in ST-expressing
cells. (A) HEK-293, (B) MCC13 or (C) Cos7 cells were transfected with 1 µg of either
EGFP or EGFP-ST for 6 h or 12 h. Cells were fixed after 24 h and stained with rhodamine-
phalloidin. Slides were then analysed using a Zeiss LSM 700 confocal laser scanning
microscope.
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Figure 3.4: Cell imaging quantification shows an increase in actin-based protrusions
in ST-expressing cells. Actin-based protrusions were counted for 75 cells per condition
using ImageJ software, in (A) HEK-293, (B) MCC13 or (C) Cos7 cell lines. Quantifications
are representative examples of 3 biological replicates.
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3.5 MCPyV ST expression induces the formation of
filopodia
The thin, filamentous nature of the actin-based protrusions formed upon MCPyV
ST expression suggests a filopodia-like character. However, to conclusively char-
acterise these protrusions, two filopodia-associated proteins were visualised us-
ing immunofluorescence in the absence and presence of MCPyV ST expression:
mDia2 [401] and IRSp53 [298]. To visualise mDia2 localisation, HEK-293 cells
were either transfected with EGFP-tagged mDia2 alone or co-transfected with
Flag-tagged MCPyV ST (ST-flag) [209]. To visualise IRSp53 localisation, EGFP
or EGFP-ST were co-transfected with myc-tagged IRSp53. Cells were then fixed
and stained with rhodamine phalloidin to visualise actin-based structures. In
control cells, mDia2 was seen to be diffuse in the cytoplasm, while in cells ex-
pressing MCPyV ST, mDia2 relocalised to the cell periphery and into the actin-
based protrusions (Figure 3.4A). Likewise, IRSp53 was observed to be diffuse in
the cytoplasm in control cells but relocalised to the cellular periphery and into
the actin-based protrusions upon the expression of MCPyV ST (Figure 3.4B). Due
to the known association of both mDia2 and IRSp53 with filopodia, this was the
first marker-based indication that MCPyV ST expression induced filopodia for-
mation specifically. To further confirm this conclusion, the localisation of an ad-
ditional filopodia marker, myosin X [402], was visualised. HEK-293 cells were
transfected with EGFP or EGFP-ST and stained for myosin X. Punctate foci of
myosin X staining can be observed at the tips of MCPyV ST-induced actin-based
protrusions (Figure 3.4C). Together, these results confirm that the protrusions in-
duced by MCPyV ST expression are filopodia.
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Figure 3.5: Screening of filopodia-associated proteins indicates MCPyV ST expression
induces filopodia formation. (A) HEK-293 cells were either transfected with 1 µ g of
EGFP-mDia2 or co-transfected with 1 µ g of EGFP-mDia2 and ST-Flag for 6 h. 12 h later
cells were fixed and stained with rhodamine-phalloidin and specific antibodies. (B) HEK-
293 cells were either co-transfected with 1 µg of EGFP and IRSp53-myc or co-transfected
with 1 µg of EGFP-ST and IRSp53-myc for 6 h. 12 h later cells were fixed and stained
with rhodamine-phalloidin and specific antibodies. (C) HEK-293 cells were either trans-
fected with 1 µg of EGFP or EGFP- ST for 6 h. 12 h later cells were fixed and stained
with rhodamine-phalloidin and specific antibodies. All slides were then analysed using
a Zeiss LSM 700 confocal laser scanning microscope.
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3.6 i293-GFP and i239-GFP-ST cell line generation us-
ing the 293 FlipInTM system
In order to reliably and consistently express MCPyV ST with a fluorescent tag,
two cell lines were produced: one that expressed GFP-tagged MCPyV ST (i293-
GFP-ST) and a control cell line that expressed GFP (i293-GFP) under doxycycline
hyclate induction. The GFP tag allows for motility to be observed in individ-
ual living cells as well as potentially observing the effects of MCPyV ST in vivo.
The GFP gene from the pEGFP-C1 plasmid and the GFP-ST fused gene from a
pEGFP-C1 backbone were subcloned first into pCR R©-Blunt vectors and then into
pcDNA5/FRT/TO vectors. Expression of both vectors was confirmed in HEK-
239 cells (Figure 3.5A).
GFP
GFP  in pcDNA5/FRT/TO
GFP-ST in pcDNA5/FRT/TO
GAPDH
i293-GFP
i293-GFP-ST
GAPDH
 0       24        48       h.p.iA B
27 kDa
38 kDa
37 kDa
Figure 3.6: Production of GFP-expressing and GFP-tagged MCPyV ST-expressing
inducible cell lines. (A) HEK-293 cells were transfected with 1 µg of EGFP-
pcDNA5/FRT/TO or 1 µg of EGFP-ST-pcDNA5/FRT/TO. Immunoblotting shows ex-
pression of GFP or GFP-ST from pcDNA5/FRT/TO. (B) i293-GFP and i293-GFP-ST cells
remained uninduced or were induced for 24 or 48 h using doxycycline hyclate. Im-
munoblotting shows expression of both GFP and GFP-ST from cells after induction.
GAPDH was used as a loading control. h.p.i. - hours post induction.
The Flp-In R© HEK-293 cell line was co-transfected with the Flp R© plasmid and
pcDNA5/FRT/TO with the GFP or GFP-ST insert at a 9:1 ratio. After an overnight
transfection cells were grown in serum-supplemented DMEM with 100 µg/ml
Hygromycin B to select cells with the integrated Flp-In R© system. Single colonies
were picked and grown under antibiotic selection. Clonal cell populations were
tested for induced expression of either GFP or GFP-ST by adding doxycycline
hyclate. Clones with highest expression and non-leaky promoters were selected
and maintained. Both the i293-GFP and i293-GFP-ST cell lines express the de-
sired proteins upon induction with doxycyline hylcate (Figure 3.5B). For the sake
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of brevity, these cell lines will be referred to as i293s when discussed together.
3.7 MCPyV ST induces cell motility in i293 and in
MCC13 cells
Filopodia are early markers of cell motility. Thus a marked increase in filopo-
dia formation may correlate to increased in cell motility. In order to investigate
this possibility, live cell imaging was performed for 24 h using i293-GFP and
i293-GFP-ST cells, which were induced using doxycycline hyclate 24 h prior to
imaging or MCC13 cells transfected with EGFP and EGFP-ST (Figure 3.6A). Dis-
tances travelled by individual cells were tracked using ImageJ (see the individual
coloured traces), and analysis shows a significant (p < 0.001) increase in distance
travelled by MCPyV ST-expressing cells over control cells (Figure 3.6B). Firstly,
this suggests that the i293-GFP and i293-GFP-ST cell lines are functional and be-
have as expected depending on MCPyV ST expression. Secondly, it confirms the
published findings [210] that MCPyV ST induced cell motility and this is measur-
able in single cells in different cell lines.
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Figure 3.7: Live cell imaging shows MCPyV ST expression enhances cell motility. (A)
i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate. After 24 h,
cell motility was measured using the IncuCyte kinetic live cell imaging system. MCC13
cells were transfected with 1 µg EGFP or EGFP ST for 6 h. After 12 h cell motility was
measured using the IncuCyte kinetic live cell imaging system. Images were taken every
30 min for a 24 h period. (B) The movement of cells was then tracked using Image J
software (n = 30). Average cell movement was calculated and significance was tested
using a two-tailed Student’s t test.
3.8 MCPyV ST-induced cell motility is directional
Directional cell motility is an important feature of cell migration in cancer [403],
as migratory cells tend to move away from the primary tumour site towards lym-
phatic or blood vessels. In order to determine whether MCPyV ST expression
promotes directionality, i293-GFP and i293-GFP-expressing cells were induced
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with doxycycline hyclate for 48 h on coverslips, then scratches were made across
the coverslips and cells were left to grow into the scratches for 6 h. Cells were
then fixed and stained for Golgi vesicles. Golgi vesicle presence in front of the
nuclei of cells facing the gap is an indication of cell polarity, and thus an indi-
rect indication of directionality [404] (Figure 3.7A). Quantification of the image
indicated that MCPyV ST expression significantly (p < 0.001) increased the per-
centage of polarised cells (Figure 3.7B). This suggests that MCPyV ST expression
induces directional cell motility.
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3.9 MCPyV ST-induced cell motility is dependent on
the action of Rho-family GTPases
The Rho-family GTPases are a superfamily of signalling molecules, a number
of which have been implicated in increased cell motility and metastasis in var-
ious cancers [405] [406] [407]. They are also well characterised regulators of
actin dynamics [388]. In order to determine whether Rho-family GTPases are
involved in MCPyV ST-induced cell motility, a selection of inhibitors known to
target Rho-family GTPases were utilised at non-cytotoxic concentrations as mea-
sured by MTS assay (Figure 3.8): ML141 and ZCL278 (Cdc42 inhibitors) [408]
[409], NSC23766 (a Rac1 inhibitor) [410], and Rhosin (a RhoA inhibitor) [411].
i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate, while
MCC13 cells were transfected with EGFP or EGFP-ST, and treated with each re-
spective inhibitor for 24 h. Cells were then imaged using the IncuCyte kinetic
imaging system, every 30 min for 24 h (Fiigure 3.9A and Figure 3.10A).
Distance travelled by individual cells were tracked using ImageJ software. No
significant differences were observed among the average distances travelled by
control cells not expressing MCPyV ST, in both untreated and treated cells with
the Rho-family GTPase inhibitors (Figure 3.9B and Figure 3.10B). Conversely,
MCPyV ST-expressing cells treated with both Cdc42 inhibitors and the RhoA
inhibitor showed reduced cell motility (p < 0.001), while no significant reduc-
tion was observed when cells were treated with the Rac1 inhibitor (Figure 3.9B
and Figure 3.10B). This suggests that Cdc42 and RhoA GTPases may be the main
Rho-family GTPases involved in facilitating MCPyV ST-induced cell motility.
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Figure 3.9: Cell viability assays for Rho-family GTPase inhibitors. (A) i293-GFP and
i293-GFP-ST cells were induced for 24 h, then treated with inhibitors ((i) ML141, (ii)
NSC27366, (iii) Rhosin, (iv) ZCL278) at different concentrations for 24 h. (B) MCC13 cells
were grown for 24 h, then treated with inhibitors ((i) ML141, (ii) NSC27366, (iii) Rhosin,
(iv) ZCL278) at different concentrations for 24 h. Cell viability was measured using the
MTS assay. Highest concentration of each inhibitor at>80% viability was used for further
experiments.
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Figure 3.10: Live cell imaging shows a dependence of MCPyV ST-induced cell motility
on Cdc42 and RhoA in i293 cells. (A) i293-GFP and i293-GFP-ST cells were induced
using doxycycline hyclate and treated with 1 µg/µl DMSO, 15 µM of ML141, 50 µM of
NSC23766 or ZCL278, or 30 µM of Rhosin. After 24 h, cell motility was measured using
the IncuCyte kinetic imaging system. Images were taken for 30 min for a 24 h period.
(B) The movement of cells was then tracked using ImageJ software (n = 25). Average cell
movement was calculated and significance was tested using a two-tailed Student’s t-test.
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Figure 3.11: Live cell imaging shows a dependence of MCPyV ST-induced cell motility
on Cdc42 and RhoA in MCC13 cells. (A) MCC13 cells were transfected for 12 h with
1µg of EGFP and EGFP-ST, and treated for 24 h with 1 µg/µl DMSO, 30 µM of ML141, 75
µM of NSC23766 or ZCL278, or 60 µM of Rhosin. Cell motility was measured using an
IncuCyte kinetic live cell imaging system. Images were taken for 30 min for a 24 h period.
(B) The movement of cells was then tracked using ImageJ software (n = 25). Average cell
movement was calculated and significance was tested using a two-tailed Student’s t-test.
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Due to the previous results of an observed effect of Rho-family GTPases on
MCPyV ST-induced cell motility, it was hypothesised that MCPyV ST-induced
filopodia formation may also be affected by Rho-family GTPase inhibitors. Specif-
ically, it was speculated that Cdc42 and/or RhoA inhibition might reduce MCPyV
ST-induced filopodia formation. In order to explore this possibility, HEK-293 cells
were transfected with EGFP or EGFP-ST cells, and treated with the specific Rho-
family GTPase inhibitors (ML141, NSC27366, Rhosin and ZCL278) for 24 h. Cells
were then fixed and stained with rhodamine phalloidin to observe actin-based
structures (Figure 3.11A). Quantitative analysis of filopodia showed a decrease in
filopodia formation when MCPyV ST-expressing cells were treated with any of
the Rho-GTPase inhibitors (Figure 3.11B), suggesting that these signal mediators
are involved in MCPyV ST-induced filopodia formation. It may be that all 3 ma-
jor Rho-family GTPases are involved in MCPyV ST-induced filopodia formation
but not cell motility. However, to further explore the possibility of any differ-
ences on MCPyV ST-induced filopodia formation by Rho-family GTPases, HEK-
293 cells were co-transfected with ST-Flag and Rho-family GTPase transdom-
inant (TD) mutants: pcDNA-5-GFP-Cdc42-T17N, pcDNA5-GFP-Rac1-T17N, or
pcDNA5-GFP-RhoA-T19N (Figure 3.12A). These TD mutants are catalytically in-
active and inhibit endogenous Cdc42, Rac1 and RhoA activity respectively. Cells
were then fixed and stained with rhodamine phalloidin to visualise actin-based
structures.
Quantitative analysis of filopodia showed a small decrease in filopodia upon co-
expression of MCPyV ST with the Rac1 TD mutant. However, a marked decrease
was observed when cells are co-transfected with either the Cdc42 TD mutant or
the RhoA TD mutant, which confirms the observation of the live cell imaging
data (Figure 3.12B). These findings suggest a definitive role for Cdc42 and RhoA
in MCPyV ST-induced filopodia formation, and further indicate that these Rho-
family GTPases are involved in MCPyV ST-induced cell motility.
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Figure 3.12: Cell imaging shows that Rho-family GTPase inhibitors reduce MCPyV
ST-induced filopodia formation. (A) HEK-293 cells were transfected with 1 µg EGFP or
EGFP-ST for 6 h and treated with 1 µg/µl DMSO, 15 µM of ML141, 50 µM of NSC23766
or ZCL278, or 30 µM of Rhosin. After 24 h cells were fixed and stained with rhodamine-
phalloidin. All slides were then analysed using a Zeiss LSM 700 confocal laser scanning
microscope. (B) Actin-based protrusions were counted for 75 cells per condition using
ImageJ software. Quantifications are representative examples of 3 biological replicates.
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Figure 3.13: Cell imaging shows that Cdc42 and RhoA transdominant mutants reduce
MCPyV ST-induced filopodia formation. (A) HEK-293 cells were mock transfected,
transfected with 1 µg ST-Flag or co-transfected with 1 µg ST-Flag and pcDNA5-GFP-
Cdc42-T17N, pcDNA5-GFP-Rac1-T17N, or pcDNA5-GFP-RhoA-T19N for 6 h. 12 h later
cells were fixed and stained with rhodamine-phalloidin. All slides were then analysed
using a Zeiss LSM 700 confocal laser scanning microscope. (B) Actin-based protrusions
were counted for 75 cells per condition using ImageJ software. Quantifications are repre-
sentative examples of 3 biological replicates.
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MCPyV ST has been shown to promote the destabilisation of microtubules via
enhancing the expression of stathmin [210]. Data presented in this chapter show
that in addition to the microtubule network, the actin cytoskeleton undergoes
changes upon MCPyV ST expression. This is visible both in changes in protein
expression and in the increase in filopodia numbers. These changes were ob-
served to greater or lesser degrees in different cell lines: HEK-293, MCC13 and
Cos7 cells. In addition, expression or upregulation of actin-associated proteins
was observed in MCC tumours when compared to a MCC-negative healthy skin
sample.
Observations involving increased filopodia and changes in actin-associated pro-
tein levels upon MCPyV ST expression led to an investigation of changes in cell
motility. Data presented in this chapter show an increase in cell motility when
MCPyV ST is expressed, in i293 and MCC13 cells. In addition, data in i293 cells
suggests that MCPyV ST-induced cell motility is directional, which is significant
in a metastatic context [403].
Rho-family GTPases have been widely studied and shown to be important in
the cell motility pathway. Therefore, their effect upon MCPyV ST-induced cell
motility was investigated, and findings presented herein suggest that Cdc42 and
RhoA appear to be involved in MCPyV ST-induced cell motility and filopodia
formation, with Rac1 potentially playing a smaller role. This involvement of Rho-
family GTPases is not without precedent, as other oncogenic viruses have been
reported to affect the Rho-family GTPases. The best-known example is SV40 ST,
whose activity leads to the rearrangement of filamentous actin networks, includ-
ing Rac-induced lamellipodia formation, Cdc42-induced filopodia formation and
loss of RhoA-dependent stress fibres. Levels of Rac1 and Cdc42 are increased in
cells expressing SV40 ST, while levels of RhoA are decreased [342]. Thus it is
possible that a similar process is occurring in cells expressing MCPyV ST, except
through interaction with PP4C instead of PP2A (this argument will be expanded
upon in Chapter 4).
Rho-family GTPases are primarily regulated via GTP cycling, with a whole range
of factors stimulating or depressing GTPase activity. Rho-family GTPase activa-
tors are known as guanine exchange factors (GEFs), promoting the exchange of
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inactive GDP molecules for active GTP molecules. GEFs in turn are regulated by
a whole range of cellular receptors [412]. In addition, Rho-family GTPases are
negatively regulated by GTPase activity promoters (GAPs) and guanine dissoci-
ation inhibitors (GDIs), which are also regulated by cellular receptors and other
upstream mediators [413]. Investigation of which of these numerous factors are
important in MCPyV ST-induced cell motility is beyond the scope of this thesis,
but well worth researching in the future. Chapter 4 expands upon the investiga-
tion of MCPyV ST-induced cell motility, including the role of phosphatases and
receptors, to develop a potential model.
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Chapter 4
The interaction between MCPyV ST
and PP4C is required for initiating
cell motility through the
dephosphorylation of β1 integrin
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The cell motility pathway is a complex and dynamic series of interactions be-
tween a multitude of cellular factors. Within the pathway, protein phosphoryla-
tion and dephosphorylation have been shown to be important methods of signal
transduction [414] [415].
MCPyV ST has been shown to interact with cellular protein phosphatases PP2A
[416] and PP4 [209] [416]. PP2A is the major serine/threonine phosphatase in
mammalian cells, and is well-characterised, ubiquitous and evolutionarily con-
served [92]. It has three different subunits: the scaffold subunit A, the regulatory
subunit B, and the catalytic subunit C. MCPyV ST is know to bind to two different
A subunits of PP2A: Aα and Aβ [209]. This binding of polyomavirus ST outcom-
petes B subunit binding, resulting in altered substrate specificity [417]. However,
surprisingly, disrupting the PP2A binding site within MCPyV ST does not affect
the tumourigenic potential of the oncoprotein [234].
PP4 is a less well-characterised cellular phosphatase, but its catalytic subunit
(PP4C) has been shown to interact with MCPyV ST [209]. This interaction has
been implicated in regulating the NF-κB pathway [209] and in microtubule dis-
sociation [210].
In Chapter 3, the Rho-family GTPases were implicated in MCPyV ST-induced cell
motility and filopodia formation. As discussed, Rho-family GTPases are central
to the cell motility pathway; however, the pathway starts upstream of Rho-family
GTPases, via cellular receptors, such as the trans-membrane integrin receptors.
In humans, integrins exist as αβ heterodimers, with 24 types of α subunits and
9 types of β subunits. Some types are found in specific tissues (e.g. α3β2 in
platelets [418]) while others are widely expressed (e.g. α5α1) [419]. Integrins
consist of large extracellular domains that bind the extracellular matrix (ECM)
and short cytoplasmic tails that link to the actin cytoskeleton [420]. The main
function of these receptors is to transmit signals from the ECM to the cell interior,
and some of these signals affect cell motility [421] and cancer progression [422].
Integrins are regulated both externally and internally, by “inside-out” signals
from kinases and phosphatases and “outside-in” signals by extracellular ligands,
which are important for signalling cascades that regulate the cell motility path-
way [423]. Several kinases have been shown to bind to β subunits, including
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Src-family kinases (SFKs) [424]. In addition, the catalytic subunit of protein phos-
phatase 1 (PP1C) has been shown to interact with αIIbβ3 [425]. These interac-
tions are thought to initiate “outside-in” signalling from the ECM. Furthermore,
a number of studies have shown the significance of phosphorylation in the activ-
ity of integrins, including β1 [426] [427]. For instance, PP2A can dephosphorylate
β1 integrin at Thr788/789 [428].
The interaction of MCPyV with cellular protein phosphatases, and the role of
MCPyV ST in inducing cell motility suggest that integrins may play a role in MCC
metastasis. This chapter begins by implicating PP4C in MCPyV ST-induced cell
motility and shows that integrins play a role in MCPyV ST-induced cell motility
(with β1 integrin as the model). Results therefore suggest a mechanism for the
action of the MCPyV ST-PP4C interaction in regulating the initiation of the cell
motility pathway via the dephosphorylation of β1 integrin.
4.2 Interaction of MCPyV ST with PP4C is required
for cell motility
It is well established that MCPyV ST interacts with protein phosphatases, specif-
ically PP2A and PP4C [209]. In order to explore whether these interactions en-
hance cell motility, two mutants of MCPyV ST were utilised: EGFP-ST:R7A, which
fails to interact with the Aα isoform of PP2A, and EGFP-ST:∆95–111, which does
not interact with the Aβ isoform of PP2A or PP4C.
HEK-239 and MCC13 cells were transfected with either EGFP, EGFP-ST, EGFP-
ST:R7A, or EGFP-ST:∆95–111, and live cell imaging performed for 24h (Figure
4.1A). Distances travelled by individual cells were then tracked using ImageJ.
HEK-293 and MCC13 cells expressing EGFP-ST:∆95–111 showed a significant
(p < 0.001) decrease in distance travelled when compared to wild type MCPyV
ST expressing cells. In contrast, HEK-293 cells expressing the EGFP-ST:R7A mu-
tant did not show a significant decrease in motility, while MCC13 cells expressing
the same construct resulted in a less motile phenotype (Figure 4.1B). Therefore,
while these results do suggest a more significant role for PP2A Aβ and/or PP4C
than PP2A Aα, further investigations were necessary to disambiguate the results.
In order to further examine results presented in Figure 4.1, i293-GFP-ST cells were
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transfected with transdominant mutants of PP2A (PP2A-TD) or PP4C (PP4C-TD)
for 6 h. Then i293-GFP and untransfected and transfected i293-GFP-ST cells were
induced using doxycycline hyclate for 24 h. Cells were then imaged for 24 h
(Figure 4.2A) and the distance travelled by individual cells was tracked using Im-
ageJ. Cells co-expressing MCPyV ST with PP2A-TD showed a decrease in motility
(p< 0.001). However, interestingly, cells co-expressing MCPyV ST with PP4C-TD
showed a greater decrease in motility (p < 0.001) (Figure 4.2B), even though the
level of expression of PP4C-TD is much lower than that of PP2A-TD. These results
further suggested a more significant for PP4C; however, further work was neces-
sary to resolve the issue of which phosphatase is central to MCPyV ST-induced
cell motility.
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Figure 4.1: Live cell imaging shows that a MCPyV ST mutant that cannot bind PP2A
Aβ or PP4C affects cell motility. (A) HEK-293 cells were transfected with 1 µg EGFP,
EGFP-ST, EGFP-ST:R7A, and EGFP-ST:∆95–111 for 6 h, while MCC13 cells were trans-
fected with 1 µg EGFP, EGFP-ST, EGFP-ST:R7A and EGFP-ST:∆95–111 for 12 h. After 12
h cell motility was measured using the IncuCyte kinetic live cell imaging system. Images
were taken for 30 min for a 24 h period. (B) The movement of cells was then tracked
using Image J software (n = 25). Average cell movement was calculated and significance
was tested using a two-tailed Student’s t test.
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Figure 4.2: Live cell imaging shows that PP2A and PP4C transdominant mutants af-
fect MCPyV ST-induced cell motility. (A) i293-GFP-ST cells were transfected with 1 µg
PP2A-TD or PP4C-TD for 6 h. i293-GFP and transfected and untransfected i293-GFP-ST
cells were induced with doxycycline hyclate for 24 h. Cell motility was measured using
the IncuCyte kinetic live cell imaging system. Images were taken for 30 min for a 24
h period. (B) Expression of PP2A-TD and PP4C-TD in MCPyV ST-expressing cells was
probed using the HA antibody. GAPDH was used as loading control. (C) The movement
of cells was then tracked using Image J software (n = 25). Average cell movement was
calculated and significance was tested using a two-tailed Student’s t test.
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Results from Chapter 3 showed that MCPyV ST expression induces filopodia
formation. Therefore it was important to determine whether the interaction of
MCPyV ST with PP2A Aα or with PP2A Aβ and/or PP4C is involved in the
formation of MCPyV ST-induced filopodia formation. For this purpose, HEK-
293 cells were transfected with either EGFP, EGFP-ST, EGFP-ST:R7A or EGFP-
ST:∆95–111. Cells were then fixed and stained with rhodamine phalloidin to
identify actin-based structures (Figure 4.3A). Results show that the expression
of EGFP-ST:∆95–111 causes a reduction in filopodia formation compared to the
expression of EGFP-ST or EGFP-ST:R7A. Quantitative analysis confirmed that the
MCPyV ST 95-111 deletion mutant reduces the formation of filopodia, while the
MCPyV ST R7A mutant has little effect (Figure 4.3B). However, this analysis was
again not sufficient to determine which MCPyV ST-phosphatase interaction was
important in cell motility and filopodia formation.
In order to specifically investigate whether PP4C activity affects MCPyV ST-induced
filopodia formation, HEK-293 cells were transfected with EGFP or EGFP-ST in the
absence and presence of PP4C-TD for 6h, fixed and stained for actin structures
(Figure 4.4A). It must be noted that the transdominant mutant of PP2A could not
be used in this analysis due to its expression resulting in aberrant cell phenotype
as highlighted by confocal imaging (data not shown). Results show that cells co-
expressing EGFP-ST and PP4C-TD show a marked decrease in filopodia forma-
tion when compared to cells expressing wild-type MCPyV ST. Quantification of
filopodia confirmed these observations (Figure 4.4B). Together, these results point
towards PP4C as the main cellular phosphatase involved in MCPyV ST-induced
cell motility and filopodia formation.
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Figure 4.3: Cell imaging shows that a MCPyV ST mutant that cannot bind PP2A Aβ
or PP4C disrupts filopodia formation. (A) HEK-293 cells were transfected with 1 µg
EGFP, EGFP-ST, EGFP-ST:R7A, and EGFP-ST:∆95–111 for 6 h. 24 h later cells were fixed
and stained with rhodamine phalloidin. All slides were then analysed using a Zeiss LSM
700 confocal laser scanning microscope. (B) Actin-based protrusions were counted for 75
cells per condition using ImageJ software. Quantifications are representative examples
of 3 biological replicates.
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Figure 4.4: Cell imaging shows the transdominant mutant of PP4C disrupts MCPyV
ST-induced filopodia formation. (A) HEK-293 cells were transfected with 1 µg EGFP,
EGFP-ST or co-transfected with 1 µg EGFP and PP4C-TD or 1 µg EGFP-ST and PP4C-TD
for 6 h. 24 h later cells were fixed and stained with rhodamine phalloidin. All slides were
then analysed using a Zeiss LSM 700 confocal laser scanning microscope. (B) Actin-based
protrusions were counted for 75 cells per condition using ImageJ software. Quantifica-
tions are representative examples of 3 biological replicates.
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4.4 The 102 residue of MCPyV ST is important in PP4C
binding, MCPyV ST-induced cell motility, and filopo-
dia formation
Previous results suggested a possibly more significant role for PP4C compared
to PP2A isoforms in MCPyV ST-induced cell motility. However, it could not be
confirmed with the constructs available. Therefore, to conclusively determine
which cellular phosphatase is responsible for MCPyV ST-induced cell motility
and filopodia formation, additional alanine-scanning MCPyV ST mutants were
produced using site-directed mutagenesis in the 95–111 region. This work was
done by Husein Abdul-Sada. Immunoprecipitation experiments were then per-
formed to identify a mutant that could distinguish between PP2A Aβ and PP4C.
Results from pulldown experiments using PP4C-Flag showed that mutating a
single residue (102) specifically abrogates PP4C binding (Figure 4.5A), while mu-
tating the neighbouring residue (103) not only abrogates PP4C binding (Figure
4.5A) but also substantially reduces the interaction with PP2A Aβ (Figure 4.5B).
These distinguishing MCPyV ST mutants could therefore be used to determine
the specific interaction between MCPyV ST and cellular phosphatases that is nec-
essary for enhancing cell motility and filopodia formation.
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Figure 4.5: MCPyV ST 102 amino acid residue is critical for PP4C binding. (A) MCC13
cells were co-transfected with FLAG-PP4C and various EGFP-ST mutants for GFP-TRAP
immunoprecipitation. Precipitates were probed for FLAG and GFP. Lysates were probed
for FLAG and GFP to confirm successful expression and for GAPDH to verify equal pro-
tein loading. (B) MCC13 cells were co-transfected with EE-PP2A Aβ and various EGFP-
ST mutants for GFP-TRAP immunoprecipitation. Precipitates were probed for FLAG and
GFP. Lysates were probed for FLAG and GFP to confirm successful expression and for
GAPDH to verify equal protein loading. This work was performed by Hussein Abdul-
Sada.
To determine which specific cellular phosphatase is involved in MCPyV ST-induced
cell motility and filopodia formation, HEK-293 or MCC13 cells were transfected
with either EGFP, EGFP-ST, EGFP-ST102A, or EGFP-ST103A for 6 h. Cells were
then imaged using the IncuCyte live cell imaging system, taking an image ev-
ery 30 min for 24 h (Figure 4.6A), and cell motility was analysed using ImageJ
software by tracing the tracks of individual cells, allowing quantification of the
distance travelled. Results showed that HEK-293 and MCC13 cells expressing ei-
ther EGFP-ST102A or EGFP-ST103A showed reduced cell motility in comparison
to cells expressing EGFP-ST (p < 0.001) (Figure 4.6B). This suggests that the spe-
cific interaction of MCPyV ST with PP4C is required for MCPyV ST-induced cell
motility.
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Figure 4.6: Live cell imaging shows that MCPyV ST mutants that cannot bind PP4C
reduce MCPyV ST-induced cell motility. (A) HEK-293 or MCC13 cells were transfected
with 1 µg EGFP, EGFP-ST, EGFP-ST102A or EGFP-ST103A for 6 h or 12 h. Cells were im-
aged using the IncuCyte live cell imaging system every 30 min for 24 h. The movement of
cells was then tracked using ImageJ software. (B) Average cell movement was calculated
(n = 25) and significance was tested using a two-tailed Student’s t-test.
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Figure 4.7: Cell imaging shows that MCPyV ST mutants that cannot bind PP4C dis-
rupt filopodia formation. (A) HEK-293 cells were transfected with 1 µg EGFP, EGFP-ST,
EGFP-ST102A or EGFP-ST103A for 6 h. 24 h later cells were fixed and stained with rho-
damine phalloidin. All slides were then analysed using a Zeiss LSM 700 confocal laser
scanning microscope. (B) Actin-based protrusions were counted for 75 cells per condi-
tion using ImageJ software. Quantifications are representative examples of 3 biological
replicates.
To confirm the association between MCPyV ST, PP4C, and filopodia formation,
HEK-293 cells were transfected with EGFP, EGFP-ST, EGFP-ST102A or EGFP-
ST103A for 6 h, then fixed and stained with rhodamine phalloidin to observe
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actin-based structures (Figure 4.7A). Together with quantitative analysis of filopo-
dia formation (Figure 4.7B), results showed that cells expressing EGFP-ST102A
and EGFP-ST103A showed a marked decrease in filopodia formation compared
to cells expressing EGFP-ST. These results support the data gathered from live
cell imaging experiments and further confirm the importance of the specific in-
teraction of MCPyV ST with PP4C to induce cell motility and filopodia formation.
4.5 Phosphomimetic mutants of Cdc42 and Rac1 show
diminished filopodia formation upon MCPyV ST
expression
Having determined the role of PP4C in MCPyV ST-induced cell motility and
filopodia formation, the next stage was to determine where the MCPyV ST-PP4C
interaction might be important in the cell motility pathway. Initially, research was
focused on the Rho-family GTPases, as there is evidence that they can be regu-
lated by phosphorylation [429]. Specifically, phosphomimetic mutants of Cdc42
and Rac1 at the Ser71 residue have shown altered activity, with the Rac1 mutant
having reduced ability to induce the formation of membrane ruffles and showing
reduced GTP binding [430]. Therefore, it was hypothesised that overexpression
of phosphomimetic mutants of Cdc42 and/or Rac1 may result in a decrease in
filopodia formation upon MCPyV ST expression compared to cells expressing
MCPyV ST alone.
To test this hypothesis, HEK-293 cells were transfected with EGFP or EGFP-ST
in the presence of one of the following: Cdc42-HA, Cdc42S71E-HA (phospho-
mimetic), Rac1-HA, or Rac1S71E-HA (phosphomimetic). Cells were then fixed
and stained with rhodamine phalloidin to observe actin structures and HA an-
tibody to visualise the Rho-family GTPase constructs (Figures 4.8A and 4.9A).
Quantitative analysis of filopodia showed a decrease in filopodia formation when
cells co-expressed MCPyV ST and either of the phosphomimetic Rho-family GT-
Pase mutants (Figures 4.8B and 4.9B). These results suggested that the MCPyV
ST-PP4C interaction may be acting at the level of the Rho-family GTPases in the
cell motility cascade.
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Figure 4.8: Cell imaging shows that the phosphomimetic Cdc42S71E mutant reduces
MCPyV ST-induced filopodia formation. (A) HEK-293 cells were transfected with 1
µg EGFP, EGFP-ST or co-transfected with 1 µg EGFP-ST and Cdc42-HA or EGFP-ST and
Cdc42S71E-HA for 6 h. 24 h later cells were fixed and stained with rhodamine phalloidin.
All slides were then analysed using a Zeiss LSM 700 confocal laser scanning microscope.
(B) and (C) Actin-based protrusions were counted for 75 cells per condition using ImageJ
software. Quantifications are representative examples of 3 biological replicates.
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Figure 4.9: Cell imaging shows that the phosphomimetic Rac1S71E mutant reduces
MCPyV ST-induced filopodia formation. (A) HEK-293 cells were transfected with 1
µg EGFP, EGFP-ST or co-transfected with 1 µg EGFP-ST and Rac1-HA or EGFP-ST and
Rac1S71E-HA for 6 h. 24 h later cells were fixed and stained with rhodamine phalloidin.
All slides were then analysed using a Zeiss LSM 700 confocal laser scanning microscope.
(B) and (C) Actin-based protrusions were counted for 75 cells per condition using ImageJ
software. Quantifications are representative examples of 3 biological replicates.
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4.6 Expression of MCPyV ST does not affect the phos-
phorylation status of Cdc42 or Rac1
To determine whether the MCPyV ST-PP4C interaction influences the cell motil-
ity cascade at the Rho-family GTPase level, phosphorylation of Cdc42 and Rac1 at
the Ser71 residue was investigated in the absence and presence of MCPyV ST ex-
pression. This particular residue was chosen because it is known to be affected by
phosphorylation [430] and because PP4C is a Ser/Thr phosphatase. i293-GFP and
i293-GFP-ST cells were transfected with HA-Cdc42 or HA-Rac1, then induced
for 48 h. Cell lysates were then probed for phosphorylated Cdc42/Rac1 (residue
Ser71) to determine if MCPyV ST expression affects the phosphorylation status
of Rho-family GTPases. However, surprisingly, results showed no change in the
phosphorylation status of Cdc42/Rac1 (Figure 4.10), indicating that the MCPyV
ST-PP4C interaction does not affect the phosphorylation status of Rho-family GT-
Pases directly.
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Figure 4.10: MCPyV ST expression does not affect the phosphorylation status of
Cdc42/Rac1. i293-GFP or i293-GFP-ST were induced with doxycyline hyclate and trans-
fected with 1 µg HA-Cdc42 or HA-Rac1 for 6 h. Cell lysates were probed for phosphory-
lated Cdc42/Rac1 at the S71 residue. GAPDH was used to measure equal loading. 2T2
was used to probe for MCPyV ST expression.
4.7 Integrin activity inhibition affects MCPyV ST-induced
cell motility
In the light of the above findings indicating that the phosphorylation status of
Cdc42 and Rac1 was unchanged upon MCPyV ST expression, upstream factors
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were investigated to uncover a possible target for the MCPyV ST-PP4C interac-
tion. Integrins are known to be important for cell adhesion, polarity, and motility,
as they initiate signalling cascades [421]. In addition, integrins have been impli-
cated in cancer progression [422], and their function can be regulated by phos-
phorylation [426].
In order to assess whether integrins play a role in MCPyV ST-induced cell motil-
ity, a range of concentrations of an integrin inhibitor, RGDS, were used. RGDS is
a tetrapeptide that has been shown to inhibit the binding of ligands to α5β1 and
ανβ3 integrins [431]. i293-GFP and i293-GFP-ST cells were induced using doxy-
cycline hyclate, while MCC13 cells were transfected with EGFP or EGFP-ST. The
cells were then treated with non-toxic concentrations of RGDS (Figure 4.11) for
24 h. Cells were imaged using the IncuCyte kinetic imaging system every 30 min
for 24 h (Figure 4.12A and Figure 4.13A). Distances travelled by individual cells
were analysed using ImageJ software and showed decreasing cell motility with
increasing RGDS concentration in a dose-dependent manner (Figure 4.12B and
Figure 4.13B). These results suggested that there is a role for integrin signalling
in MCPyV ST-induced cell motility as treatment with RGDS tetrapeptide affected
cell motility.
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Figure 4.11: Cell viability assays for RGDS and RGES. (A) iGFP and iGFP-ST cells were
induced for 24 h, then treated with peptides ((i) RGDS, (ii) RGES) at different concentra-
tions for 24 h. (B) MCC13 cells were grown for 24 h, then treated with peptides ((i) RGDS,
(ii) RGES) at different concentrations for 24 h. Cell viability was measured using the MTS
assay. Highest concentration of inhibitor at >80% viability was used for inhibition stud-
ies.
However, in order to confirm that the results obtained are significant, this exper-
iment was repeated using non-toxic concentrations of a control peptide, RGES
(Figure 4.11) in i293 and MCC13 cells. Cells were imaged using the IncuCyte
kinetic imaging system every 30 min for 24 h (Figure 4.14A and Figure 4.15A).
Distances travelled by individual cells were analysed using ImageJ software. Re-
sults showed no change in cell motility with increasing RGES concentration (Fig-
ure 4.14B and Figure 4.15B). These results confirmed that integrins are important
in MCPyV ST-induced cell motility.
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Figure 4.12: Integrin inhibitor RGDS reduces MCPyV ST-induced cell motility in i293
cells. (A) i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate and
treated with 1 µg/µl DMSO or 1 µM, 10 µM, 50 µM, or 100 µM RGDS. After 24 h, cell
motility was measured using an Incucyte kinetic live cell imaging system. Images were
taken for 30 min for a 24 h period. The movement of cells was then tracked using ImageJ
software. (B) Average cell movement was calculated (n = 25) and significance was tested
using a two-tailed Student’s t-test.
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Figure 4.13: Integrin inhibitor RGDS reduces MCPyV ST-induced cell motility in
MCC13 cells. (A) MCC13 cells were transfected for 24 h with 1µg of EGFP and EGFP-ST,
and treated with 1 µg/µl DMSO or 1 µM, 10 µM, 50 µM, or 100 µM RGDS. After 24 h, cell
motility was measured using an Incucyte kinetic live cell imaging system. Images were
taken for 30 min for a 24 h period. The movement of cells was then tracked using ImageJ
software. (B) Average cell movement was calculated (n = 25) and significance was tested
using a two-tailed Student’s t-test.
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Figure 4.14: Control peptide RGES does not reduce MCPyV ST-induced cell motility
in i293 cells. (A) i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate
and treated with 1 µg/µl DMSO or 1 µM, 10 µM, 50 µM, or 100 µM RGES. After 24 h, cell
motility was measured using an Incucyte kinetic live cell imaging system. Images were
taken for 30 min for a 24 h period. The movement of cells was then tracked using ImageJ
software. (B) Average cell movement was calculated (n = 25) and significance was tested
using a two-tailed Student’s t-test.
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Figure 4.15: Control peptide RGES does not reduce MCPyV ST-induced cell motility
in MCC13 cells. (A) MCC13 cells were transfected for 24 h with 1 µg of EGFP and EGFP-
ST, and treated with 1 µg/µl DMSO or 1 µM, 10 µM, 50 µM, or 100 µM RGES. After 24
h, cell motility was measured using an Incucyte kinetic live cell imaging system. Images
were taken for 30 min for a 24 h period. The movement of cells was then tracked using
ImageJ software. (B) Average cell movement was calculated (n = 25) and significance was
tested using a two-tailed Student’s t-test.
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4.8 Inhibition of integrin activity affects MCPyV ST-
induced filopodia formation
As integrin activity was found to be important in MCPyV ST-induced cell motil-
ity, it was hypothesised that integrin activity would also affect filopodia forma-
tion. To determine whether that is the case, HEK-293 cells were transfected with
EGFP or EGFP-ST for 6 h, then treated with 100 µM RGDS or the control pep-
tide RGES for 24 h. Cells then fixed and stained with rhodamine phalloidin to
visualise actin-based structures (Figure 4.16A). Quantitative analysis of filopo-
dia showed that treatment of cells expressing MCPyV ST with RGDS show a re-
duction in filopodia compared to untreated cells expressing MCPyV ST (Figure
4.16B). These results supported previous results that integrins are implicated in
MCPyV ST-induced cell motility.
139
4.8 Inhibition of integrin activity affects MCPyV ST-induced filopodia
formation
A
B
%
 o
f t
ot
al
 n
um
be
r o
f p
ro
tru
si
on
s
0
3
6
9
12
15
18
21
24
27
30
Protrusion length, μm
0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12
GFP
GFP: 100μM RGDS
GFP-ST
GFP-ST: 100 μM RGDS
%
 o
f t
ot
al 
nu
m
be
r o
f p
ro
tru
sio
ns
0
3
6
9
12
15
18
21
24
27
30
Protrusion length, μm
0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12
GFP
GFP, 100 μM RGES
GFP-ST
GFP-ST, 100 μM RGES
C
Figure 4.16: Integrin inhibitor RGDS reduces MCPyV ST-induced filopodia formation.
(A) HEK-293 cells were transfected with 1 µg EGFP or EGFP-ST for 6 h, then treated with
100 µM RGDS or RGES for 24 h. Cells were then fixed and stained with rhodamine
phalloidin. All slides were then analysed using a Zeiss LSM 700 confocal laser scanning
microscope. (B) and (C) Actin-based protrusions were counted for 75 cells per condi-
tion using ImageJ software. Quantifications are representative examples of 3 biological
replicates.
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4.9 Expression of MCPyV ST affects the phosphory-
lation of β1 integrin at Thr788/789
The importance of integrins in MCPyV ST-induced cell motility and filopodia for-
mation suggested a possibility that integrin phosphorylation could be affected by
MCPyV ST-PP4C interaction. Importantly, integrin activity can be regulated by
phosphorylation [426]. Specifically, the effect of RGDS on MCPyV ST-induced
filopodia formation and cell motility suggested that α5β1 and/or ανβ3 may be
involved. As HEK-293 cells do not express ανβ3 [432], α5 and/or β1 were con-
sidered for further investigation. Notably, β1 phosphorylation status can be reg-
ulated at the Thr788/789 residues [428].
Thus in order to determine whether MCPyV ST expression affected β1 phospho-
rylation, HEK-293 cells were transfected with EGFP, EGFP-ST, EGFP-ST102A or
EGFP-ST103A for 6 h. Cell lysates were probed for phosphorylated β1 integrin
at Thr788/789. Results showed a reduction in the phosphorylation levels of β1
integrin at these sites upon MCPyV ST expression. However, phosphorylation
levels remained the same upon the expression of the PP4C-non-binding mutants
EGFP-ST102A and EGFP-ST103A (Figure 4.16A). Densitometry showed a 3-fold
decrease in the phosphorylation levels of β1 at Thr788/789 upon MCPyV ST ex-
pression (Figure 4.17B).
These results suggest a potential model for MCPyV ST-induced cell motility (Fig-
ure 4.18). Briefly, the MCPyV ST-PP4C interaction leads to the reduction of β1
integrin phosphorylation levels at Thr788/789. This then affects downstream sig-
nalling that ultimately enhances filopodia formation and cell motility in MCPyV
ST-expressing cells.
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Figure 4.17: MCPyV ST expression reduces the phosphorylation levels of β1 integrin
at Thr 788/789 residues. (A) HEK-239 cells were transfected with 1 µg EGFP, EGFP-ST,
EGFP-ST102A or EGFP-ST103A for 6 h. Cell lysates were probed for phosphorylated
Thr 788/789 residues of β1 integrin. GAPDH was used to measure equal loading. 2T2
was used to probe for MCPyV ST expression. (B) Exposed film with immunoblotting
results was scanned and uploaded onto ImageJ software, which was used to compare
band density (n=3).
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Figure 4.18: A model for MCPyV ST-induced cell motility. The MCPyV ST-PP4C leads
to the dephosphorylation of β1 integrin. This then leads to the initiation of the cell motil-
ity pathway, mediated via the Rho-family GTPases.
4.10 Discussion
MCPyV ST can interact with Ser/Thr cellular phosphatases PP2A Aα, PP2A Aβ
and PP4C, and these interactions have been well documented [20] [209]. MCPyV
ST interaction with PP4C in particular seems to be important in promoting cell
motility [210]. While PP4C is not as well characterised as PP2A, it has been im-
plicated in a variety of cellular functions, including apoptosis, DNA mutation,
and cell proliferation [433], as well as a number of cell signalling pathways [434].
Moreover, PP4C has been found to be upregulated in some cancers [435]. In ad-
dition, it was recently reported that PP4C is involved in destabilising the micro-
tubule network to promote cell motility [210]. Results presented in this chapter
implicate PP4C in actin dynamics, as MCPyV ST-induced filopodia formation ap-
pears to be dependent upon the MCPyV ST-PP4C interaction.
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Having described the role of Rho-family GTPases in MCPyV ST-induced cell
motility and filopodia formation in Chapter 3, a potential effect on the phos-
phorylation status of Cdc42 and Rac1 was explored upon MCPyV ST expression.
However, it appears that the MCPyV ST-PP4C interaction does not act at the level
of these signal mediators. Therefore, upstream factors were investigated, in par-
ticular the cell surface receptors integrins. Data presented in this chapter suggest
that integrins, including β1, play a role in MCPyV ST-induced cell motility and
filopodia formation.
Integrins are cellular receptors known to be important in the cell motility path-
way, particularly in Rho-family GTPase cycling [436]. RGDS, an integrin inhibitor
was used to determine whether integrins were important in MCPyV ST-induced
cell motility. RGDS is a tetrapeptide found on fibronectin, fibrinogen α, and
von Willebrand factor [437] [438], and is known to inhibit α5α1 and ανα3 inte-
grins [431]. Results showed that increasing RGDS concentrations lead to a dose-
dependent reduction in MCPyV ST-induced cell motility and filopodia formation.
As β1 integrin is expressed in HEK-293 cells, it was decided to focus on this
particular integrin. A further reason was the fact that PP2A has been shown
to dephosphorylate β1 integrin at Thr788/789 [428]. It was observed that levels
of Thr788/789 phosphorylation were reduced upon MCPyV ST expression, and
that the change in phosphorylation is dependent on the interaction of MCPyV ST
with PP4C. Thus a mechanism has been put forward, suggesting that the MCPyV
ST-PP4C interaction leads to the dephosphorylation of β1 integrin. This in turn
activates the cell motility pathway. Moreover, it is possible that other phosphory-
lation sites, such as Ser785, are involved, although this was not explored in this
chapter. Notably, changes in the phosphorylation status Ser785 has been shown
to affect cell motility in chicken cell lines [427]. Furthermore, other changes in
the phosphorylation status of other integrins may also be important in MCPyV
ST-induced cell motility. This area requires further research beyond the scope of
this thesis.
The overall findings of Chapters 3 and 4 suggest a possible mechanism (Figure
4.18), wherein the MCPyV ST-PP4C interaction leads to the dephosphorylation
of one or more Ser/Thr residues of one or more integrins, including β1. These
changes in phosphorylation status then act to initiate the cell motility cascade
which, through the Rho-family GTPases, results in increased filopodia formation
and cell motility. These findings further contribute to the hypothesis that the
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MCPyV ST-PP4C interaction is central in promoting the metastatic phenotype of
MCC. Therefore, this interaction is a viable drug target and worth pursuing in
future research.
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Chapter 5
Merkel cell polyomavirus small T
antigen-induced cell motility
depends on the activity of
intracellular chloride channels
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5.1 Introduction
Cell motility depends on the ability of cells to change their internal volume. This
process is driven by changes of the ionic balance in cells [326] [439], which in
turn depends on the activity of ion channels. Ion channels allow the passage of
ions between the interior of the cell and the interstitial fluid and play a role in a
whole range of cellular processes required for the proper functioning of tissues
and organs. This makes them frequent drug targets [440].
Some of the major ions involved in cell physiology are sodium, potassium, and
chloride. Sodium is the major extracellular ion, and is vital to maintaining the
osmolality of interstitial fluid, lymph, and blood [441]. Potassium is the major in-
tracellular cation [441], and a large group of potassium channels are dedicated to
tightly controlling potassium influx and efflux. Chloride is the major extracellu-
lar anion [441], and a variety of different chloride channels also maintain cellular
chloride homeostasis.
In order to control the homeostasis of ions, ion channels are gated. Chloride chan-
nel gating, depending on the channel type, may be regulated by transmembrane
voltage (voltage-gated channels), cell swelling, binding of signalling molecules
(ligand-gated anion channels), various ions (anions, pH, or calcium), phospho-
rylation of intracellular residues, or binding or hydrolysis of ATP. Voltage-gated
chloride channels are involved in setting the resting membrane potential of cells,
and as well as chloride, they can conduct other anions, for example bicarbon-
ate, iodide, and nitrite [442]. There are several different families of voltage-gated
and ligand-gated chloride channels, including the large CLC family, the cystic fi-
brosis transmembrane conductance regulator (CFTR) chloride channel, calcium-
activated chloride (CaCC) channel family, and the intracellular chloride channel
(CLIC) family [443].
The CLIC family consists of seven highly-conserved members: p64 and CLIC1-
6, and exist both as soluble proteins and membrane-bound channels. They are
unique amongst chloride channels in their capacity to exist as both intracellular
soluble proteins and transmembrane channels, being expressed in many differ-
ent intracellular compartments [444]. As such, members of the CLIC family have
been implicated in a variety of cellular functions, including motility [445], an-
giogenesis [446], brain and skeletal muscle formation [447], apoptosis [448], and
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cancer [449]. For example, CLIC1 is upregulated in a number of cancers, includ-
ing colon cancer [450] and prostate cancer [451].
In this chapter, the link between MCPyV ST-induced cell motility and the activ-
ity of chloride channels is explored. This investigation was undertaken due to
the involvement of chloride channels in other cancers, and their known role in
cell motility. The chapter begins by showing that inhibition of chloride channels
reduced MCPyV ST-induced cell motility and filopodia formation. Furthermore,
chloride channels of the CLIC family, particularly CLIC1 and CLIC4, are impli-
cated in MCPyV ST-induced cell motility, with increased relocalisation to the cell
surface, especially CLIC4, as a potential mechanism of action.
5.2 MCPyV ST expression increases the activity of ion
channels
Changes in cellular current indicate the activation of ion channels. In order to
determine whether MCPyV ST expression induces changes in the activity of ion
channels, HEK-293 cells transfected with EGFP or EGFP-ST were patch clamped
and the resulting changes in current were measured for single cells. This work
was done by Yuahuei Jiang. Results show a dramatic increase in the current of
MCPyV ST expressing cells with increasing voltage as compared to controls (Fig-
ure 5.1). These results are the first indication that MCPyV ST expression leads to
a change in the activity levels of ion channels.
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Figure 5.1: Patch clamping of HEK-293 cells shows an increase in current upon MCPyV
ST expression. HEK-293 cells were transfected with 1 µg EGFP or EGFP-ST for 6 h. 48 h
post-transfection cells were patch clamped and membrane currents were recorded from
single fluorescing cells. Cells were held at -80 mV and pulses were applied to potentials
between ±100 mV. Current-voltage relationships were constructed for each cell by plot-
ting the steady-state current at the end of the pulse against the pipette potential. n = 15
(GFP) or 22 (GFP-ST). This work was performed by Yuahuei Jiang.
Results from the patch clamping studies indicated that there was an overall change
in current upon MCPyV ST expression. However, for the scope of this thesis,
chloride channels were the focus of further investigation due to their above-
mentioned involvement in cell motility and cancer. Furthermore, chloride chan-
nels are less well-studied than, for instance, potassium channels, thus any poten-
tial involvement of chloride channels in MCPyV ST motility would be completely
novel in the context of virus-induced cancer progression.
5.3 Broad-spectrum chloride channel inhibitors affect
MCPyV ST-induced cell motility
In order to determine whether chloride channels play a role in MCPyV ST-induced
cell motility, a selection of inhibitors known to target a broad range of chloride
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channels were utilised at non-toxic concentrations as measured by MTS assay
(Figure 5.2): DIDS [452], NPPB [453] and RIAA [454].
i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate, while
MCC13 cells were transfected with EGFP or EGFP-ST, and treated with each re-
spective inhibitor for 24 h. Cell motility was then imaged using the IncuCyte
kinetic imaging system, every 30 min for 24 h (Figure 5.3A and Figure 5.4A). Dis-
tance travelled by individual cells were tracked using ImageJ software. No signif-
icant differences were observed among the average distances travelled by control
GFP-expressing cells not expressing MCPyV ST, in both untreated and treated
cells with the broad-spectrum chloride channel inhibitors (Figure 5.3B and Fig-
ure 5.4B). Conversely, MCPyV ST-expressing cells treated with any of the broad-
spectrum chloride channel inhibitors showed significant decrease in cell motility
compared to untreated cells (p < 0.001) (Figure 5.2B and Figure 5.3B). These find-
ings suggested that chloride channels are involved in MCPyV ST-induced cell
motility.
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Figure 5.2: Cell viability assays for broad-spectrum chloride channel inhibitors. (A)
iGFP and iGFP-ST cells were induced for 24 h, then treated with inhibitors ((i) DIDS, (ii)
NPPB, (iii) RIAA) at different concentrations for 24 h. (B) MCC13 cells were grown for 24
h, then treated with inhibitors ((i) DIDS, (ii) NPPB, (iii) RIAA) at different concentrations
for 24 h. Cell viability was measured using the MTS assay. Highest concentration of each
inhibitor at >80% viability was used for further experiments.
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Figure 5.3: Live cell imaging shows blocking chloride channels with broad-spectrum
inhibitors reduces MCPyV ST-induced cell motility in i293 cells. (A) i293-GFP and
i293-GFP-ST cells were induced using doxycycline hyclate and treated with 1 µg/µl
DMSO, 50 µM of DIDS or RIAA, or 25 µM of NPPB. After 24 h, cell motility was mea-
sured using the IncuCyte kinetic imaging system. Images were taken every 30 min for a
24 h period. (B) The movement of cells was then tracked using ImageJ software (n = 25).
Average cell movement was calculated and significance was tested using a a two-tailed
Student’s t-test.
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Figure 5.4: Live cell imaging shows blocking chloride channels with broad-spectrum
inhibitors reduces MCPyV ST-induced cell motility in MCC13 cells. (A) MCC13 cells
were transfected for 12 h with 1 µg of EGFP and EGFP-ST, and treated for 24 h with 1
µg/µl DMSO, 100 µM of DIDS or RIAA, or 50 µM of NPPB. After 24 h, cell motility was
measured using the IncuCyte kinetic imaging system. Images were taken every 30 min
for a 24 h period. (B) The movement of cells was then tracked using ImageJ software
(n = 25). Average cell movement was calculated and significance was tested using a a
two-tailed Student’s t-test.
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Finally, to confirm these observations, a haptotaxis migration assay was per-
formed. Haptotaxis migration assays investigate the three-dimensional migra-
tion of cells towards a chemoattractant (e.g. FCS) across a permeable chamber.
i293-GFP and i293-GFP-ST cells were induced with doxycycline hyclate, trans-
ferred to haptotaxis plates, and treated with the three broad-spectrum chloride
inhibitors for 24 h. Cells were then allowed to migrate for 24 h according to the
assay manufacturer’s instructions. Migration was measured by fluorescence af-
ter staining cells that migrated into the chambers and resuspending them in the
buffer provided (Figure 5.5). Results confirmed that chloride channel inhibitors
reduce MCPyV ST-induced cell motility. HEK-293 cells were used as migration
controls.
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Figure 5.5: Haptotaxis assay shows blocking chloride channels with broad-spectrum
inhibitors reduces MCPyV ST-induced cell migration. i293-GFP and i293-GFP-ST cells
were induced using doxycycline hyclate and treated with 1 µg/µl DMSO, 50 µM of DIDS
or RIAA, or 25 µM of NPPB. After 24 h, cells were transferred into migration wells (coated
with collagen I), inhibitors were added at appropriate concentrations and allowed to mi-
grate from serum-free to 10% FBS conditions for 24 h. Migratory cells were stained and
measured at 560 nm to quantify migration. Average cell migration was calculated and
significance was tested using a a two-tailed Student’s t-test (n = 3). Untreated HEK-239
cells were used as controls.
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broad-spectrum chloride channels is not additive
In addition to looking at the effects of individual broad-spectrum chloride chan-
nel inhibitors on MCPyV ST-induced cell motility, it was decided to investigate
whether this effect was additive by assessing the combined effects of inhibitors.
i293-GFP and i293-GFP-ST cells were induced using doxycycline hyclate, while
MCC13 cells were transfected with EGFP or EGFP-ST, and treated with pairs of
inhibitors for 24 h. Cells were then imaged using the IncuCyte kinetic imaging
system, every 30 min for 24 h (Figure 5.6A and Figure 5.7A). Distance travelled by
individual cells was tracked using ImageJ software. No additional additive effect
was observed either in i293-GFP, i293-GFP-ST, or MCC13 cells upon treatment
with pairs of inhibitors, suggesting that the motility reducing effect of individual
chloride channel inhibitors was sufficient to block the chloride channels involved
in MCPyV ST-induced cell motility (Figure 5.6B and Figure 5.7B). Interestingly,
there was no additive effect on control cells expressing GFP either.
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Figure 5.6: Live cell imaging shows the effect of broad-spectrum chloride channel in-
hibitors on MCPyV ST-induced cell motility in i293 cells is non-additive. (A) i293-GFP
and i293-GFP-ST cells were induced using doxycycline hyclate for 24 h, and then treated
with combinations of two inhibitors (50 µM DIDS/25 µM NPPB, 50 µM DIDS/50 µM
RIAA, 25 µM NPPB/50 µM RIAA). After 24 h, cell motility was measured using the In-
cuCyte kinetic imaging system. Images were taken every 30 min for a 24 h period. (B)
Cell movement was then tracked using ImageJ software (n = 25). Average cell movement
was calculated and significance was tested using a a two-tailed Student’s t-test.
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Figure 5.7: Live cell imaging shows the effect of broad-spectrum chloride channel
inhibitors on MCPyV ST-induced cell motility in MCC13 cells is non-additive. (A)
MCC13 cells were transfected for 12 h with 1 µg EGFP or EGFP-ST, then treated with
combinations of two inhibitors (100 µM DIDS/50µM NPPB, 100 µM DIDS/100 µM RIAA,
50 µM NPPB/100 µM RIAA). After 24 h, cell motility was measured using the IncuCyte
kinetic imaging system. Images were taken every 30 min for a 24 h period. (B) Cell
movement was then tracked using ImageJ software (n = 25). Average cell movement was
calculated and significance was tested using a a two-tailed Student’s t-test.
157
5.5 Disruption of MCPyV ST-induced cell motility by broad-spectrum
chloride channels is reversible
5.5 Disruption of MCPyV ST-induced cell motility by
broad-spectrum chloride channels is reversible
Once it was determined that broad-spectrum chloride channels affect MCPyV
ST-induced cell motility, it was decided to investigate whether this effect was
reversible. i293-GFP and i293-GFP-ST cells were induced using doxycycline hy-
clate, while MCC13 cells were transfected with EGFP or EGFP-ST, and treated
with each respective inhibitor for 24 h. Cells were then imaged using the In-
cuCyte kinetic imaging system, every 30 min for 24 h, washed, and imaged for
further 24 h using the IncuCyte kinetic imaging system. Results showed that
in both i293-GFP-ST and MCPyV ST-expressing MCC13 cells motility recovers
after washing out the broad-spectrum chloride channel inhibitors, although full
recovery is seen only in MCC13 cells (Figure 5.8). These results indicate that the
broad-spectrum chloride channel inhibitors act specifically on ion channels, and
the effect on MCPyV ST-induced cell motility is not non-specific.
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Figure 5.8: Live cell imaging shows the effect of broad-spectrum chloride channel in-
hibitors on MCPyV ST-induced cell motility is reversible. (A) i293-GFP and i293-GFP-
ST cells were induced using doxycycline hyclate and treated with 1 µg/µl DMSO, 50 µM
DIDS or RIAA, or 25 µM NPPB. After 24 h, cell motility was measured using the IncuCyte
kinetic imaging system. Images were taken every 30 min for a 24 h period. Cells were
washed with PBS and cell motility was measured every 30 min for a further 24 h using
the IncuCyte kinetic imaging system. The movement of cells was then tracked using Im-
ageJ software (n = 25). Average cell movement was calculated and significance was tested
using a a two-tailed Student’s t-test. (B) MCC13 cells were transfected with 1 µg EGFP
or EGFP-ST for 12 h and treated with 1 µg/µl DMSO, 100 µM of DIDS or RIAA, or 50
µM of NPPB. After 24 h, cell motility was measured using the IncuCyte kinetic imaging
system. Images were taken every 30 min for a 24 h period. Cells were washed with PBS
and cell motility was measured every 30 min for a further 24 h using the IncuCyte kinetic
imaging system. The movement of cells was then tracked using ImageJ software (n = 25).
Average cell movement was calculated and significance was tested using a a two-tailed
Student’s t-test.
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5.6 Broad-spectrum chloride channel inhibitors affect
MCPyV ST-induced filopodia formation
Due to the previous results of an observed effect of broad-spectrum chloride
channel inhibitors on MCPyV ST-induced cell motility, it was hypothesised that
MCPyV ST-induced filopodia formation may also be affected by these inhibitors.
In order to explore this possibility, HEK-293 cells were transfected with EGFP or
EGFP-ST cells, and treated with the broad-spectrum chloride channel inhibitors
(DIDS, NPPB, and RIAA) for 24 h. Cells were then fixed and stained with rho-
damine phalloidin to observe actin-based structures (Figure 5.6A). Quantitative
analysis of filopodia showed a decrease in filopodia formation when MCPyV ST-
expressing cells were treated with any of the broad-spectrum chloride channel
inhibitors (Figure 5.6B). Together, these results suggest that inhibiting chloride
channels affects MCPyV ST-induced cell motility and filopodia formation.
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Figure 5.9: Cell imaging shows that broad-spectrum chloride channe inhibitors reduce
MCPyV ST-induced filopodia formation. (A) HEK-293 cells were transfected with 1 µg
EGFP or EGFP-ST for 6 h and treated with 1 µg/µl DMSO, 50 µM of DIDS or RIAA, or
25 µM of NPPB. After 24 h cells were fixed and stained with rhodamine-phalloidin. All
slides were then analysed using a Zeiss LSM 700 confocal laser scanning microscope. (B)
Actin-based protrusions were counted for 75 cells per condition using ImageJ software.
161
5.7 Quantitative proteomic analysis shows that MCPyV ST expression affects
CLIC family protein levels
5.7 Quantitative proteomic analysis shows that MCPyV
ST expression affects CLIC family protein levels
CLIC family chloride channels have been implicated in cell motility [445] and
cancer [450]. Previous work in the Whitehouse laboratory has utilised a SILAC-
based quantitative proteomic approach to determine potential alterations in the
host cell proteome upon inducible MCPyV ST expression in a HEK-293-derived
i293-ST cell line [210]. Further analysis of this data focusing on chloride channels
highlighted two CLIC family proteins upregulated upon MCPyV ST expression.
These proteins are shown in Table 5.1.
Table 5.1: Quantitative proteomic analysis shows an increase in CLIC family protein
levels upon MCPyV ST expression
Protein Fold change over unin-
duced
Peptide
hits
Function
CLIC1 5.7 10 Regulation of fundamental
cellular processes via chlo-
ride homeostasis [455]
CLIC4 4.4 11 Regulation of fundamental
cellular processes via chlo-
ride homeostasis [455]
To confirm increased levels of CLIC1 and CLIC4 expression upon MCPyV ST in-
duction, i293-ST cells remained uninduced or were induced with doxycycline hy-
clate for 48 h. In addition, MCC13 cells were transfected with EGFP or EGFP-ST.
Cell lysates were then analysed by immunoblotting, and upregulation of CLIC1
and CLIC4 expression was confirmed upon induction of MCPyV ST, in both i293
and in MCC13 cells (Figure 5.10A). CLIC1 increased 2.7-fold in i293-ST and 1.4-
fold MCC13 cells, while CLIC4 increased 6-fold in i293-ST cells and 8.8-fold in
MCC13 cells (Figure 5.10B).
This increase in chloride channel levels appears to be at the translation stage, as
transcription levels, measured by RT-qPCR, are unchanged in i293-ST cells upon
MCPyV ST expression (Figure 5.10C). This could be due to previous findings that
MPCyV ST deregulates translation rather than transcription [234]. These results
indicated that the expression of CLIC family proteins is altered upon MCPyV ST
expression, which may have implications in MCPyV ST-induced cell motility.
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Figure 5.10: CLIC family proteins are upregulated upon MCPyV ST expression. (A)
i293-ST cells remained uninduced or were incubated for 48 h in the presence of doxycy-
cline hyclate. After induction, cell lysates were probed for CLIC1 and CLIC4 using spe-
cific antibodies. MCC13 were transfected with 1 µg EGFP or EGFP-ST for 12 h. Lysates
were probed for CLIC1 and CLIC4. GAPDH was used as a measure of equal loading, the
2T2 hybridoma was used to probe for MCPyV ST expression. (B) Exposed film with im-
munoblotting results was scanned and uploaded onto ImageJ software, which was used
to compare band density (n = 3). (C) i293-ST cells remained uninduced or were incu-
bated for 48 h in the presence of doxycycline hyclate. After induction, cellular RNA was
extracted using phenol/chloroform, reverse transcribed and RT-qPCR was performed.
Transcript levels were analysed using the comparative CT method (n = 3).
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In order to investigate whether, like actin-associated proteins, CLIC family pro-
teins are expressed and/or upregulated in MCPyV-positive MCC tumours, two
unrelated MCC tumour samples were used (MCC1 and MCC2). Healthy skin
was used as a negative control. All samples were homogenised, lysed, and soni-
cated, and then probed for CLIC1 and CLIC4. CLIC1 appears to be upregulated
in MCC1 and MCC2 compared to healthy skin. CLIC4 appears to be expressed
to detectable levels in MCC1 and to a lesser degree MCC2, but not in healthy
skin (Figure 5.11). Therefore, similar to actin-associated proteins, these differ-
ences may be due to varying expression of MCPyV T antigen in samples or due
to other unique tumour features. Overall, however, these results confirm the ob-
servations made in cell culture experiments, indicating that certain CLIC family
proteins are affected upon MCPyV ST expression and may play a role in MCPyV-
positive MCC tumourigenesis.
- + +MCPyV ST
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CLIC4
CLIC1
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Figure 5.11: CLIC family proteins are expressed in MCPyV-positive MCC tumours.
Healthy skin, MCC1, and MCC2 were crushed using a mortar and pestle on dry ice, lysed
with RIPA buffer for 30 min on ice and then further homogenised by sonication (5 min,
10 s on/10 s off). Tissue lysates were then probed for CLIC1 and CLIC4. GAPDH was
used as a measure of equal loading, the 2T2 hybridoma was used to probe for MCPyV ST
expression.
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5.9 Depletion of CLIC1 and CLIC4 disrupts MCPyV
ST-induced cell motility
Due to the increased expression of CLIC1 and CLIC4 in MCC tumour samples
and MCPyV ST-expressing cell lines, the effect of depleting these chloride chan-
nels on MCPyV ST-induced cell motility was investigated. i293-GFP and i293-
GFP-ST cells were transfected with scrambled or CLIC1- and/or CLIC4-specific
siRNA, then induced with doxycycline hyclate. Similarly, MCC13 cells were
transfected with EGFP or EGFP-ST and scrambled or CLIC1 and/or CLIC4 siRNA.
Results show good levels of CLIC1 and CLIC4 depletion in both i293 and MCC13
cells, both as single and double knockdowns (Figure 5.12A and Figure 5.13A).
Cells were then imaged using the IncuCyte kinetic imaging system, every 30 min
for 24 h (Figure 5.12B and Figure 5.13B).
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Figure 5.12: Live cell imaging shows CLIC1 and/or CLIC4 depletion reduces MCPyV
ST-induced cell motility in i293 cells. (A) i293-GFP and i293-GFP-ST cell lysates were
probed for successful knockdown with specific CLIC1 and CLIC4 antibodies. GAPDH
was used as loading control and 2T2 hybridoma was used to show MCPyV ST expres-
sion. (B) i293-GFP and i293-GFP-ST cells were transfected with 10 nmol scrambled or
CLIC1 and/or CLIC4 siRNA for 12 h, then induced using doxycycline hyclate for 24 h.
48 h post-knockdown, cell motility was measured using the IncuCyte kinetic imaging
system. Images were taken every 30 min for a 24 h period. (C) The movement of cells
was then tracked using ImageJ software (n = 25). Average cell movement was calculated
and significance was tested using a a two-tailed Student’s t-test.
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Figure 5.13: Live cell imaging shows knocking down CLIC1 and/or CLIC4 reduces
MCPyV ST-induced cell motility in MCC13 cells. (A) MCC13 cell lysates were probed
for successful knockdown with specific CLIC1 and CLIC4 antibodies. GAPDH was used
as loading control and 2T2 hybridoma was used to show MCPyV ST expression. (B)
MCC13 cells were transfected with 10 nmol scrambled or CLIC1 and/or CLIC4 siRNA
for 12 h, then with 1 µg of EGFP and EGFP-ST for 12 h. 48 h post-knockdown, cell motility
was measured using the IncuCyte kinetic imaging system. Images were taken every 30
min for a 24 h period. (C) The movement of cells was then tracked using ImageJ software
(n = 25). Average cell movement was calculated and significance was tested using a a
two-tailed Student’s t-test.
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Distance travelled by individual cells were tracked using ImageJ software. No
significant differences were observed among the average distances travelled by
control cells with knockdown of CLIC1 and/or CLIC4, in both single- and double-
knockdown cells (Figure 5.12C and Figure 5.13C). Conversely, cells expressing
MCPyV ST which had CLIC1 and/or CLIC4 depleted showed significant de-
crease in cell motility compared to cells expressing CLIC1 and/or CLIC4
(p < 0.001) (Figure 5.9B and Figure 5.10B). Interestingly, in i293 cells the effect
was smaller than in MCC13 cells, even though the knockdown levels are com-
parable (Figure 5.12B and Figure 5.13B). Results do show that depletion of either
CLIC1 or CLIC4 leads to a similar level of motility inhibition as the depletion of
both at the same time. This could indicate that both channels play an equally
important role in MCPyV ST-induced cell motility.
5.10 CLIC1 and CLIC4 show increased plasma mem-
brane localisation upon MCPyV ST expression
CLIC family proteins have been shown to relocalise from inside cells to the cell
surface in angiogenesis[456] and to invadopodia [457]. Changes to CLIC1 and/or
CLIC4 localisation on the surface of cells may lead to changes in the uptake or re-
lease of chloride, which may in turn play a role in changes in cell volume which
could affect cell motility. Therefore it was determined whether MCPyV ST ex-
pression would affect the cell surface localisation of CLIC family proteins using a
flow cytometry-based assay.
HEK-293 cells were transfected with EGFP and EGFP-ST, fixed and stained for
cell surface CLIC1 and CLIC4. Flow cytometry was performed and results showed
changes in the proportion of cells staining for CLIC1 and CLIC4 upon MCPyV ST
expression (Figure 5.14A). Gating was set for both CLIC1 and CLIC4 according
to their isotype controls (Figure 2.1, Materials and Methods). These changes were
quantified and analysis suggested that upon MCPyV ST expression, CLIC1 in-
creases 1.5-fold on the cell surface while CLIC4 increases 2.2-fold on the cell sur-
face (Figure 5.14B). These findings suggest that both CLIC1 and CLIC4 relocalise
to the cell surface upon MCPyV ST expression. Interestingly, there seems to be
somewhat greater relocalisation by CLIC4. This may indicate a more important
role for this CLIC family protein in MCPyV ST-induced cell motility, but more
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research needs to be done to explore this possibility, as depletion studies suggest
an equal effect by either CLIC1 or CLIC4.
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Figure 5.14: Flow cytometry shows relocalisation of CLIC1 and CLIC4 to the cell sur-
face. (A) HEK-293 cells were transfected with 1µg EGFP and EGFP-ST for 6 h. Cells
were fixed with 2% paraformaldehyde, then stained with specific CLIC1 and CLIC4 anti-
bodies. Flow cytometry was performed and gating was set according to isotype controls
(see Figure 2.1). FITC-A corresponds to EGFP fluorescence and APC-A corresponds to
secondary antibody staining. (B) Proportions of cells expressing EGFP-ST and stained
for CLIC1 or CLIC4 were analysed and compared to proportion of cells expressing EGFP
and stained for CLIC1 or CLIC4 (n = 3).
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MCPyV ST induces cell motility and filopodia formation via the cell motility
pathway mediated by Rho-family GTPases (Chapter 3) and initiated via integrin
signalling (Chapter 4). In addition, it appears that ion channels are also involved
in MCPyV ST-induced cell motility and filopodia formation, potentially via re-
localisation to the cell surface initiated by the expression of MCPyV ST. Chlo-
ride channels have been implicated in cancer progression [458], although little
research has so far been done in this field, particularly in the context of virus-
induced cancers.
Data presented in this chapter indicate that expression of MCPyV ST affects cellu-
lar ion flow. Chloride channels are implicated in these mechanisms, particularly
due to the findings that blockage of these channels by broad-spectrum inhibitors
affects MCPyV ST-induced cell motility and filopodia formation. In addition,
quantitative proteomic analysis showed that MCPyV ST expression upregulates
the protein levels of two CLIC family proteins: CLIC1 and CLIC4. Supporting
the role in MCPyV ST-induced motility of these chloride channels, depletion of
CLIC1 and CLIC4 leads to the reduction of MCPyV ST-induced cell motility.
The effect of the CLIC family of chloride channels on cell motility has been docu-
mented previously for both CLIC1 and CLIC4. Interestingly, CLIC1 has been im-
plicated in regulating the cell surface expression of integrins, including β1 and α3
[445], while CLIC4 is required for transforming growth factor (TGF)-β signalling,
leading to increased epithelial to mesenchymal transition [459]. In addition, both
CLIC1 and CLIC4 have been implicated in the development and progression of
a number of different cancers, including colon cancer [450], prostate cancer [451],
pancreatic cancer [460], and ovarian cancer [461].
Results presented in this chapter suggest that chloride channels, specifically CLIC1
and CLIC4, contribute to MCPyV ST-induced cell motility via relocalisation to the
cell surface, thus allowing for increased anion flow. Interestingly, CLIC1 relocali-
sation has previously been implicated in tumourigenesis [462]; however, MCPyV
ST expression appears to also affect CLIC4 levels and relocalisation to the cell
surface. Therefore, it is possible that CLIC4 plays a significant role in MCPyV ST-
induced cell motility and thus MCC metastasis. This would be a novel discovery,
as so far CLIC1 has been the most widely-studied of member of the CLIC fam-
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ily proteins and implicated more extensively in cell motility. In order to further
explore these possibilities, more research on the mechanism by which MCPyV
ST acts on CLIC1 and CLIC4 needs to be performed. One avenue of investiga-
tion could be the relationship between integrins, which have been implicated in
MCPyV ST-induced cell motility in Chapter 4, and the CLIC family proteins.
Furthermore, future investigations into the mechanisms of how MCPyV ST ex-
pression promotes relocalisation of CLIC1 and CLIC4, e.g. via changes in phos-
phorylation, might provide a potential therapeutic target. Another potential mech-
anism of action could be via the actin cytoskeleton [463], which, as shown in
Chapter 3, is also affected by MCPyV ST expression. Finally, blocking CLIC fam-
ily proteins, CLIC1 and CLIC4, might be another therapeutic pathway. Currently,
there are no specific inhibitors available for either channel, and research in this
area could prove fruitful in tackling not only MCC, but a host of other metastatic
cancers.
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MCC is a highly aggressive and metastatic cancer of neuroendocrine origin that
presents as nodules on sun-exposed areas of skin. It arises from Merkel cells,
which are situated on the basal layer of the epidermis. Merkel cells are mechanore-
ceptors that are stimulated by light touch, and they form the Merkel cell-neurite
complex [170]. MCC tends to spread through the dermal lymphatic system, and
is associated with early establishment of distant metastases and a poor 5-year
survival rate [177]. MCPyV has been established as the causative agent of MCC
in at least 80% of cases [20]. It is found monoclonally integrated in both primary
tumours and metastases [20].
MCPyV is a polyomavirus, and expresses two oncogenes from its T antigen locus:
LT and ST. MCPyV LT acquires truncating mutations in MCC tumours, render-
ing it replication-defective [20]. Due to the acquisition of these specific mutations
and a monoclonal pattern of integration, MCPyV is thought to be a direct tu-
mourigenic agent rather than a passenger virus. While in most tumourigenic
polyomaviruses, such as SV40, LT is thought to be the major oncoprotein, in
MCPyV, ST is the major transforming factor [234]. In addition, MCPyV ST has
also been shown to promote cell motility [210], so is likely to be involved in MCC
metastasis. This is not without precedent, as other tumour viruses, such as SV40,
HPV, and EBV can all promote metastasis, via a variety of mechanisms, such
as alteration of cell adhesion complexes, production of MMPs, gene expression
modulation, and cytoskeletal reorganisation [342] [464] [465].
Previously, identification of MCC tumours was particularly difficult and often
mistaken for small-cell carcinoma of the lung, which presents as a visibly simi-
lar tumour [179]. Currently, positive CK20 staining along with neuroendocrine
biomarkers, e.g. chromatogranin and somatostatin, is used to detect MCC for
diagnostic purposes [180]. However, there is still no specific therapeutic regime
available for MCC. Therefore, research in this area should ultimately lead to po-
tential drug targets and treatments in order to improve MCC patient survival and
care.
The discovery of MCPyV has opened up new avenues of research in MCC treat-
ment, with research into the tumourigenic and metastatic mechanisms induced
by MCPyV oncoproteins potentially providing novel drug targets. One such tar-
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get is illustrated in the role of MCPyV LT in upregulating a cellular oncogene,
survivin, which is essential for the survival of MCPyV-positive MCCs [259]. In
fact, YM155, a small molecular inhibitor of surivin, has been shown have a cy-
tostatic effect on MCC tumours in mice xenografts [272]. Furthermore, a small-
molecule tyrosine kinase inhibitor, pazopanib, is currently undergoing phase II
clinical trials as a potential MCC treatment [273]. Recently, together with deter-
mining a host cell line for MCPyV, it was also shown that trametinib is a potent
inhibitor of MCPyV infection [220], although the utility of this drug in the later
stages of MCC might be low. Therefore the field for new MCPyV-positive MCC
drugs, particularly ones that act in later stages of the disease, is wide open.
Previous work in the Whitehouse laboratory performed high-throughput quanti-
tative SILAC-based proteomic analysis [210] using a cell line capable of inducible
expression of MCPyV ST to identify differentially-expressed proteins on MCPyV
ST expression. SILAC-based analysis coupled with LC-MS/MS and bioinformat-
ics is a way to explore the host cell proteome, and is an informative tool for
the study of virus-host interactions [466]. Bioinformatic analysis showed that
MCPyV ST expression promotes the differential expression of a number of pro-
teins involved in the regulation of the cytoskeleton and cell motility, both asso-
ciated with the microtubule network [210] and with the actin cytoskeleton. In
addition, MCPyV ST expression was found to promote the expression of pro-
teins associated with cell adhesion, various junctions, and the EMT. This line of
research is currently being explored.
Initial findings in multiple cell lines showed that MCPyV ST expression upreg-
ulates actin-associated proteins and leads to the increase in the numbers and
lengths of actin-based protrusions that were then determined to be filopodia. In
addition, enhanced expression of actin-associated proteins was observed in MCC
tumours when compared to MCC-negative healthy skin. These changes in actin-
associated protein expression and in the presence of early motility markers led to
the development of two cell lines, i293-GFP and i293-GFP-ST, in order to explore
MCPyV ST-induced cell motility in live cells. Previous observations that MCPyV
ST induces cell motility both in inducible and in MCC13 cells were confirmed.
In addition, directionality studies showed that MCPyV ST promotes directional
motility, and this provides further evidence of MCPyV ST-induced cell motility
being metastatic in nature, as directionality is important in metastatic migration
[403].
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The actin cytoskeleton and cell motility are regulated by Rho-family GTPases.
Findings presented in this thesis suggest that Cdc42 and RhoA appear to be in-
volved in MCPyV ST-induced cell motility and filopodia formation, with Rac1
potentially playing a smaller role. Interestingly, other oncogenic viruses also af-
fect the Rho-family GTPases. For instance, SV40 ST activity leads to the rear-
rangement of filamentous actin networks, including Rac-mediated lamellipodia
formation, Cdc42-mediated filopodia formation and the loss of RhoA-dependent
stress fibres. SV40 ST expression upregulates Rac1 and Cdc42 and downregu-
lates RhoA [342]. However, no direct changes in Rho-family GTPase levels were
observed in MCPyV ST-expressing cells, suggesting that MCPyV ST uses an al-
ternative mechanism to manipulate the actin cytoskeleton. Future research in
this area could focus on the many activators and inhibitors of the Rho-family
GTPases, in order to determine which ones play a role in MCPyV ST-induced cell
motility. There are approximately 60 known activators and 70 known inactivators
of Rho-family GTPases [467]. Some of these factors are highly specific for single
Rho-family GTPases, e.g. Fgd1 for Cdc42 [468] or p115RhoGEF for Rho [469],
while others can act on multiple Rho-family GTPases, e.g. Vav1 on Cdc42, Rac,
and Rho [470]. A number of Rho-family GTPase activators, guanine exchange
factors (GEFs), are known oncogenes, involved in various cancers, including Dbl
in diffuse B cell lymphoma [471], Ect2 in multiple human cancers [472], and Ost
in osteosarcoma [473]. Therefore, it may be that a particular GEF or a subset
of GEFs are specifically involved in activating Rho-family GTPases in MCPyV-
positive MCCs. One potential target for initial investigation could be Vav1, a GEF
that has been implicated in neuroblastoma and melanoma, as well as pancreatic,
lung, and breast cancers [474]. Regardless, research into the cell motility sig-
nalling pathway in the context of MCPyV-positive MCC would further enhance
the mechanism proposed in Chapter 4. Furthermore, potential specificity of such
activators and/or inhibitors could provide possible drug targets to explore for
MCC.
It has been demonstrated that MCPyV ST interacts with multiple cellular Ser/Thr
phosphatases, including PP2A Aα, PP2A Aβ, and PP4C [234] [209]. In particular,
the MCPyV ST interaction with PP4C seems to be important in promoting cell
motility via microtubule stabilisation [210]. In addition, PP4C depletion reduces
levels of active Cdc42 and Rac1 in HEK-293 cells, suggesting that it may play a
role in actin dynamics [475]. In this thesis, immunoprecipitation studies found
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that the exact binding site for PP4C on MCPyV ST is residue 102, allowing the
generation of specific MCPyV ST mutants which can specifically distinguish be-
tween PP2A Aβ and PP4C binding. This novel mutant was then used to show
that the MCPyV ST-PP4C interaction is necessary for cell motility and filopodia
formation.
In order to try and determine where in the cell motility pathway the MCPyV ST-
PP4C interaction was functioning, changes in Rho-family GTPase phosphoryla-
tion status were initially investigated upon MCPyV ST expression. Surprisingly,
no changes were observed for Cdc42 or RhoA at the Ser71 residue. Therefore,
activators upstream of the Rho-family GTPases were investigated. Upstream of
the Rho-family GTPases and their activators in the cell motility pathway are mul-
tiple different families of receptors. One such family, the integrins, are important
in forming cell-matrix adhesion in cell motility. It was found that inhibiting inte-
grin activity in MCPyV ST-expressing cells reduced motility in a dose-dependent
manner, as well as reducing filopodia formation. Finally, findings presented in
this thesis show that MCPyV ST expression reduces the phosphorylation levels
of β1 integrin at Thr788/789, in contrast to the PP4C non-binding mutants. These
findings allow for a mechanism of MCPyV ST-induced cell motility and filopo-
dia formation (illustrated in Figure 4.18), where MCPyV ST interaction with PP4C
leads to the dephosphorylation of integrins, which activates the cell motility path-
way. PP2A has been shown to dephosphorylate β1 integrin at Thr788/789 [428],
and it may be that other phosphorylation sites, such as Ser785 [427] on β1 integrin
could be altered upon MCPyV ST expression. Specifically, a dephosphorylatedβ1
integrin mimic at Ser785 promotes cell spreading and migration in fibroblast and
teratocarcinoma cells [427]. Moreover, other integrins as well as other receptors
may also play a role in MCPyV ST-induced cell motility and filopodia formation.
For example, the sensitivity of MCPyV ST-expressing MCC13 cells to the RGDS
peptide suggests a potential role for ανβ3 integrins [431]. Further research in
this area would help flesh out the model and add layers of complexity to the
signalling that takes place upon MCPyV ST induction of cell motility.
These findings stress the importance of the MCPyV ST-PP4C interaction and
highlight it as a novel drug target, particularly in the later stages of MCC, where
it has such a poor prognosis. Further research in this area could focus on block-
ing the specific protein-protein interaction. One example is the potential to use
structure-based rational drug design to identify a small molecule inhibitor that
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blocks the MCPyV ST-PP4C interaction. The Whitehouse laboratory has gener-
ated a predicted MCPyV ST structural model, based upon the known structure
of the homologous SV40 ST protein. To identify small molecule inhibitors a vir-
tual high-throughput screening campaign could be conducted using the Leeds
proprietary structural screening library. Surface volume analysis (SPROUT, Sym-
biosis) of the MCPyV ST interface may indicate potential sites for targeting small
molecules. Thereafter, docking sites could be virtually modelled and virtual hits
prioritised to assess if these inhibitor molecules affect MCPyV ST-induced cell
motility. Moreover, in a parallel approach, small molecules could be identified
that mimic features of the binding interface of PP4C. Although the issue with this
approach is the lack of a crystal structure for PP4C, particularly complexed with
MCPyV ST. Another issue would be the therapeutic window, as PP4C is a host
factor involved in many different cellular functions. A way to overcome these
issues is to use blocking antibodies or peptides to disrupt the MCPyV ST-PP4C
interaction. One particularly interesting avenue of research would be developing
adhirons to block the PP4C binding site on MCPyV ST. Adhirons are novel, ther-
mostable scaffold proteins with variable regions that can be raised as binders to a
protein of interest [476]. Theoretically, an adhiron raised against the 102 residue
(and neighbouring residues) of MCPyV ST would prevent the interaction with
PP4C without affecting normal cellular functions of the protein phosphatase.
Finally, this thesis also presents novel findings that MCPyV ST-induced cell motil-
ity depends on intracellular chloride channels (CLICs), specifically focusing on
CLIC1 and CLIC4. Initial patch clamping showed that expression of MCPyV ST
affects cellular ion flow, and chloride channels were implicated due to findings
that broad-spectrum chloride channel inhibitors reduce MCPyV ST-induced cell
motility and filopodia formation. Furthermore, quantitative proteomic and im-
munoblotting analysis showed that MCPyV ST expression upregulates the pro-
tein levels of CLIC1 and CLIC4 in multiple cell lines and in MCPyV-positive MCC
tumour samples, while siRNA depletion of these chloride channels leads to the
reduction of MCPyV ST-induced cell motility. In addition, CLIC1 and CLIC4
likely contribute to MCPyV ST-induced cell motility by relocalising to the cell sur-
face, allowing for increased ion flow. CLIC1 relocalisation has been previously
implicated in cancer, with CLIC1 being visualised on the plasma membrane of
glioblastoma cells but not of normal progenitor cells [462], as well as localising to
the invadopodia in several cancer cell lines [457]. However, results presented in
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this thesis show greater increases of expression and relocalisation of CLIC4 upon
MCPyV ST than CLIC1. Therefore, it may be that CLIC4 is more important in
MCC tumourigenesis, although more research needs to be done to explore the
precise mechanism by which chloride channels act on MCPyV ST-induced cell
motility. Interestingly, CLIC1 has been implicated in regulating the cell surface
expression of integrins, including β1 and α3 integrins [445]. The MCPyV ST-
PP4C interaction has been shown in this thesis to affect β1 integrin, thus linking
this dephosphorylation with CLIC activity ought to be explored further. CLIC4
regulates transforming growth factor (TGF)-β signalling, leading to increased ep-
ithelial to mesenchymal transition [459], and ongoing work in the Whitehouse
laboratory is exploring the role of MCPyV ST in EMT. In addition, both CLIC1
and CLIC4 have been implicated in the development and progression of a num-
ber of different cancers, including colon cancer [450], prostate cancer [451], pan-
creatic cancer [460], and ovarian cancer [461].
Future investigations into the details of how MCPyV ST expression promotes
relocalisation of CLIC1 and CLIC4, e.g. via changes in phosphorylation, might
provide a potential therapeutic target. Another potential mechanisms of action
could be via the actin cytoskeleton [463], which is also affected by MCPyV ST
expression, as presented in this thesis. Finally, blocking CLIC family proteins,
CLIC1 and CLIC4, might be another therapeutic pathway. There are some chlo-
ride channel modulators currently available, with the vast majority working on
the cystic fibrosis transmembrane conductance regulator (CFTR) due to its role
in cystic fibrosis and on ligand-gated chloride channels (GABA (γ-aminobutyric
acid)- and glycine-activated) due to their role in the central nervous system [440].
There are no specific blockers for most CLIC family proteins at the moment, al-
though broad-spectrum chloride channel inhibitors like the ones used in exper-
iments presented in this thesis do have an effect on CLICs. RIAA is thought to
block CLIC1 [477], although it has not been used in a therapeutic setting. No
specific inhibitors are currently available for CLIC4. Research in this area could
prove fruitful in tackling not only MCC, but many other malignancies. Inter-
estingly, the crystal structures of both CLIC1 and CLIC4 have been elucidated,
which could provide data to discover additional blockers [478] [479].
Another entire avenue of research to explore regarding MCPyV ST and its role
in cancer metastasis is the effect of MCPyV ST on cell-cell and cell-matrix adhe-
sion, EMT, and expression of kinases associated with cell motility. In fact, some
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preliminary work being undertaken in the Whitehouse laboratory suggests that
kinases like FAK are involved in MCPyV ST-induced cell motility, and that there
are changes in the expression of various EMT markers in the presence of MCPyV
ST.
In addition, some members of the ADAM (a disintegrin and metalloproteinase)
family have been found to be upregulated upon MCPyV ST expression in quanti-
tative proteomic analysis, as well as showing differential cell surface distribution
in the presence and absence of MCPyV ST (personal communication, Nnenna
Nwogu, Whitehouse laboratory). ADAMs are membrane-anchored glycopro-
teins and regulatory enzymes associated with cell adhesion and the shedding or
cleavage of certain receptors, e.g. integrins [480] [481] [482]. ADAMs are catalyt-
ically inactive until autocatalysis, but can cleave the ectodomain of membrane
proteins upon activation [483]. Quantitative proteomic analysis suggests that
ADAM10 and ADAM17 are upregulated upon MCPyV ST expression. ADAM10
has previously been shown to play a role in cancer. For instance, ADAM10 upreg-
ulation in non-small cell lung cancer and nasopharyngeal carcinoma leads to in-
creased cell migration [484] [485]. ADAM17 is overexpressed in some breast can-
cers [486] and promotes cell invasion in prostate cancer [487]. These two ADAM
proteins are currently being investigated in the context of MCPyV ST, and may
be potential drug targets. Further research into other enzymes involved in cell
adhesion, motility, and invasion, such as MMPs, may yield additional targets.
In summary, this thesis explores the role of MCPyV ST in cell motility. Results
presented herein implicate MCPyV ST in reorganising the actin cytoskeleton and
promoting cell motility via integrin signalling mediated by the Rho-family GT-
Pases. In addition, interaction between MCPyV ST and the cellular phosphatase
PP4C has been shown to be central to MCPyV ST-induced cell motility and filopo-
dia formation. These findings allow a molecular mechanism to be proposed
wherein the MCPyV ST-PP4C interaction activates the cell motility pathway via
integrin dephosphorylation. Finally, the CLIC family of chloride channels is im-
plicated in facilitating MCPyV ST-induced cell motility via cell surface relocali-
sation. All these findings increase current understanding of the function of the
major MCPyV oncoprotein in MCC and propose new potential therapeutic tar-
gets for the treatment of this aggressive and deadly cancer.
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